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ABSTRACT
The relative proportions of lymphocyte subsets in the 
peripheral blood constitute a measure of immune status. 
Results of research to establish whether or not individuals 
with lung cancer differ in their lymphocyte composition have 
conflicted due to failure to control for factors other than 
cancer that affect lymphocyte balance. This study was 
designed to quantitatively estimate the effects of variables 
such as disease (lung cancer), smoking, age, circadian and 
circannual rhythms, and dietary factors on lymphocyte 
subsets. Questionnaires were given to 64 white males with 
primary lung cancer and 219 cancer-free white males and a 
blood sample was obtained. Lymphocytes were labelled with 
subset-specific, fluorescence-tagged antibodies and analyzed 
on a fluorescence-activated cell sorter (FACS). A computer 
algorithm for processing the FACS data was invented and 
utilized to determine proportions positive.
The CD3-CD22-CD56 lymphocyte profile was modelled using 
bivariate loglinear multivariable regression. Disease, age, 
smoking, hour-of-day, month-of-year, weekly intake of 
vegetables, and percentages of daily calories from fat and 
from alcoholic drinks were significant main effects and 
there were significant age-by-smoking, disease-by-month, 
and disease-by-vegetable-intake interactions. Smokers' 
profiles did not mature with increasing age while
non-smokers showed an increase in natural killer cells of 10 
percentage points from age quartile <51 years to quartile 
>68 years. Subjects with >28% of their calories in fat 
averaged 5% more CD3+ and 4% fewer CD22+ cells than those 
with <28% fat in their diets. Lung cancer patients had 1% 
fewer CD22+ and 1% more CD3+ lymphocytes than controls, had
11.7% HLA-DR+ lymphocytes that were not CD22+ compared to 
6.6% for controls, and averaged 24% lymphocytes compared to 
37% for controls. Their lymphocyte profiles were different 
from controls' in pattern of circannual variation and 
patients showed more extreme effect from a low-vegetable 
diet than controls. Patients reported a higher fat intake, 
and more occupational exposures to carcinogenic substances, 
but did not differ from controls in 6-carotene consumption.
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INTRODUCTION
"Cancer is one of the most serious health problems in 
Louisiana, second only to heart disease" (Task Force on 
Environmental Health, 1984) . Cancer mortality rates for all 
males and for black females in Louisiana between 1968 and 
1978 were well above the national average during the same 
period. In particular, lung cancer accounts for 85% of the 
difference between Louisiana's cancer mortality and the 
average rates for the United States as a whole (Fontham, et 
al. 1988). Mortality rates from lung cancer among white 
males were 28% higher than U.S. rates for the period 1968-77 
(Task Force on Environmental Health, 1984) and lung cancer 
has been the leading cause of death among American men since 
1950 (Loeb et al. 1984) . Reasons for the higher risk in 
Louisiana are unknown but early epidemiologic studies 
focussed on environmental factors. More recently, Fontham 
and Correa contended that lifestyle is the major modifier, 
citing an the exceptionally high prevalence of smoking among 
southern Louisianians. They implicate inadequate diet, 
secondarily (Fontham et al. 1988).
Cancer is a complex disease that can affect most 
tissues and organs of the body and can be induced by
1
disparate agents including viruses, chemicals, and 
radiation. Mechanisms for tumor induction and progression 
are still not well defined, although in general they involve 
alteration of cell DNA which codes for molecules critical to 
the regulation of cell growth and division. Susceptibility 
factors, such as deficiencies in the immune system, have not 
been characterized either. Since experimental induction of 
cancers in humans would be unconscionable, the etiology of 
human cancers has, for the most part, been explored 
observationally through epidemiologic methods. Furthermore, 
cancers are relatively rare events, therefore most 
investigations have been of the relatively economical, 
retrospective, case-control type. Case-control studies have 
the limitation of not establishing the precedence of the 
putative cause. Such studies can, however, provide clues 
toward the identity of tumorigenic agents, conditions, or 
processes. Experimental induction of tumors in animals with 
suspected agents or under conditions of vulnerability then 
strengthens the hypothesis that they are carcinogenic for 
man.
Classical epidemiologic studies in man have seldom 
involved biologic assays, but neither have laboratory 
studies adequately attended to effect-modifying factors 
intrinsic to the individuality and uniqueness of each human 
being. Human beings are not comparable to one another in 
the same way that inbred strains of experimental animals
3are, therefore one has to identify covariates relevant to 
the process being studied and adjust for these through 
design and/or with statistical methods. There has been a 
trend over the last decade or two to incorporate biophysical 
measures into epidemiologic methodology to obtain more 
quantitative information about etiologic processes of and 
mechanisms of resistance to disease. "Biochemical
epidemiology" combines the advantages of both laboratory 
science and survey methods (Brown et al. 1989). Measurement 
of in vivo carcinogen load, nutritional status, and 
immunologic parameters have been applications of this 
approach. The current study focussed on (1) immune status, 
as reflected by lymphocyte subset profiles, (2) its 
modulation by smoking, diet, and life-style factors, and (3) 
its possible role in the etiology of lung cancer.
The hypothesis that was the basis for the work to be 
described below is that environmental exposures and life­
style factors such as smoking and inadequate diet are both 
important components of lung cancer etiology and that either 
or both can modulate the immune system in such a way as to 
enhance susceptibility to lung cancer. Specific objectives 
included:
(1) identification of life-style and environmental 
factors which affect lymphocyte subset balance in the 
peripheral blood compartment, and
4(2) identification of differences in 
leukocyte/lymphocyte subset profiles between lung cancer 
patients and controls, after controlling for confounding 
variables, which might
(a) be useful for early diagnosis, or
(b) contribute to the understanding of immunologic 
defenses against lung cancer.
To address this hypothesis and these objectives, a 
case-control study incorporating a questionnaire that 
addresses diet, smoking behavior, and environmental/occupa­
tional exposures, and a laboratory assay that provides a 
measure of immune competence was designed and conducted. 
Results of this study are the substance of this 
dissertation.
REVIEW OF THE LITERATURE
Epidemiologic studies in Louisiana.
Early studies suggested that shipbuilding, sugarcane 
farming, other agriculture, mining, commercial fishing, and 
certain jobs within the petroleum industry were occupations 
in Louisiana that correlated with higher risk of lung 
cancer. Welders, workers in oil fields, operators, 
boilermakers, and painters were specific jobs which were 
more frequently recorded for cases than for controls 
(Rothschild and Mulvey 1982; Gottlieb, et al. 1979; Gottlieb 
and Stedman 1979; Gottlieb 1980). Residence within a mile 
of chemical or petroleum industries or near lumber 
industries was also tentatively identified as conferring a 
higher risk (Gottlieb, Shear, and Seale 1982). Most of the 
initial studies were based on analysis of death-certificate 
information. While useful for hypothesis generation, such 
sources did not include information on smoking, diet, or 
other possible confounders and lacked historical information 
on places of residence and other occupations (Wong and 
Foliart 1989).
Subsequent studies that incorporated interview data did 
support higher risks associated with sugar-cane farming 
(increased risk among smokers only) and shipbuilding
5
(Rothschild and Mulvey, 1982). The risk in shipbuilding 
appears to be associated with exposure to asbestos and is 
also elevated among asbestos cement workers (Wong and 
Foliart 1989). Since shipbuilding and sugar cane farming 
are predominantly industries of the southern parishes, they 
correlate with the geographic distribution of lung cancer in 
Louisiana as well. The findings of five cohort studies of 
refinery and chemical workers, however, indicated that there 
was no significantly increased risk associated with 
employment in those industries (Wong and Foliart 1989). 
Since workers in those industries would presumably be 
exposed to higher doses of potential carcinogens than
residents of areas surrounding the plants, the negative 
findings of these industrial studies also are evidence
against hypotheses of higher risk among residents near
refineries and chemical plants. Case-control studies with 
interview data have also failed to find an association of 
lung cancer with residence near industries (Wong and Foliart 
1989).
Smoking and lung cancer.
Smoking is associated with a number of cancers 
including those of the lung, larynx, oral cavity, esophagus, 
bladder, kidney, pancreas, cervix, and stomach (Subar, 
Harlan, and Mattson 1990). Greater than 95% of primary lung 
cancers among men and more than 85% among women, are
associated with smoking (Loeb et al., 1984). Of the most
common histologic types of lung cancer, small-cell and 
squamous-cell tumors are the most strongly correlated with 
smoking. In addition to their statistical association with 
smoking, small cell and squamous cell tumors also tend to 
occur in the upper lobes of the lungs, which are thought to 
be more heavily exposed during cigarette smoking than the 
lower lobes (Celikoglu et al. 1986). In one study of 2668 
lung cancer cases, only 1.9% of the males were non-smokers 
and 13% of the females were non-smokers (Kabat, Geoffrey, 
and Wynder 1984). In a 10-year prospective study of 6,027 
men, 45 years of age and older, none of the 83 0 men who had 
never smoked on a regular basis developed lung cancer. 
Among the other 5197 men who had smoked there were 121 lung 
cancer cases. A dose-response gradient in risk, based on 
number of cigarettes smoked per day, was demonstrated for 
each histologic type of lung cancer except for the poorly 
differentiated squamous-cell tumors and large-cell tumors 
(for the latter of which there were too few cases; Weiss et 
al. 1972). According to a recently reported study in 
Louisiana involving 1253 cases of lung cancer, 98 percent of 
both white and black male cases, 94 percent of black female 
cases, and 88 percent of white female cases were smokers or 
former smokers (Fontham, Chen and Correa 1988) .
A Louisiana study was also the first to document an 
increased risk of lung cancer among the non-smoking spouses 
of smokers (Correa et al. 1983). The relative risk for
8spouses of people with less than 40 pack-years of cigarette 
smoking (equivalent to one pack per day for 40 years) was 
1.48 and that for those married to people with greater than 
40 pack-years of exposure was 3.1. Several other studies in 
the U.S.A. and other countries have also concluded that 
there is a connection between passive smoking at home and in 
the work place with the development of lung cancer (Hirayama 
1987) . However a number of studies have not found an 
increased risk from passive smoking. Comparability among 
these studies is not especially good due to differences and 
flaws in design. Evaluation of the combined results of nine 
such studies (meta-analysis), however, led to the conclusion 
of an overall odds ratio of 1.12 with a 95% confidence 
interval of 0.95-1.30, that is, a non-significantly elevated 
risk (Fleiss and Gross 1991). Despite the inconsistency of 
epidemiologic findings, there is physiologic evidence that 
exposure to the cigarette smoke of others is detrimental. 
Decrements in lung function, based on measurement of forced 
expiratory volumes and flow rates, were found among both 
children whose mothers smoked and adult, non-smoking spouses 
of smokers (Loeb et al. 1984).
Carcinogenic properties of tobacco.
Tobacco smoke is a complete carcinogen, that is, it 
contains both initiating and promoting compounds. It is 
commonly accepted that polycyclic aromatic hydrocarbons
(PAH) are the major initiator carcinogens in pyrolyzed 
tobacco although they constitute less than 0.003% weight of 
the smoke condensate or tar. They are relatively unreactive 
in themselves but are activated to strongly electrophilic 
intermediates by normal mammalian enzymes termed mixed 
function oxidases (isozymes of the cytochromes P-450; 
Gelboin 1980). These enzymes themselves are induced 2- to
135-fold by smoking (Conney 1982). The reactive diol
epoxide intermediates then can bind covalently to DNA, 
usually to the 2-amino group of guanine (Sims et al. 1974; 
Jeffrey et al. 1977). Cell transformation and tumor 
initiation correlate with the formation and persistence of 
this adduct (Nakayama 1984; Stowers 1985; Autrup, 1982). 
Damaged DNA can be detected and repaired by mechanisms
present in the affected cell. It is known, however, that
smokers have subnormal capacity to repair damaged DNA 
(Setlow 1983). If the cell replicates before the damage is 
repaired, a mutation may occur. Such a mutation in genes 
which code for key proteins that regulate cell division and 
differentiation constitutes initiation.
Initiation is not sufficient to produce a tumor; at 
least one other event termed promotion must take place. 
When a synthetic mixture of 17 of the most commonly 
identified PAH, combined in proportions comparable to their 
natural occurrence in the tar, was applied to mouse skin at 
a dose representative of the amount contained in a
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carcinogenic amount of tar, the PAH did not induce tumors. 
However, when this synthetic mixture was added to a 
tumorigenic dose of tar, the tumor yield was enhanced 
greater than two-fold (D. Hoffmann, et al. 1978). This 
indicated that constituents in the tar acted synergistically 
with the PAH, that is, they were promoters, and also that 
the PAH are responsible for a large fraction of the 
tumorigenicity of cigarette smoke condensate.
An epidemiologic study in Finland indicated that 
workers exposed to high concentrations of PAH experience a 
higher risk of lung cancer (RR=1.7; Rantanen 1983). The 
mutagenicity of the urine of these workers validated their 
high exposure. PAH adducts to DNA in blood lymphocytes as 
well as antibodies in peripheral blood to such adducts have 
been detected among persons occupationally exposed to PAH 
(Harris et al. 1985). The demonstration of DNA adducts in 
human tissues, which are similar to those known to occur 
during tumor induction in animals, strongly suggests that 
exposure to PAH occupationally or through smoking are 
causally related to the development of cancer in humans.
Cocarcinogenesis and promotion by constituents in 
tobacco smoke and the suppression of DNA-repair mechanisms 
by smoking might be as important or more important than 
initiation by constituents of tobacco smoke. The 
carcinogenic effects of other exposure to PAH or exposure to 
other carcinogens can be substantially amplified by
concurrent cigarette smoking. It is well documented that 
the risks of mesothelioma and of lung cancer among people 
exposed to asbestos are elevated for smokers compared to 
non-smokers. For non-smokers who worked with asbestos, the 
risk relative to that of men who neither smoked nor worked 
with asbestos was 5 times. Smokers who did not work with 
asbestos had a relative risk of 11, but those smokers who 
also worked with asbestos had 53 times the risk of unexposed 
non-smokers for lung cancer (Wagner 1984)I There is
evidence in several studies that smoking acts 
synergistically with exposure to uranium in causing lung 
cancer among uranium miners (Loeb 1984), and smoking more 
than 30 grams of tobacco per day seems to interact with 
heavy alcohol intake to greatly increase the risk of 
laryngeal cancer (Doll and Peto 1981).
Smoking in Louisiana.
Since most lung cancer can be attributed to smoking, 
could the excess lung cancer in Louisiana be due to a 
relatively high prevalence of smoking among Louisianians? 
A National Health Interview Survey in 1979 found that 36.9% 
of men over age 17 and 28.2% of women reported themselves to 
be smokers and showed that prevalence of smoking had 
declined since 1965. In the subsequent nationwide Current 
Population Survey (CPS) of 1985, 30.6-32%1 of all male
*Range indicates confidence interval around the survey- 
estimated prevalence.
respondents and 24.3-25.7% of the female respondents over 
the age of 16 reported themselves to be regular smokers, 
showing a further decline. Louisiana ranked 19th among the 
fifty states in overall smoking prevalence for males 
(33.1±3.3%) and 43rd for prevalence among females 
(22.3±2.7%). The four-state region which contained 
Louisiana, Texas, Arkansas, and Oklahoma reported 33.6±1.4% 
of white men and 37.3±3.4% of black men as smokers. The 
rates for white men were about 3% higher than the national 
average and those for black men at the national average 
(Marcus et al. 1989). Given these statistics, higher
prevalence of smoking would not account for a 28% excess of 
lung cancer among white males in Louisiana.
Somewhat different figures were reported from a 1983 
lifestyles survey among men over 3 0 years of age in 
Louisiana: 34.7-38.7% (compared with the CPS average of
33.6%) of white men and 46.9-54% (CPS average = 37.3%) of 
black men reported themselves to be current smokers (Correa 
and Johnson 1983). The somewhat higher rates among white 
males might have resulted from not including the younger age 
groups in this survey, since smoking prevalence was highest 
in the 3 0-49-yr age groups in the CPS. Correa's rates for 
black males, however, are so much higher than the regional 
average for black males (30.5-44.1%) in the CPS that the 
confidence intervals of the two estimates do not overlap. 
This would lead one to wonder if one study or the other had
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a biased population sample. Although Louisiana did not have 
an exceptionally high prevalence of smoking in the early 
1980s, it is still possible, that smoking prevalence among 
white males in Louisiana was truly higher than the national 
prevalence in the late 1950s and the early 1960s, a time 
period which would be more relevant for induction of cancers 
which were diagnosed between 1968 and 1977.
Lung cancer rates were higher in southern parishes of 
Louisiana than in the northern part of the state. Comparing 
lifestyles of men within an area of high lung cancer 
mortality to those of men within an area of the state with 
half the rate or less, Correa found that higher percentages 
of both white and black men smoked, a higher percentage of 
smokers used non-filter cigarettes, more whites reported 
that their parents were smokers, and smokers had taken up 
the habit at an earlier age in the area where there was 
higher mortality (Correa and Johnson 1983). Thus 
particularly intense smoking behaviors in parts of the state 
may have contributed disproportionately to the state-wide 
excess of lung cancer.
Other factors in lung cancer.
Smoking can be considered a necessary, if not 
sufficient cause for perhaps 85-90% of male lung cancers and 
over 70% of lung cancer among females (Loeb, et al. 1984). 
The portion of risk attributable to smoking for Louisianians 
was estimated to be 90% (Fontham, Chen, and Correa 1988).
However since non-smokers can succomb to lung cancer but not 
all smokers do succumb, there must be factors other than 
smoking which contribute to the development of lung cancers. 
Lee and coworkers (Lee, Fry, and Forey 1990) demonstrated 
that the recent declines in age-specific lung cancer rates 
for younger men and women in England and Wales from 1950 
onwards cannot be entirely explained by changes in the 
"cumulative constant tar cigarette consumption" during the 
same period. This discrepancy is also evident for emphysema 
and especially for chronic obstructive lung disease. While 
it is perhaps the most important single factor in the 
etiology of lung cancer, smoking does not account for all 
lung cancers.
Although much attention has been focussed upon smoking 
as the major cause of lung cancer, very little is known 
about the etiology of the disease among non-smokers. 
Occupational exposures, which have been identified as 
increasing risks for lung cancer independently of smoking, 
are arsenic, bischloromethyl ether, chromium, ionizing 
radiation, mustard gas, nickel, and PAH. It is worthy of 
note that Correa found higher percentages of smokers in 
those industries thought to be associated with high rates of 
lung cancer in southern Louisiana, than in other occupations 
(Correa and Johnson 1983). Overall, however, occupational 
exposures are considered to account for only about 4% of all 
cancers (Correa and Johnson 1983).
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Males appear to be more susceptible to lung cancer than 
females. In a retrospective study of 1939 squamous cell 
carcinoma, small cell carcinoma and adenocarcinoma patients, 
who were diagnosed in Canada between 1979 and 1986, men out­
numbered women in the ratios of 5.4:1, 3.0:1, and 1.6:1 for 
each of the three types respectively. The excess of lung
cancer among males relative to females could not be
attributed either to the 7-15% higher prevalence of smoking 
among males or to the fact that males were likely to have 
smoked more cigarettes per day than females.
The relative incidence of the various histologic types 
of lung cancer varies from one geographic area to another 
but overall squamous-cell carcinoma has been the most common 
type, followed by either small-cell carcinoma or
adenocarcinoma and finally large-cell carcinoma (Dodds, 
Davis and Polissar 1986). The prevalence of the strongly 
smoking-associated squamous-cell carcinoma has been 
decreasing in recent years, however, and that of
adenocarcinoma has been increasing (Rothschild 1982).
Some cell types of lung cancer, adenocarcinoma for 
instance, are less strongly associated with smoking than 
others. In the Canadian study, 14% of patients with 
adenocarcinoma (3.8% for men and 28% for women) had never 
smoked, while <3% of those with squamous cell or small cell 
carcinomas had been lifetime non-smokers. Among men in this 
study, cell type was not related to duration or intensity of
smoking as expressed in pack-years, but among women, those 
with small cell tumors had experienced exposure in pack- 
years which was significantly higher than that of women with 
the other two histologic types (McDuffie, Klaassen, and 
Dosman 1990). Some studies have documented an increasing 
proportion of adenocarcinoma over time among diagnosed lung 
cancers (Dodds, Davis, and Polissar 1986). This might 
partially be due to the reduction in incidence of the more 
strongly smoking-related cancers as the prevalence of 
smoking declines in that population. Another group has 
observed that among cases of lung cancer first diagnosed at 
autopsy, the male-to-female ratio is lower (24:19) and non- 
smokers are more common (30% of 40 cases compared to 8% of 
107 cases) than among cases diagnosed prior to death 
(McFarlane, Feinstein, and Wells 1986). These findings may 
indicate both that lung cancer among non-smokers is under 
diagnosed, and that important etiologic factors other than 
smoking are being overlooked. Maleness as a susceptibility 
factor, the relative increase in adenocarcinoma of the lung 
with respect to other cell types, and the incidence of lung 
cancers in non-smokers, all have eluded explanation.
Genotype and lung cancer.
An excess of lung cancer among relatives of lung cancer 
patients has been reported, even after correction for 
smoking (Tokuhata and Lilienfeld 1963). Lynch et al. (1986) 
observed that the cumulative risk (CR) for relatives of lung
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cancer patients for developing any type of cancer was 
elevated over that of the general population and that the CR 
of getting non-smoking-related cancers was higher than that 
of getting smoking-associated cancers. Only relatives of 
those with adenocarcinoma of the lung (as opposed to other 
histologic types of lung cancer) had more lung cancer per se 
(Lynch et al. 1986) . The relatives of probands who had 
multiple primary tumors had significantly more cancer than 
relatives of those with a single cancer.
The close relatives of lung cancer patients also have 
been observed to have higher rates of impaired lung function 
and chronic obstructive pulmonary disease than those of 
patients with non smoking-related cancers, even when never- 
smokers were excluded from the analysis and variables were 
included to adjust for the effects of smoking (Lynch and 
Lynch 1989). A heritable weakness in the pulmonary system 
which predisposes individuals to chronic obstructive lung 
disease, might also render them more susceptible to lung 
cancer.
A study of the first degree relatives (i.e. parents, 
full siblings and children) of 337 white lung cancer 
patients in Louisiana showed a greater overall risk for 
cancer compared to families of the probands' spouses. The 
risk remained significant after adjustment for age, sex, 
cigarette smoking, and occupational/industrial exposure. 
The same proportions of relatives of the probands and their
spouses were smokers, but the relatives of probands were 1.4 
times as likely to smoke 2 or more packs per day and 1.3 
times as likely to have accumulated 60 or more pack-years of 
exposure. Increased risk was found among families of 
probands both for lung cancer and for cancers of the larynx, 
brain and nervous system, bone, endocrine glands, ovary, 
kidney, bladder, esophagus and stomach and leukemias- 
lymphomas (OOi et al. 1986) . Furthermore the crude odds 
ratios for having multiple relatives with cancer increased: 
ORj = 1.67, 0R2 = 2.16, OR3 = 3.66, and OR4&more =5.04 (Sellers 
et al. 1987) .
A Canadian study showed increased risk among first- 
degree relatives of lung cancer patients for having 2 or 
more persons within the relationship affected with cancer of 
any type, for having a multigenerational pattern of cancer, 
and for having multiple primary cancers within individuals 
(McDuffie 1991) . Most of the excess cancers among patients' 
relatives were smoking-related and interviews of siblings of 
patients and controls showed that 68% of patients' siblings 
smoked while only 47% of controls' did. Therefore in this 
study, family history is confounded with smoking and no 
attempt was made to partition the risk. A trend of 
increasing odds ratios for having multiple relatives with 
cancer, similar to that in the Louisiana study, was also 
found here.
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Studies are also underway to assess the role of the p53 
gene in carcinogenesis. P53 codes for a protein which 
regulates transcription in cell nuclei and is thought to 
restrain cell growth and division. Dysfunctional, mutated 
forms of this gene have been found to be associated with 
various forms of cancer, including lung cancer (Lewis 1991; 
Takahashi et al. 1989).
The frequency of sister chromatid exchanges (SCE) in 
cultured lymphocytes is also thought to be a heritable 
susceptibility marker for cancer. SCE were more frequent in 
the lymphocytes of lung cancer patients than they were among 
controls. When controls were divided by family history of 
cancer into high-risk and low-risk groups, the level of SCE 
among the high risk individuals was indistinguishable from 
that of patients. Both patients and high-risk controls 
responded with increased SCE when their lymphocytes were 
cultured with benzo-a-pyrene compared to low-risk controls 
(Lynch and Lynch 1989). High levels of SCE could be due to 
enhanced activation of carcinogens, defective repair 
mechanisms for carcinogen-damaged DNA, chromosomal 
instability, or combinations of the three.
Genetic differences in the ability to metabolize 
carcinogens, specifically in the balance of activation to 
detoxification pathways has been proposed as one reasonable 
biogenetic mechanism for variance in susceptibility to 
cancer (Harris et al. 1980). Of particular interest are the
cytochromes P450, a family of enzymes responsible for 
metabolizing xenobiotics. Their genes are polymorphic; 
individuals may vary in their ability to metabolize 
xenobiotics by as much as a factor of 100. Several studies 
have found that high inducibility of aryl hydrocarbon 
hydroxylase, the P450 enzyme which activates members of the 
PAH family, is more prevalent among lung cancer patients 
than among controls (Lynch and Lynch 1989). It has also 
been established that P450dbl is the specific human isozyme 
responsible for metabolizing the anti-hypertensive drug 
debrisoquine and that persons who are high metabolizers of 
debrisoquine have an enhanced risk for developing lung 
cancer. If these people are also occupationally exposed to 
carcinogens, the two factors interact synergistically, 
resulting in a substantially higher risk than that expected 
if the effects were additive (Caporaso et al. 1989). Thus 
there is specific biochemical evidence for genes which 
influence susceptibility to lung cancer by enhancing the 
metabolism (activation) of carcinogens, inhibiting DNA 
repair mechanisms, or disrupting normal regulation of cell 
growth and division.
While it is true that most lung cancer patients have 
been smokers, and that smokers have 25 times the risk of 
non-smokers for developing lung cancer (Subar, Harlan, and 
Mattson 1990), perhaps no more than 10-15% of smokers will 
develop lung cancer. What it is that is different about
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those who smoke but do not get lung cancer is not known. 
Either there is an element of the causal chain of events 
which has not yet been identified, or there is a protective 
mechanism which most but not all smokers possess.
Campaigns to educate the public to the dangers of 
smoking and various programs have been established to help 
smokers break the habit. Among the younger age groups in 
several countries lung cancer rates are leveling off or even 
decreasing (Kurihara 1987). It is improbable, however, that 
the practice of smoking cigarettes will diminish to the 
point where it is of negligible public health concern 
(Pierce et al. 1989). Although prevalence of smoking has 
declined since 1965 when 51.1% of males and 33.3% of females 
reported themselves to be smokers, the proportion of smokers 
who smoke more than 25 cigarettes per day increased from 
13.7% in 1965 to 22.4% in 1979 (Loeb et al. 1984). The 
heavier smokers tend not to relinquish the habit. Therefore 
it would be valuable to be able to discriminate the high- 
risk smoker from the low risk smoker for the purpose of 
earlier diagnosis as well as to provide additional 
motivation for quitting. In addition, the determinants, 
other than smoking, of risk for lung cancer, particularly 
adenocarcinoma, should be identified since rates of 
adenocarcinoma appear to be increasing (Kurihara 1987). 
Such an indicator of risk would presumably be a construct of 
multiple behavioral and physiologic traits.
22
Diet and cancer.
It has long been recognized that diet affects one's 
health. Current media debates of the effects of diet on 
health, are perhaps most prominantly focussed on heart 
disease, but much consideration has been given to dietary 
factors which may influence resistance to cancer as well. 
On the basis of many studies of the relationship of diet to 
susceptibility to cancer, it has been estimated that as much 
as 30% of all cancers are due to dietary factors (Doll and 
Peto 1981). Particular foods and/or nutrients have been 
found to be associated with cancers of specific tissues, for 
example, cruciferous vegetables inversely with colon cancer, 
salted and smoked foods with stomach cancer, and alcoholic 
beverages with cancer of the larynx. Vitamins A and C have 
been most often identified as protective against lung cancer 
although results have not been consistent. Diets high in 
protective factors may be one reason that some smokers avoid 
lung cancer. If diet could also be linked to some 
physiologic element of the body's defense system, such as 
some parameter of immune status, the hypothesis of an 
important role for diet in cancer prevention would be 
strengthened and better defined.
"In a dozen case-control and cohort studies, high 
intake of fruits and vegetables containing carotenoids has 
been associated with a reduced risk of lung cancer," (Willet 
1990) . At first it was thought that vitamin A was
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responsible for increased resistance to lung cancer. Some 
animal studies demonstrated that vitamin A could reverse 
metaplastic changes in cells and promote differentiation to 
maturity, protect animals from acquiring tumors, and inhibit 
the progression of already induced cancers under some 
conditions. Unfortunately, these findings were not entirely 
consistent.
Vitamin A is available to humans either as the 
preformed retinyl esters from animal sources or as 
carotenoids derived from green leafy vegetables or green and 
yellow vegetables and fruits. Certain of the carotenoids, 
specifically a-carotene, 6-carotene, and cryptoxanthin, are 
metabolized to vitamin A, primarily in the intestine but 
perhaps also in the liver (Peto et al. 1981). A few early 
studies, in which plasma drawn before the diagnosis of lung 
cancer was analyzed for retinol levels, indicated a 
protective effect for plasma retinol, but these results were 
not verified by further studies. Instead it was a 
carotenoid which emerged as the protective factor and not 
preformed vitamin A (Zieglar et al. 1984) . It was found 
that higher levels of plasma 6-carotene were protective, but 
there was no difference in the pre-diagnostic levels of 
retinol or carotenoids other than 6-carotene. That a 
carotenoid rather than retinol is apparently the protective 
factor is, in fact, more reasonable because plasma levels of 
retinols are tightly regulated by homeostatic mechanisms and
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are not influenced much by increased intake. Levels of 
carotenoids can vary widely and directly reflect levels of 
intake.
Differences in intakes of fruits and vegetables among 
residents of northern and southern parishes of Louisiana 
were correlated with higher rates of lung cancer in the 
southern region of the state. This lifestyles study in 
Louisiana also found an inverse relationship between dietary 
carotene intake and squamous-cell and small-cell carcinomas, 
but not for adenocarcinoma. It was retinol intake which was 
inversely associated with adenocarcinoma of the lung (Correa 
et al. 1988) . However a 1981-82 study in Los Angeles County 
involving 149 cases of adenocarcinoma in women provided 
evidence for a strongly protective effect of 6-carotene 
against adenocarcinoma (Wu, et al. 1985).
The mechanisms through which 6-carotene would act to 
protect an individual from neoplastic disease are not known. 
Physiologic and chemical effects are both possible. 
Carotenoids are known to be efficient quenchers of singlet 
oxygen and 6-carotene, in particular, is a good scavenger 
for free radicals (Burton and Ingold 1984). 6-Carotene 
protects mice from psoralen-induced phototoxicity by 
quenching intermediate active species (Giles, Warner, and 
Kornhauser 1985). It was also found to reduce chromosomal 
breaks in the bone marrow of mice exposed to benzo-a-pyrene 
and mitomycin C (Raj and Katz 1985) . This ability to
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deactivate certain intermediate active species could be 
directly protective against cancer initiation. Chewers of 
the combination of betel nut, lime, and tobacco are at high 
risk for oral cancer and micronucleated cells are 
characteristic of their buccal mucosa. 6-Carotene was shown 
to be effective in preventing the formation of such 
micronuclei among chewers in the Phillipines, (Stich et al.
1984) .
Enhancement of immune defenses by 6-carotene has also 
been postulated. There was a rise in the number of CD4 + 
lymphocytes and total CD3+ lymphocytes but not of CD8 + 
lymphocytes per mm3 in human blood following daily, oral, 
180-mg doses of 6-carotene (Alexander, Newmark, and Miller
1985). Such changes in analogous subsets have also been 
observed in mice. Mice supplemented with vitamin A or 6- 
carotene were also able to reject incompatible skin grafts 
more rapidly than controls and in other experiments, the 
growth of tumors was slowed with supplementation 
(Alexander, Newmark, and Miller 1985). Recent studies 
suggest that cigarette smoking itself lowers plasma levels 
of 6-carotene independently of reported intake of green and 
yellow vegetables (Willet 1990). The association of plasma 
levels of 6-carotene with lung cancer is therefore 
confounded with smoking. Risk of lung cancer, adjusted for 
smoking, among individuals with low intakes and low serum 
levels of vitamin A and carotenoids was 1.3 to 2.7 times
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that of persons with high intakes and high serum levels. 
Among smokers the enhancement of the risk of lung cancer 
when there is inadequate intake of carotenoids/vitamin A 
could range from 1.3 to 8.1 times. (Subar, Harlan, and 
Mattson 1990).
6-Carotene and vitamin A may not be the only 
constituents of fruits and vegetables which are protective. 
Vitamin C intake has been found to be inversely related to 
some cancers, but the evidence with respect to lung cancer 
has been mixed. An inverse gradient was found in Louisiana 
between vitamin C consumption and squamous- and small-cell 
cancers (Fontham et al. 1988). The authors suggest that the 
effect might be significant among Louisianians, when it has 
not been found to be significant in other studies, because 
a national study has shown that dietary intakes of vitamin 
C are particularly low in Louisiana compared to the rest of 
the country. Fifteen percent of low-income Louisianians and 
9% of higher income residents were found to be low or 
deficient in serum levels of vitamin C (Ten-State Nutrition 
Survey 1968-70). Dietary data from the Bogalusa Heart Study 
suggests that Louisiana children do not ingest the 
recommended daily allowance (RDA) of vitamins A and C 
(Correa et al. 1988). Of the children surveyed, 25-50% did 
not get the RDA of vitamin A and 15-36% reported intakes of 
less than V 3 the RDA of vitamin C. Thus low intake of these 
important nutrients prevails from an early age.
Some studies have also found that folate might be 
protective against lung and cervical cancers. Low folate 
levels are associated with cervical dysplasia and 
supplementation with folate tends to reverse the dysplastic 
process (Butterworth et al. 1982). Organic nitrites, 
nitrous oxide, cyanates, and isocyanates in cigarette smoke 
destroy vitamin B12 and folate, resulting in reduced levels 
of both vitamins in peripheral blood of smokers. Smokers 
with potentially premalignant bronchial squamous metaplasia 
had lower levels of both folate and vitamin B12 than smokers 
with normal sputum cytology. In a preliminary, randomized, 
double-blind trial supplementation with 10 mg of folate and 
500 /xg of hydroxocoalbumin (vitamin B12) for four months 
caused improvement in the degree of metaplasia among those 
so supplemented compared to the group who received the 
placebo (Heimburger et al. 1988). Vegetables are a major 
source of folate.
Another dietary association which has appeared in some 
studies of lung cancer is the inverse association of lung 
cancer with the consumption of dairy products and eggs. A 
gradient effect over quartiles of intake relative to the 
highest intake was observed although the increased risk 
ratio was significant only for the lowest two quartiles of 
intake (Wu et al. 1985).
A Norwegian group of investigators found an intriguing 
interaction between alcohol intake and vitamin A index in
estimating the risk of lung cancer. For those with low 
vitamin A intake, persons with a high alcohol intake had 
3.7-fold higher odds for developing lung cancer compared to 
non-drinkers, while those who had a high vitamin A intake 
and a high alcohol intake had one-fifth the odds of non­
drinkers. The finding is plausible on the basis of animal 
studies which showed that animals who were fed ethanol
regularly maintained higher plasma and tissue levels of
vitamin A but lower liver stores than control animals
(Kvale, Bjelke, and Gart 1983). In a Japanese study,
however, those who drank alcohol were found to have about 
30% lower serum levels of 6-carotene than non-drinkers 
(Shibata et al. 1989; Stryker et al. 1988) . In a regression 
of serum 6-carotene on age and on dummy variables for 
categories of intake of green and yellow vegetables, 
drinking, smoking, and city of residence, drinking had the 
highest estimated coefficient of the categorical variables.
If drinking does indeed affect the protective effect of 6- 
carotene or vitamin A against cancer, failure to look for 
and to control for this relationship may have led to some of 
the inconsistencies in results in previous studies of 
vitamin A and lung cancer risk.
Smoking and drinking are independent behaviors although 
use of cigarettes is commonly associated with use of 
alcohol. Smokers are more likely to drink beer regularly 
and to consume larger guantities of all alcoholic beverages
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on any particular occasion (Centers for Disease Control
1989) . Some studies estimate that 7% of the adult 
population are alcoholics and over 80% of these smoke 
cigarettes as well (Difranza and Guerrera 1989). It was 
suggested above that alcohol intake might potentiate a 
protective effect of high vitamin A intakes and at the same 
time worsen the risk associated with inadequate intake. 
Although drinking is known to lower plasma levels of ft- 
carotene, perhaps the plasma and tissue levels of vitamin A 
are enhanced with high levels of ethanol intake. This 
relationship deserves further investigation. Furthermore 
the effects of alcohol intake on the immune system have not 
been reported and might have relevance for the risk of 
cancer.
There is recent evidence from the Second National 
Health and Nutrition Examination Survey (NHANES II) that 
smokers do not consume as nutritious a diet as non-smokers. 
Smokers tend to eat fewer fruits, vegetables, and high-fiber 
grains and therefore less vitamin C, folate, fiber, and 
vitamin A than non-smokers and intake varies inversely with 
smoking intensity. Interestingly however, former smokers 
had eating patterns which were no different than those of 
never smokers (Subar, Harlan, and Mattson 1990). The 
inverse association of vitamin C intake with increasing 
smoking intensity was subsequently verified in data from two 
other epidemiologic studies. Ex-smokers had intakes
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intermediate between current smokers and non-smokers 
(Gridley, McLaughlin, and Blot 1990) . If it is true that 
former smokers revert to healthier eating patterns when they 
stop smoking, this would imply that smoking has effects upon 
appetite and that this is an important component of the 
mechanism by which smoking increases the chances of 
developing not only lung cancer, but other smoking-related 
cancers as well.
Methods of obtaining information on diet.
Dietary information is obtained from interviews or 
questionnaires completed by the subjects. The question of 
the validity of food-frequency instruments has received a 
good deal of attention (Chu et al. 1984; Willett et al.
1985) . The issue of what should serve as the "gold 
standard" in judging the quality of a particular method is 
the major problem. Comparisons of food frequency data to 
intakes recorded in a diet diary or to the estimates made by 
a third person such as a spouse suffer from the likelihood 
that errors in the responses could be correlated to an 
unknown extent. For instance subjects and spouses may both 
over- or under-estimate the use of a certain food. More 
objective standards are those based on a biochemical or 
physiologic response, e.g., blood levels of a particular 
nutrient (Willett et al. 1983). Even these, however, do not 
necessarily fluctuate in proportion to the intake of foods 
containing that substance. Individuals vary in their
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digestive and absorptive processes. Absorption of one 
nutrient sometimes depends upon what other foods are 
consumed with it. The blood levels of certain nutrients, 
like vitamin A, are regulated within narrow limits by 
homeostatic mechanisms and correlate with intake only at the 
extremes of deficiency or toxic surplus. Finally, genetic 
differences can affect the individual's usual blood level of 
a substance such as cholesterol.
Diet recall methods suffer from the inability of 
subjects to remember accurately just what he ate more than 
1 or 2 days previously. Over that short interval, there is 
a good deal of intraindividual variation such that the last 
day's intake might not be representative of his usual intake 
(Sempos et al. 1985). A 7-day diet record might be a more 
accurate method but requires a substantial commitment on the 
part of the respondent and therefore reduces participation 
rates to the point where representativeness of the sample is 
questionable.
This problem of validity of dietary data assessment 
must also be considered in the context of the uncertainties 
in other, more-accepted strategies of measurement of 
physical characteristics. For example, single measurements 
of blood pressure are notoriously imprecise, yet we consider 
them to be valid and meaningful estimates. Furthermore, it 
is important to be clear about the objectives of 
measurement. The goal of a clinician is usually validity
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for the individual. In population studies, however, the 
reliability of the assessment for each individual is not so 
important as that of the mean intake for each subgroup of 
individuals. Additionally, it is of little importance if 
the estimates are biased in one direction or the other, so 
long as the subgroups of interest can be ranked in 
categories of low, medium, and high intake (Block 1982).
Food frequency questionnaires have been found to be a 
reasonable if not a perfect method for gathering useful 
dietary data which has validity on the group level. They 
are easily self-administered and therefore practical and 
cost efficient methods for large studies. They yield 
estimates which correlate well with diet histories and diet 
records (Block 1982), and permit the useful grouping of 
subjects into categories by level of intake.
Tumor immunity.
The role of the immune system in defense against 
neoplastic disease is a complex issue which is still far 
from resolution. Both non-specific and specific immune 
responses probably participate (Ada 1981). Strongly 
antigenic tumors in mice can induce a specific cell-mediated 
immune response, but most tumors in humans are thought to be 
only weakly antigenic (Stutman 1975; Melief, Cornelis, and 
Schwartz 1975; Doherty, Knowles, and Wettstein 1984). 
Studies of immunosuppressed transplant patients or those 
with immune deficiencies show that only certain kinds of
tumors are increased. Specifically these are non-Hodgkins 
lymphomas, hepatocarcinoma, cervical carcinoma, soft tissue 
sarcomas, and skin cancers, all of which have been 
tentatively linked to viruses (Matas, Simmons, and Najarian 
1975; Purtilo, et al. 1984). In contrast, the common 
cancers: lung, gastrointestinal, prostate, and breast are 
not increased. This suggests that in humans only neoplasia 
associated with viral infection would be combated by a 
specific, antigen-driven immune response (Kinlen 1985). 
However, culture of pleural-effusion lymphocytes with 
mitomycin-C-treated autologous tumor cells has been used 
successfully to generate cytotoxic T-cell effectors which 
were specific for the host's lung tumor, but inactive 
against allogeneic targets (Uchida and Moore 1985) . This 
finding indicates that antigen-specific immune responses to 
lung neoplasia may be important but that they are either 
suppressed or difficult to measure with current assay 
systems.
Several leukocyte types have been implicated as 
defenders against malignant cells including macrophages, 
cytotoxic T-lymphocytes (CTL) with antigen specificity, 
natural killer cells (NK; also called "large granular 
lymphocytes"), and another lymphocyte called a lymphokine- 
activated killer (LAK; Rosenberg and Mule 1985) which may 
overlap the NK population. NK are lymphocytes which are 
defined by their morphology and their ability to lyse
cultured tumor cells (specifically cells of the human 
myeloid leukemia cell line K562) in a non-MHC-specific 
manner. In rats NK cells were shown to be the major 
effectors in limiting the development of metastatic lung 
tumors when the animals were challenged intravenously with 
tumor cells (Weissler et al. 1987) . Unlike NK, LAK can 
lyse freshly isolated, but not cultured, tumor cells in 
vitro. The precursor of LAK is a null cell but is not a NK 
because anti-CD2 + C  destroys cells with NK activity but 
not cells which differentiate to LAK in response to IL2. 
The phenotype of the effector is CD3+CD8+ but like NK, its 
action is not MHC-restricted (Grimm et al. 1982) . 
Regression in the tumor burdens of some humans treated with 
LAK and/or interleukin 2 (IL2) demonstrates that these
components of the human immune system are able to inhibit 
and even reverse tumor progression (Rosenberg and Lotze 
1986; Rosenberg et al. 1987).
There are numerous reports in the literature that 
present evidence of immune suppression among patients with 
cancer. Some immune responses seem to be correlated with 
disease progression and others not. Lymphoblastogenesis 
assays with mitogens concanavalin A (ConA) and poke weed 
mitogen (PWM) appear to correlate with prognosis for lung 
cancer patients (Watanabe et al. 1990). Assay of NK 
activity in peripheral blood lymphocytes (PBL) was less 
definitively correlated. Peripheral blood monocytes from 8
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of 31 lung-cancer patients had reduced cytocidal activity 
toward cultured tumor cells compared to monocytes from 
healthy controls (Nakata et al. 1985). Patients' monocytes 
showed reduced ability to upgrade complement receptor 
expression and the degree of inhibition was proportional to 
the spread of disease. Although valuable for estimating 
extent of disease and therefore prognosis for survival, 
these assays are probablly not relevant for susceptibility 
evaluation, early diagnosis, or treatment.
Tumor infiltrating lymphocytes (TIL) function
differently from PBL in the autologous mixed lymphocyte 
reaction. PBL from lung cancer patients responded poorly, 
while pleural effusions of lung cancer patients contained 
enough responding cells to give results comparable to the 
blood of healthy donors (Uchida and Micksche 1982). TIL 
from patients with metastatic melanoma matured into tumor- 
specific cytotoxic lymphocytes (LAK ?) and not NK upon 
culture with recombinant IL2 (rIL2), whereas PBL required 
repeated culture with rIL2 and autologous tumor cells to 
develop tumor-specific effectors, and non-specific effectors 
were produced as well. TIL from patients with sarcomas, 
lung cancers, renal cell carcinomas and carcinomas of the 
head and neck were reported to have MHC-nonrestricted CTL 
activity rather than autologous tumor cell-specific CTL 
activity after culture with rIL2 (Itoh, Platsoucas, and 
Balch 1988). But TIL from patients with lung adenomas and
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squamous cell and large-cell carcinomas of the lung, after 
culture with IL2 possessed both non-specific and specific 
antitumor cytolytic potential (Rabinowich et al. 1987).
Typically, TIL were found to be inactive when freshly 
isolated from the tumor but after culture with rIL2 
demonstrated tumor-cell cytolytic capacity. One subset of 
TIL which was originally negative for CD3 and CD8, matured 
in the presence of rIL2 to a CD8+ T-cell. These tumor- 
derived cells had greater activity against autologous tumor 
cells than similarly cultured CD8+ cells from PBL or 
lymphocytes isolated from normal lung tissue (Rabinowich. et 
al. 1987). This evidence, then, supports the thought that 
the host does mount a specific immune response to a tumor 
and that tumor-specific effector cells are either generated 
within the tumor or home there. However, the response is 
purportedly suppressed at the tumor site, perhaps by tumor- 
secreted factors. Since the tumor-specific effectors home 
to the tumor compartment and are not present in the 
peripheral blood, they would not be useful for diagnostic or 
predictive purposes unless attraction of specific subsets of 
cells to the tumor site produces an alteration of their 
prevalence in the accessible peripheral blood.
The levels of NK activity in peripheral blood (Uchida 
and Micksche 1981; Weissler, Nicod, and Toews 1987) and lung 
tissues of cancer patients have been investigated but 
without clear trends. The results obtained seemed to depend
upon methods by which the cells to be evaluated were 
isolated and purified. Studies of cells obtained by lavage 
(Berman et al. 1990; Pitchenik, Guffee, and Stein-Streilein 
1987) and by extraction from minced lung tissue (Bordignon 
et al. 1982b; Deshazo et al. 1987; Weissler, Nicod, and 
Toews 1987) indicate that monocytes can elaborate suppressor 
factors which diminish natural killer activity in the lungs 
(Uchida and Micksche 1983; Weissler, Nicod, and Toews 1987). 
Since the effect of pulmonary macrophages can be abolished 
by indomethacin, Weissler postulated that prostaglandins or 
other products of the arachidonic acid cascade could be the 
inhibiting factor. The tumor itself might also produce 
suppressor factors (North and Awwad 1990; Nakata et al. 
1985, Hakim 1988); suppression of responsiveness of NK 
correlates with stage of the disease (presumably tumor 
burden). A serum-borne factor from the blood of 
bronchogenic cancer patients blocked the activation of PBL 
LAK of both patients and of normal controls with IL2 in 
vitro, but even patients' lymphocytes could respond if human 
serum was replaced with fetal calf serum (Dunlap et al. 
1990).
It would seem then that there is considerable evidence 
that there are immune defenses against neoplasia and that 
tumor-specific and non-specific cytotoxic lymphocytes exist 
and accumulate at the tumor site. There also seem to be 
mechanisms for up-regulating and down-regulating responses.
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The establishment of neoplasia probably indicates a state of 
immune suppression mediated by tumor-secreted factors, fac­
tors secreted by host leukocytes responding to other stim­
uli, and in the case of lung cancer, by exposure to compon­
ents of tobacco smoke. The complexity of the system and the 
impossibility of reproducing the host environment in vitro 
has made it difficult to delineate the operative mechanisms.
Smoking and the immune system.
Smoking perturbs the immune system. The active 
component is unknown; approximately 6000 different chemicals 
have been isolated from cigarette smoke. A recent review 
summarizes most of the known effects in animals and humans 
of both mainstream and environmental smoke (Johnson et al. 
1990). Light-to-moderate smokers had 25% higher total 
leukocyte counts than non-smokers, but had normal to 
slightly elevated ratios of helper (CD4) to suppressor (CD8) 
subsets, while heavy smokers had a low CD4+h-CD8+ ratio 
(Ginns et al. 1982a; Petitti and Kipp 1986). Leukocyte 
counts were increased in smokers, especially in heavy (>3 0 
cigarettes per day) smokers who inhaled (Johnson et al.
1990), but the proportion of leukocytes which were lympho­
cytes was not different from that in non-smokers (Miller et 
al. 1982) . No significant age or sex effects were found in 
the leukocyte parameters measured by Miller, but the total 
population was only 95 men and women who ranged in age from
39
22 to 72 and there may not have been sufficient numbers to 
find differences. Tollerud and coworkers (1989a) found 
reduced numbers and percentage of Leu-lla+ (labels Fc 
receptor) cells (presumably natural killer cells) in both 
smokers and ex-smokers. He also found increased numbers of 
all leukocytes, a slightly higher proportion of eosinophils, 
and a higher CD4+-hCD8+ ratio among smokers compared to non- 
smokers. The percentage of CD4+ cells tended to increase 
among smokers with the number of cigarettes smoked per day 
(Tollerud et al. 1989b).
Natural killer activity in smokers, expressed as the 
percent specific 51Cr released from target cells, was 13.7 +/_ 
1.6 compared to 29.0 +/_ 3.0% in non-smoking controls (Ginns 
et al. 1985). Effector cells were peripheral blood 
lymphocytes isolated by Ficoll-Hypaque fractionation. The 
cause of this deficit could have been reduced numbers of NK 
among PBL or suppression by regulatory lymphocytes or 
monocytes. Metastasis in melanoma patients has been 
observed to be inversely associated with NK activity among 
PBL. Furthermore among persons who have had a melanoma 
excised, smokers have a higher incidence of blood-borne 
metastasis than non-smokers (Burton 1983a), suggesting that 
this was due to reduced NK activity in the blood of smokers.
Smokers average lower levels of IgG, IgA, and IgM and 
higher levels of IgE than non-smokers, but no dose-response 
relationship could be detected. Smokers responded as well
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as non-smokers to vaccination with A2 influenza but 
unprotected smokers were more susceptible to infection than 
non-smokers. In general, smokers were more susceptible to 
infections of the lungs and of the urinary tract than non- 
smokers (Johnson et al. 1990).
The effects of smoking on the immune system would 
appear to be reversible within a relatively short time. 
After cessation of smoking, NK activity, IgM and IgG levels, 
and leukocyte counts in 35 subjects returned to levels of 
non-smokers within 3 months, while the levels in 29 subjects 
who continued to smoke did not change (Hersey, Pendergast, 
and Edwards 1983). An earlier study (Miller et al. 1982) 
found that relative percentages of CD8+ T-cells and the 
CD4+-s-CD8+ ratio returned to normal among heavy smokers 
within 6 weeks of smoking cessation. These findings imply 
that any susceptibility factor, which is associated with the 
effects of smoking on the immune system, relates to one of 
the earlier steps in the carcinogenic process, since 
increased risk for developing cancer persists for a decade 
or more after one stops smoking.
Lung cancer and leukocyte subsets.
Lung cancer is a disease which is highly fatal, mostly 
because it is not diagnosed in the early, localized stage. 
What is needed is a practical, non-invasive test which can 
identify persons at high risk for, or in the earliest stages
of lung cancer. As monoclonal antibodies to leukocyte- 
subset-specific surface molecules have become available and 
more is learned about the function of lymphocyte subsets, 
interest has been generated in whether relative proportions 
of various subsets of lymphocytes in peripheral blood have 
a meaningful relationship to disease or to susceptibility 
for disease. The most well-known such link is the 
correlation between CD4+t-CD8+, helper: suppressor ratios with 
clinical acquired immune deficiency syndrome (AIDS). Is 
there a lymphocyte profile which correlates with 
vulnerability to lung cancer or with early stages of the 
disease?
Studies relating prevalence of specific subsets of 
lymphocytes to malignant disease states date back to the 
1970s. It is difficult to compare the results of these 
early studies, however, because (1) some were done by 
fluorescence microscopy and others by flow cytometry, (2) 
different antibodies were used to define the subset of 
interest, (3) the study subjects varied in characteristics 
from study to study, for example age, sex, smoking, treated 
vs untreated and stage of disease among patients, and (4) 
results were calculated as absolute counts/mm3 in some 
studies and as relative proportions in others. The 
difficulty with consideration of absolute counts/mm3 is that 
the variability of blood volume among individuals is 
introduced into the estimate. Counts may vary with state of
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hydration, leukocyte proportion, and lymphocyte proportion. 
Each subset as a percentage of total lymphocytes would 
theoretically have much better among-subjects comparability.
The studies of the mid-1970s used the presence of the 
receptor for sheep erythrocytes (CD2) to define T-cells, 
whereas today CD3 is considered to be the pan-T-cell marker 
and CD3'CD2+ NK are not regarded as T-cells. A deficit in 
CD2+ lymphocytes was noted among cancer patients, including 
lung cancer patients, in several of these early studies 
(Dellon et al., 1975; Kaszubowski et al. 1980). Dellon also 
observed a trend toward decreased numbers of CD2+ 
lymphocytes with severity of disease (control, localized, 
regional, metastatic). The differences of means among 
groups were statistically significant at P < 0.05 for
squamous cell, oat cell and undifferentiated carcinomas and 
it is likely that a test for linear trend would have proved 
significant for the adenocarcinoma group as well.
As more subset-specific antibodies became available, a 
deficiency in percentage of CD4+ helper cells and an 
increase in percentage of CD8+ suppressor/cytotoxic cells 
and major histocompatibility class II molecule-bearing 
cells (HLA-DR+) among advanced cancer patients was reported 
(Dillman et al. 1984). Similarly decreased CD4+ cells and 
increased CD8+ and HLA-DR+ cells were found among CD2+ 
lymphocytes in patients with chronic myelocytic leukemia; 
the percentage of HLA-DR+ (activated) T-cells was highly
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correlated with percent CD8+ (Velardi et al. 1984) . Velardi 
also observed that almost 14% of CD3+ lymphocytes were 
neither CD4+ nor CD8+. In fact, these cells might have been 
low-density CD8+ and not observed as positive under 
fluorescence microscopy. Estimation of CD8+ lymphocytes by 
microscopy gave values which were consistently lower than 
estimates on the same samples by flow cytometry (Kreuzfelder 
et al. 1987).
Balch reported deficits in percentages of HNK-1+ 
(CD57 + ) cells, some of which are NK, among 22 lung cancer 
patients as well as patients with melanoma and cancers of 
the breast, head and neck, and colon (Balch et al. 1982). 
Balch controlled for the effects of age and sex in his study 
and found that HNK-1+ cells were more prevalent in the older 
age groups and among men compared to women.
Ginns and his associates were the first investigators 
to control for smoking in their analyses. Persons with 
metastatic lung tumors displayed reduced percentages of CD3 + 
and CD4+ T-cells and a reduced CD4+-rCD8+ ratio. Percentage 
of CD3+ and CD8+ lymphocytes tended to increase and CD4 + 
cells to decrease with intensity of smoking. After 
adjustment for smoking, the profiles of persons with squa­
mous cell carcinoma (n=10) were not different from normal 
smokers and patients with adenocarcinoma (n=7) had decreased 
percentages of CD8+ cells and an increased CD4+-fCD8+ ratio 
(Ginns et al. 1982b). Ginns's report was based on only 17
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cases of primary lung cancer (Ginns et al. 1982a), however, 
and there may not have been enough power in those numbers to 
detect other differences which did, in fact, exist. An 
attempt to correlate subset percentages with stage of 
disease also was not definitive, probably because of the 
small number of patients (21, including metastatic lung 
tumors). There were no linear trends with three-group 
comparisons (control, limited disease, advanced disease) 
whether stage, lymph node involvement, or tumor burden were 
the criteria (Ginns, Rogol, and Murphy 1983) .
Other studies may have shown negative results because 
of size as well. Eleven patients with bronchogenic 
carcinoma were compared with 10 young non-smokers, 12 older 
non-smokers and 11 smokers. No differences were seen in 
0KT11+ T-cells (CD2, sheep erythrocyte receptor), CD4+, and 
CD8+ subsets of T-cells, NKH-1+ cells, the CD29+ subset of 
CD4+ cells, or the CD4+-j-CD8+ ratio, but the CD45R+ subset of 
CD4+ cells was reduced in the cancer patients (Kratikanont 
et al. 1987). No adjustment for age, sex, time of sampling, 
or smoking levels was done. The mean age of cancer patients 
(62.8) was considerably older than that of the other groups: 
30.9, 55.8, and 48.0, respectively.
Dellon suggests that low T-lymphocyte counts might 
antecede squamous cell carcinoma of the lung, thus being a 
susceptibility marker (Dellon et al. 1975). Or it could be 
that diminished numbers of lymphocytes, in consequence of
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the disease, might precede other signs and symptoms of 
malignancy and allow earlier diagnosis. With the present 
repertoire of monoclonal antibodies specific for markers 
which define functional subsets of lymphocytes and the 
highly developed technology of flow cytometry (Hoffman et 
al. 1980), it is now feasible to define mononuclear cell 
profiles in humans more extensively and precisely than was 
possible in some of previous studies. Furthermore, we are 
aware that it is important to control or adjust for such 
factors as age, sex, smoking, and even time that the sample 
was drawn (Levi et al 1985; Ritchie et al, 1983). Failure 
to take such factors into consideration probably explains 
many of the conflicting results in previous studies and 
inadequate sample size was responsible for inability to 
detect effects in some instances.
Flow cvtometrv.
The technology of flow cytometry continues to evolve as 
of this writing. It had its beginnings in work by Moldavan 
in 1934 and Gucker et al. in 1947, but it was Wallace 
Coulter in 1956 who developed the first useful instrument 
which could differentiate and count blood cells based on 
size (Landay, Ohlsson-Wilhelm and Giorgi 1990). The 
Herzenbergs at Stanford designed an instrument which could 
separate cells stained with fluorescence-labelled 
antibodies. Their 1972 version incorporated an argon laser 
and was subsequently developed by Becton Dickinson
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Immunocytometry Systems (BD) into the 1986 FACS 440 used in 
this study (Landay, Ohlsson-Wilhelm and Giorgi 1990). 
Improved, more versatile, and more user-friendly 
fluorescence-activated cell sorters (FACS) continue to be 
developed .
Concise descriptions of the mechanics of cell sorting 
and analysis is given by Landay (Landay, Ohlsson-Wilhelm and 
Giorgi 1990), Jackson (Jackson and Warner 1986), and Haynes 
(Haynes 1988). Briefly, it is accomplished by passing a 
suspension of fluorochrome-labelled cells through a small 
orifice, such that the cells pass one at a time through the 
laser beam. Light is scattered at small angles which depend 
upon the size of the cell and at wide angles (90°) in a 
manner that is characteristic of the internal structure or 
granularity of the cell. If the cell bears one or more 
specific markers labelled by fluorescein- (green-) or 
phycoerythrin- (red-) tagged ligands (usually antibodies), 
light energy is absorbed as the cell passes through the 
laser beam and light is emitted at wavelengths 
characteristic of the fluorochromes used. The scattered 
light and fluorescence emissions are detected and measured 
using an optical system composed of selected light filters, 
photodiodes, and photomultiplier tubes. Signals are then 
amplified, digitized and stored by a computer for further 
processing.
An instrument with a single laser is able to measure up 
to four attributes of each cell: size, granularity, and the 
presence (or absence) and surface density of up to two cell- 
surface antigens. Forward scatter (size) and side scatter 
(granularity) can be used to discriminate lymphocytes from 
granulocytes, monocytes, and erythrocytes. Then with 
appropriate antibodies to cell-surface molecules which 
distinguish subsets of lymphocytes from one another in terms 
of their function, one can estimate the relative abundance 
of functional subsets of interest among lymphocytes from the 
peripheral blood.
Problems have arisen when flow cytometric data from one 
laboratory was compared to that of another (Ault 1988). 
Differences in instruments from different manufacturers and 
the difficulty of maintaining the same analytical 
environment from day to day using the same instrument induce 
variability. Handling of samples and methods of labelling 
also affect the results obtained (Ashmore, Shopp, and 
Edwards 1989; Green and Stelzer 1988; Landay and Muirhead
1989). Cell surface differentiation antigens in human 
blood were found to be stable for up to three days when the 
whole blood was stored at room temperature (Shield et al.
1983), but when stored at 4°C overnight, reactivity toward 
Til, 0KT3, and 0KT4 antibodies was decreased while levels of 
0KT8 remained the same (Weiblen, Debell and Valeri 1983). 
Bongers and Bertrams (1984) report good stability if
lymphocytes were isolated soon after drawing the blood and 
then stored in a lymphocyte stabilization medium (Park and 
Terasaki 1974) for up to 72 hours. Ashmore (Ashmore, Shopp, 
and Edwards 1989) report lower viability in cells isolated 
from blood which had been stored for 24 hr. at 4°C, a higher 
percentage of CD20+ B-cells, and lower percentages of 0KT3+, 
0KT4+, and 0KT8+ as well as lower CD8+CD11' and CD4+CD29+ 
subsets. Samples labelled, then fixed with paraform­
aldehyde2 were stable for some parameters for up to two 
weeks at 4°C if washed with Hank's balanced salt solution 
after fixation, but unwashed, fixed cells changed in forward 
scatter properties and diminished in fluorescence intensity 
over a 2-week period (Lai, Edison, and Chused 1988).
The time of day and the time of year in which the 
sample is drawn has to be taken into consideration. Diurnal 
variation in the total WBC and percentage of lymphocytes 
has been documented (Levi et al. 1985; Ritchie et al. 1983) 
but there was less variation in the percentages of subsets 
than in the cellular concentration (cells of each subset per 
mm3) in the blood (Kidd and Vogt 1989) . In fact in
Ritchie's work, when results were expressed as percentage of 
total lymphocytes, only Leu-3a+ (CD4) and HNK-1+ (Leu-7, 
CD57) subsets varied significantly. Giorgi (1986) also
2(CH20)n, a polymeric form of formaldehyde.
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reported that percentages and numbers of CD4+ cells vary in 
a circadian manner, dropping between 8:00 a.m. and noon, 
then rising throughout the afternoon and sustaining their 
highest numbers throughout the night. CD4+-j-CD8+ ratios, 
then, showed a parallel circadian variation. There was 
seasonal variation, as well (Abo et al. 1984; Levi et al. 
1988) . The numbers of subjects used and the numbers of time 
intervals at which measurements were taken in these studies 
were too small to adequately define seasonal patterns.
Delay in processing samples can result in lower 
viability of cells and lead to differential loss of subsets 
(Park and Terasaki 1974; Ashmore, Shopp, and Edwards 1989) . 
Procedures utilized to reduce or eliminate extraneous cells 
from the sample can also lead to selective loss of subsets 
of interest. For instance separation of lymphocytes from 
other leukocytes on a Ficoll-Hypaque density gradient (FH) 
resulted in differentially lower estimates for CD8+ cells 
and in decreased stability of fixed, labelled cells compared 
to those from lysed, whole blood (Renzi and Ginns 1987). 
DePaoli and coworkers also reported selective loss of CD8+ 
cells using FH and increased percentages of large granular 
lymphocytes with the Leu-7+CD16+ phenotype (DePaoli et al.
1984) . Still another group reported that FH separation 
resulted in lower estimates on all markers measured compared 
to measurements on lysed whole blood (Green and Stelzer 
1988) . Although gradient centrifugation is done to remove
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monocytes and granulocytes, in fact there are residual cells 
of these types retained in the sample and the longer the 
blood is kept before processing, the greater the problem. 
It is thought that the lower estimates and increased 
variability with this method may be due to this 
contamination with unwanted cells (Green and Stelzer 1988) .
Investigators disagree with respect to the methods for 
gating of data, that is, the selection of the events which 
are to be considered lymphocytes. One's results are highly 
dependent upon the base population selected for the 
denominator and how comparable that is from subject to 
subject (Vitale et al. 1987). The problem arises because 
monocytes and residual erythrocytes and platelets overlap 
the limits of the lymphocyte population in scatter 
properties. To minimize the number of non-lymphocytes in 
the denominator population a window is selected which 
includes most, but not all of available lymphocytes. But 
the various subsets of lymphocytes are not completely 
homogeneous in scatter properties either. NK cells are 
larger and more granular than most lymphocytes; B cells and 
CD4+ T-cells are characteristically small. Estimates of NK 
cells, B cells, and of CD4+ cells were proportionally biased 
depending upon whether a gate containing 95% of lymphocytes 
or one containing 98% of lymphocytes was chosen (Loken et 
al. 1990). Fleisher also demonstrated that natural killer 
cells, some T-cells including the majority of HLA-DR+ T-
cells, and some B-cells are excluded from the tight window 
'•usually" chosen to select lymphocytes (Fleisher, Marti, and 
Hagengruber 1988). He proposed monocyte depletion via 
treatment with nickel carbonyl before gradient 
centrifugation so that open gating (no gating) could be 
used. Recently systems of gating based on identifying 
lymphocytes by two-color distribution on a pair of 
antibodies which label lymphocytes, monocytes, and 
granulocytes differentially have been developed to help to 
define the best scatter window for lymphocytes (Loken et al.
1990) .
Monoclonal antibodies with the same molecular 
specificity (see Table 1) often give different estimates of 
percentage positive, perhaps because of differing affinity 
of binding, or a difference in the epitope bound (Kootte et 
al. 1988) . For instance CD4+-rCD8 + ratios were greater when 
the BD antibodies Leu-3 (CD4) and Leu-2 (CD8) were used than 
those obtained when the Coulter reagents T4 and T8 were 
employed (Schuerch et al. 1987; Henny et al. 1986b). 
Antibodies are not always as specific as first thought. 
They may not label 100% of the subset which they supposedly 
define and they may label small numbers of other subsets. 
For example, Leu-7 (CD57; Knapp et al. 1989a) was first 
thought to be a marker for NK (Lanier et al. 1983) ; it 
labels 40-60% of all large, granular lymphocytes (Weissler 
et al. 1987), but it was also found on a subset of CD8 +
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CLUSTER
CD Number
CD2
CD3
CD4
CD7
CD8
CD11
CD14
CD16
CD22
CD29
CD45r
CD56
CD57
(none)
TABLE 1
DIFFERENTIATION ANTIGENS
Clones
OKT11, Leu-5b 
OKT3, Leu-4 
OKT4, Leu-3a 
T3-3A1
OKT8, Leu-2
Leu-15, OKM1
63D3, Leu-M3 
Leu-llb 
Leu-14 
4B4
2H4, Leu-18
NKH-1, Leu-19 
HNK-1, Leu-7 
MMA
Target Cell
T-cells, NK
Mature T-cells
Helper T-cells
T-cells, NK, 
B-cells(?)
Cytotoxic/Suppressor 
T- cells, NK
Suppressor subset 
of CD8+ T-cells, 
Monocytes and 
neutrophils
Monocytes
NK and neutrophils
B-cells
Memory T-cells
Naive T-cells, NK, 
B-cells
NK
NK, T-cell subset
Neutrophils, mono­
cytes, activated 
T-cells
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cytotoxic T-cells, on a subset of B-cells, on brain cells, 
and curiously enough, on some small-cell lung tumor cell 
lines (CD56 or NKH-1 was also present on those small-cell 
tumor lines; Koros et al. 1986). Later it was found that NK 
function was restricted to those CD57+ cells which also 
carry the Fc receptor CD16 (Lanier et al. 1986a). The NKH-1 
antibody (Griffin et al. 1983) is thought to be more 
sensitive and specific than Leu-7 for cells with NK 
activity. Not all CD8+ cells carry CD3 either; CD8 is found 
on some NK-cells, which are CD3' (Ault 1988), but CD8 is at 
lower density on NK-cells than on T-cells (Perussia, 
Fanning, and Trinchieri 1983).
Choice of fluorochrome can affect the determination of 
proportion that are positive by 3 percentage points or more 
(Kootte et al. 1988). Whereas phycoerythrin (PE) is a good 
partner to use with fluorescein isothiocyanate (FITC) for 
double-labelling experiments, it must be kept in mind that 
the phycobiliprotein PE is a very large molecule (72-240 kd) 
which can in some cases interfere with antibody binding 
(Hoffman 1988) .
Flow cytometric lymphocyte subset profiles.
Giorgi (1986) asserted that "standards for normal 
levels of the various lymphocyte subsets have not been 
established, so that each laboratory must generate its own 
reference range. "There is no 'gold standard' against which
flow cytometric data can be measured" (Kidd and Vogt 1 9 8 9 ) .  
Variations associated with gender, age, race, and smoking 
have been described. A decrease in the percentages of C D 3 + 
cells and of C D 8 + cells has been observed among elderly men 
compared to men under 4 0  years of age (Nagel, Chrest, and 
Adler 1 9 8 1 )  . The deficit in CD8 was also reflected in a 
higher C D 4 +-rCD8+ ratio among older men. The proliferating 
capacity of C D 8 + cells and their cytolytic capacity seem to 
diminish in older subjects as well (Mariani, et al. 1 9 9 0 ) .  
Lymphocytes with the marker of naivete, C D 4 5 R ,  decrease with 
age and their reciprocal subset ( C D 2 9 + ) increase. The 
percentage of C D 4 + cells with neither C D 4 5 R  or CD29  
increases also. The proportion of lymphocytes with a NK 
phenotype increases throughout life (Abo, Cooper, and Balch
1 9 8 2 )  .
Alterations occur in leukocyte subset balance during 
viral or bacterial illness. Expansion of lymphocyte 
populations in the former or macrophage and granulocyte 
populations in the latter are expected. Chronic exposure to 
UV radiation such as in sunbathing has been shown to depress 
levels of circulating CD4+ cells (Burton et al. 1983b).
Markers used in this study.
For purposes of clarity, each reagent antibody should 
be referenced by the CD designation of its target antigen, 
the unique name assigned by the World Health Organization
(WHO) Subcommittee on Immunology (Knapp et al. 1989), rather 
than by the common name determined by its origin. Various 
clones raised against particular cell-surface molecules, 
such as the OK series developed by Ortho Pharmaceutical Co. 
(Kung and Goldstein 1980) or the Leu- series developed by 
BD, received common names at development and before they 
were typed by WHO, but have a single CD designation which is 
specific for the cell-surface molecule to which they bind. 
They do not necessarily bind the same epitope, but do react 
with the same molecule. It is important to note, however, 
which particular clone is utilized in a specific study 
because of the small differences in estimated percentage 
positive which were noted above for different clones with 
the same CD specificity.
CD3 is the non-variant, T-cell-glycoprotein molecule 
which is associated with the receptor complex Ti for 
antigen. Although the bonding between CD3 and Ti is not 
covalent, the molecules co-modulate from the cell surface 
when either is precipitated by its antibody. Most CD3 
antibodies induce proliferation of cultured PBL, and induce 
non-specific cytotoxicity in a test cytotoxic T-cell clone. 
Added to unseparated PBL, CD3 antibody enhances poke-weed- 
mitogen-induced production of IgM, however if B cells and T 
cells are first isolated then recombined, the effect of CD3 
antibody is to down-regulate IgM production (Gorog, Batory, 
and Lanzaveccia 1987). The precise function of the CD3
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molecule is unknown but it may be involved in signal 
transduction (Krensky, Lanier, and Engleman 1985). The 
lymphocytes which bear this molecule are a subset of cells 
bearing CD2, the receptor for sheep erythrocytes. Cells 
which bear CD2 but not CD3 are considered to be NK cells and 
conversely, most cells which have NK activity do not 
express the CD3 molecule.
CD7 might function as an Fc receptor for IgM, although 
some cell lines are positive for CD7, yet do not bind IgM. 
It is thought that the 3A1 antibody binds an epitope on the 
CD7 molecule other than the Fc receptor and that the latter 
is mutated in the cell lines which do not bind IgM. It is 
found on most, but not all T cells and some NK cells (and 
perhaps on a "small" subset of B cells; Sandrin et al. 
1987). Modulation of the CD7 molecule causes a partial 
inhibition of the mixed lymphocyte reaction (Lazarovits et 
al. 1987). a-CD7 binds up to 85% (Haynes, Eisenbarth, and 
Fauci 1979; Haynes et al. 1980; Eisenbarth et al. 1980) of 
CD2+ lymphocytes (T cells and NK cells) in peripheral blood. 
Since this antibody was readily available, it was included 
in the panel to be compared with the CD3 antibody in the 
proportion of cells bound.
The CD4 molecule discriminates the helper/inducer 
subset of T cells and is also found at low density on 
monocytes. Helper cells are necessary accessory cells for 
antigen-specific immune responses and normally comprise
about 60% of T cells in peripheral blood. Antibodies 
reactive with the CD4 antigen may be specific for any one of 
5 to 7 available epitopes. Certain individuals have been 
found whose lymphocytes are not reactive or have very low 
reactivity to OKT4, yet they react with another a-CD4, Leu- 
3, and apparently function normally (Taylor et al. 1987). 
CD4 appears to function as a receptor for the invariant or 
monomorphic part of the class II major histocompatibility 
antigen (MHC). Short peptide sequences have been identified 
which bind either to the J3, domain of HLA-DR or to the outer 
surface of the CD4 molecule and block the interaction of the 
two cells (Durandy and Fischer 1987). The CD4 molecule is 
essential, then, for antigen-presenting cells to activate 
helper cells and it also functions as the receptor for class 
II MHC antigen on target cells on the rare occasion when a 
CD4 lymphocyte differentiates into a cytotoxic effector.
a-CD45 designates antibodies which bind to "leukocyte 
common antigen," a 180-220kd glycoprotein molecule found on 
more than 95% of all leukocytes. A variant of this molecule 
is designated CD45R or CD45restricted. Cells which bind a-CD45R 
antibodies at high density have the characteristics of naive 
or less mature lymphocytes. When activated by
phytohemagglutinin (PHA) they convert to expression of CD29 
at high density and reduced expression of CD45R, and they do 
not revert when stimulation is discontinued (Sanders, 
Makgoba, and Shaw 1988). The addition of a-CD45R with PHA
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enhances cell proliferation, probably by up-regulating the 
receptor for interleukin 2 (IL-2, Cobblod, Hale, and
Waldmann 1987; Ledbetter et al. 1985).
The CD45R+ subset had previously been described among 
CD4+ T cells as suppression inducers since they induced CD8+ 
T cells to inhibit the production of immunoglobulin by poke- 
weed-mitogen-driven B cells (Morimoto et al 1985a), but 
could not provide help for antibody production. The CD29+ 
subset were considered the help inducers because they could 
enhance production of antibody in response to antigen 
stimulation. Further studies led to a reinterpretation, 
however. Upon stimulation with immobilized a-CD3, neo-natal 
and presumably naive T cells, which are high in CD45R and 
low in CD29, were capable of producing IL-2 upon 
stimulation, but not the repertoire of cytokines with which 
adult T cells responded (Ehlers and Smith 1991). Since IL-2 
is all that was required to generate cytotoxic effector 
cells against allogeneic targets (Yamashita, Bullington, and 
Clement 1990), it is possible that the induction of 
suppressor cells requires only IL-2 as well, thus explaining 
the observed effects of CD45R+ T cells. The CD45R molecule 
is found on approximately 42% of unfractionated peripheral- 
blood T lymphocytes, on about the same fraction of CD4+ T 
cells, on 54% of CD8+ T cells, on 5-30% of monocytes, and on 
over 30% of B cells and null cells in the peripheral blood 
(Coulter Immunology product bulletin 1988).
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Lymphocytes which express high densities of CD45R carry 
little CD29 and vice versa. CD29 was first used to identify 
a subset of CD4+ T cells. The function associated with this 
marker was the provision of help for PWM-driven 
immunoglobulin production by B cells, for which the subset 
was characterized as a helper-inducer population. CD4+ T 
cells bearing CD29 were also observed to act as inducers of 
activation among CD8+ cytotoxic T cells (Kalish, Morimoto, 
and Schlossman 1985).
The CD2 9bright subset proliferates sluggishly when 
stimulated by Concanavalin A or in the autologous mixed 
lymphocyte reaction AMLR, while its reciprocal subset, the 
CD45Rbright subset, responds well in AMLR (Morimoto et al. 
1985b). CD4+CD45R+ T cells also are activated by 
immobilized anti-CD3 antibody and cytokines, whereas 
CD4+CD29+ cells are not (Wasik and Morimoto 1990). This is 
what one might expect from immature cells and differen­
tiated cells, respectively. Later work led to the sugges­
tion that CD29+ cells would be better described as memory 
cells since they respond to specific antigen to which they 
were sensitized in vivo. Consistent with this definition is 
the observation that they are rarely found in neonatal cord 
blood and increase in prevalence with age (Sanders, Makgoba, 
and Shaw 1988; DePaoli, Battistin, and Santini 1988). Since 
the proportion of antigen-specific cells increases with age, 
this might be one reason why the T cells of older people are
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less responsive to non-specific stimuli like lectins. 
Weksler found that older people had the same number and 
percentage of T cells as the young but that only V 4 to V 2 °f 
them could proliferate in response to lectins (PHA; Weksler 
1980) . The 4B4 (CD29) antigen is found on about 41% of
peripheral blood T cells, on a similar proportion of CD4+ T 
cells, on 43% of CD8+ T cells, on 5-30% of B cells, and on 
over 30% of null cells, macrophages and thymic lymphocytes 
(Coulter Immunology product bulletin 1988).
Whereas CD29 and CD45R are expressed in high density on 
mutually exclusive subsets of CD4+ T cells, there are some 
16-30% of helper/inducer cells which do not express large 
quantities of either (Coulter product bulletins; Morimoto 
1985a) . The proportion of CD45R'CD29' cells increases with 
age. Could these perhaps represent tolerized cells? When 
the cells identified by expression of CD29 or CD45R were 
defined as help-inducers or suppression-inducers, the 
inclusion of those antibodies in this study seemed more 
relevant. With the present understanding of CD29 and CD45R 
as markers of memory and naive cells, respectively, the 
meaning of any differences found between subgroups will not 
be as easily interpreted.
The subset of CD3+ T cells which is the reciprocal of 
the CD4+ population, bear CD8 . Normal ratios of CD4 to CD8 
T cells are approximately 3:2, but variation around that 
value is considerable. Immature thymocytes can carry both
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CD4 and CD8 molecules, but mature PBL bear one or the other. 
CD8 cells function predominantly as cytotoxic effectors or 
suppressor cells, although CD8+ cells with helper function 
have been documented. The ratio of CD4 to CD8 is thought to 
reflect balance in immune status.
The CD8 antigen functions as the receptor for a 
monomorphic epitope on Class I MHC molecules. Antigen- 
specific cytotoxic T lymphocytes can kill only cells which 
bear autologous Class I molecules. Antibody to CD3 can 
induce non-specific cytotoxicity in a CD8+ cell line. The 
reaction against a Class-I negative target cell line was 
inhibited by many anti-CD8 antibodies including many which 
did not bind epitopes which recognize Class I antigen. This 
would indicate more of a regulatory role than one of cell 
adhesion for the CD8 molecule (van Seventer et al. 1987).
Little is known about the mechanisms by which CD8+ 
suppressor cells are activated and function. The role of 
antigen is unclear since antigen-depleted CD4+ inducer cells 
were able to cause CD8+ responders to differentiate into 
antigen-specific suppressor cells and only CD3 and Class I 
MHC molecules on the inducer cells were required. The CD3 
and CD8 molecules were essential on the responder cell 
(Krensky, Lanier, and Engleman 1987) . Cross-linkage of CD3 
with CD8 or CD4 molecules on a lymphocyte activates the 
cell. Furthermore cross-linkage of CD3 with either CD8 or 
CD4 mediated by either MHC Class I or MHC Class II molecules
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in the thymus may determine whether a specific immature 
CD4+CD8+ thymocyte develops into a helper (CD4+) or a 
cytotoxic/suppressor (CD8+) lymphocyte (Emmrich 1987).
The FITC-conjugated Leu-2a was used for double­
labelling with PE-conjugated C D l l b - r C D 1 8 .  C D l l b / C D 1 8  is the 
receptor for the inactivated form of bound complement 
molecule C3 (C3b;) and its function on granulocytes is to 
induce phagocytosis. It is curious that it identifies the 
subset of CD8+ cells with suppressor function rather than 
cytotoxic cells (Clement, Grossi, and Gartland 1984a). 
CDllb/CD18 belongs to a family of leukocyte function- 
associated antigens (LFA) which all share a common 90kd B- 
chain glycoprotein, designated CD18, and varying a-chains. 
This family of molecules mediates intercellular adhesion 
among leukocytes. From inhibition studies CD18 seems to be 
the molecule which effects adhesion; antibodies to the en­
chains are less than 10% efficient at inhibiting adhesion 
among polymorphonuclear leukocytes (PMN; Patarroyo and 
Ansotegui 1987).
CDllb antibodies precipitate a glycoprotein of 155kd 
found on monocytes and PMN, but only on CD8+ suppressor 
lymphocytes and some NK cells (Zarling and Kung 1980; 
Clement, Dagg, and Landay 1984b. The CDllb+ NK subset 
probably also is dimly CD8+ which means that the only way to 
distinguish them from CD8+CDllb+ suppressor T cells is 
through the presence or absence of the CD3/T.i complex.
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0KM1 is another antibody to CDllb. Cross-linking C3b; 
receptors on monocytes and PMN enhances phagocytosis of IgG 
coated particles via Fc receptors and under certain 
circumstances, also allows the internalization of soluble 
ligands and C3bi-coated particles in the absence of IgG. 
The exposure of PMN to sheep erythrocyte ghosts coated with 
C3bi induced a respiratory burst (Fearon and Wong
1983).
W6/32 binds a monomorphic determinant on the Human 
Lymphocyte Antigens (HLA) A,B, and C, the MHC class I 
antigens. It not only precipitates these molecules from the 
PBL of all humans, it reacts with the PBL of all primates. 
In addition to lymphocytes W6/32 is found on PMN, monocytes, 
and eosinophils, but not on erythrocytes (Barnstable et al. 
1978). The presence of the associated B2 microglobulin is 
essential to retain the conformation of the antigenic site, 
but W6/32 does not bind to the smaller molecule (Brodsky 
and Parham 1982; Parham, Barnstable and Bodmer 1979). W6/32
should label all living PBL giving an estimate of the 
quality of the sample.
One of the human MHC class II antigens is commonly 
designated HLA-DR. L243 was identified as an antibody to a 
monomorphic determinant on this highly polymorphic molecule 
(Lampson and Levy 1980). B cells and monocytes present 
antigen to T cells in the context of HLA-DR molecules. CD4 
on helper/inducer T cells acts as a receptor for a
monomorphic determinant on the HLA-DR molecule while the 
CD3/T.i complex interacts with antigen and another portion of 
the HLA-DR molecule. HLA-DR can also be expressed by 
activated T cells as demonstrated in allogeneic mixed 
leukocyte culture (Evans et al. 1978). It will appear on 
CD8+ cells during cytomegalovirus infection and efforts have 
been made to correlate levels of HLA-DR on PBL and rejection 
of renal transplants (Henny et al. 1986a). In this study, 
the number of activated T cells can be estimated by the 
difference between the prevalence of HLA-DR+ lymphocytes and 
the number of B cells.
A surface marker which normally appears only on 
activated cells is the receptor for transferrin (CD71), the 
protein which transports iron in the bloodstream (Goding and 
Burns 1981). Resting, normal cells do not express this 
molecule and thus PBL should be negative for it.
Another marker of activation is the interleukin 2 
receptor (IL-2R, CD25). Exposure to mitogens or antigen 
stimulates T cells to express the receptor for this growth 
regulating lymphokine. Increased numbers of PBL show this 
marker in the presence of an acute viral infection (Coulter 
Immunology product bulletin, 1986) . Cross-linking of CD2 or 
CD3 is another stimulus which increases the expression of 
IL-2R. For a long time the presence of this molecule on T 
cells only was studied, but subsequently it was recognized 
that activated monocytes and activated B cells could also
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bear IL-2R (Herrman et al. 1985; Olive et al. 1986). There 
is evidence that CD3' NK also are responsive to IL-2 
(Trinchieri 1986). There are actually two IL-2R/s, a high- 
affinity receptor on a 75kd protein and a lower-affinity Tac 
antigen on a 55kd molecule which is highly glycosylated. 
The two molecules appear on the surface of the cell as a 
complex. The "anti-Tac" antibody binds to the low affinity 
receptor but blocks the binding of IL-2 to the high-affinity 
receptor thus blocking many IL-2-dependent immune responses 
(Waldmann, Goldmann, and Tsudo 1987).
The antibody 63D3 reacts with the CD14 molecule which 
appears in high density on monocytes. Granulocytes and B 
cells stain weakly and lymphocytes other than B cells do not 
react at all. Some granulocytic leukemias also react weakly 
(Ugolina et al 1980). The glycoprotein is also found in 
varying amounts in the blood as though it is a peripheral, 
easily shed molecule (Bazil, Horejsi, and Hilgert 1987). 
This antibody is useful for estimating the amount of 
monocytic contamination within the lymphocyte scatter 
window.
The antibody MMA reacts with an antigen found 
predominantly on cells of myelomonocytic origin, but which 
can be induced on T cells, particularly CD4+ helper/inducer 
cells, by culture with ConA. Depletion of MMA+ cells 
abrogated proliferative reponses in the remaining cells to 
mitogens and antigen, but the addition of 10% MMA+ cells
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restored proliferative capacity. The antigen is present on 
the bone marrow cells which are the precursors of 
granulopoietic colony-forming cells (Hanjan, Kearney, and 
Cooper 1982). MMA on a lymphocyte, then, probably indicates 
an activated T cell. In our hands, the MMA antibody in 
excess was lytic to monocytes and granulocytes.
Most peripheral blood B cells express a glycoprotein 
antigen, which exists as a heterodimer with glycoprotein 
chains of 130 and 140 Jed (Ling, Maclennan, and Mason 1987) . 
Cross-linking of this antigen does not activate B cells of 
itself, but will enhance activation by anti-Ig antibodies or 
by antigen, and the presence of CD22 is necessary for Ca2+ 
influx and activation to be induced by anti-/x antibodies 
(Pezzutto, et al. 1987) . CD22 is exclusively a B-cell 
antigen, i.e., is not expressed by T cells, monocytes, 
platelets, granulocytes, thymocytes, or activated T cells. 
It is characteristically strongly expressed on Hairy-Cell 
Leukemia cells, and is found on all non-Hodgkin's lymphomas 
of B-cell type which were tested (Schwarting, Stein, and 
Wang 1985).
There is a subpopulation of lymphocytes which are 
larger than other lymphocytes and contain cytoplasmic 
azurophilic granules. Among these are cells which have the 
ability to Jcill tumor cells, particularly those of the K562 
line, without antigen- or MHC-restriction. They have been 
called "natural killer" cells (NK) and are thought to be an
important defense against neoplastic processes. While there 
are subsets of CD3+ cells which have natural killer 
activity, NK are generally considered to be CD3'. The 
genes which code for the T-cell antigen receptor T; are 
neither rearranged nor expressed on NK. Most if not all NK 
bear Fc receptors (CD16) and the CD11/CD18 LFA-1 complex and 
blocking either of these will inhibit NK function. 
Crosslinking CD2 on these cells enhances their effector 
capacity. While the above molecules seem to participate in 
NK function, they are not unique to NK but are expressed by 
other cytotoxic effectors as well. At least some NK are
able to respond to IL-2, but it is not known that all NK
respond (Hercend et al. 1985; Trinchieri 1986). Therefore
there has been considerable confusion about the phenotype 
and properties of the NK.
NKH-1 (against CD56) is an antibody which is thought to 
be more specific for lymphocytes with natural killer
activity than any other marker found thus far. CD56 is an 
isoform of the neural cellular adhesion molecule (N-CAM) and 
thus is found on neuroectodermal cells. NKH-1 has also been 
detected on human small-cell lung tumor lines and is found 
on a primitive invertebrate, the sea urchin. The latter 
suggests evolutionary conservation of the molecule (Koros et 
al. 1987). Addition of an IgM NKH-1 antibody and complement 
to lymphocytes removed essentially all NK activity (Hercend 
et al. 1985) as did FACS elimination of lymphocytes labelled
with the IgGl NKH-1 antibody (Griffin et al. 1983) and with 
the Leu-19 antibody to CD56 as well (Lanier et al. 1986b). 
NKH-1 was found on 9 of 9 NK lines, one of which also bore 
CD3 (Lanier et al. 1986b). In double-labelling experiments, 
27% of NKH-1+ cells expressed CD8, 74% were CD2+, 80% were 
CDllb+, 85% bore Leu-7 (CD57), while 2% or less expressed 
CD3, CD4, HLA-DR, CD14 (monocytes), or CD20 (B-cells) . 
Addition of OKM1 antibody (a-CDllb) with complement 
diminishes NK activity but does not eliminate it (Zarling 
and Kung 1980). Therefore, while CD56+ cells seem to 
include all of those lymphocytes with natural killer 
activity, they are heterogeneous with respect to other
surface markers and it may be that not all CD56+ cells are
NK.
The consensus is that cells with natural-killer 
activity bear a Fc receptor for IgG (CD16; Phillips and 
Babcock 1983). CD16 is involved in cellular activation; 
specifically bridging of the CD2 molecule to the CD16
molecule is required for enhancement of NK cytolysis.
Certain antibodies are capable of forming such a bridge and 
hence activating the cell, or at higher temperatures (37°C), 
co-modulating CD2 and CD16 from the surface (Anasetti et al. 
1987). Antibodies which bind only CD2 or only CD16, 
however, do not co-modulate the other molecule, so there is 
no evidence for association of CD2 and CD16 such as that 
which exists between CD3 and T;. In addition, enhancement
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or inhibition of NK function can be produced by antibodies 
reacting with either CD2 or CD16 individually depending upon 
the epitopes to which they bind (Uggla et al. 1987) . CD16 
is also found on neutrophils, but is not the same molecule 
as the Fc receptor on B lymphocytes. a-CD16 (Leu-llb) does 
not label monocytes (Perussia et al. 1984).
Susceptibility to lung cancer seems to have multiple 
components, which can interact with environmental, genetic, 
and behavioral factors. Furthermore all of these things 
impact immune defenses. In the study of disease etiology 
and particular factors, it is vital to measure and adjust 
for other factors known to be involved. Otherwise the 
results of studies done under varying conditions may be 
inconsistent, non-comparable, and of limited value. 
Accounting for known components of the variance in data also 
increases the probability of recognizing additional effects 
because the variance properly attributed to each factor 
comes out of the "error" variance. The statistical test for 
the significance of a factor is, of course, based on the 
ratio of the effect variance to the error variance.
MATERIALS AND METHODS
Selection of study subjects.
Lung cancer cases were volunteers from among white male 
patients who came to Mary Bird Perkins Cancer Center (PCC) 
for irradiation of their tumors between January 29, 1988 and 
January 4, 1990. Patients were considered eligible for the 
study if they had not received prior radiation treatment or 
chemotherapy for their disease and were judged by their 
doctors to be strong enough to participate.
Healthy white males of a similar age to the patients 
were needed for comparison subjects. A man was not 
eligible if he had ever had a cancer other than skin cancer. 
A two-to-one ratio of smokers to non-smokers was sought, 
such that smokers might be discriminated into a group more 
like patients and a group more similar to non-smokers. A 
3:1 ratio of controls to patients was planned in order to 
optimize the efficiency of the study (Rothman 1986, 99) .
Volunteers were recruited from among spouses of female 
patients at PCC, from community and civic organizations 
within the 11-Parish area which comprises the Mary Bird 
Perkins Tumor Registry (Figure 1) , and from among those 
informed of the study through a brochure (Appendix B) 
displayed at PCC.
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Figure 1. The Mary Bird Perkins Tumor Registry 
jurisdiction.
Initial contact with an organization was made by mail. 
A brief description of the study and a copy of the 
questionnaire accompanied a request to address a regular 
meeting of the group for the purpose of recruiting 
volunteers. At a typical meeting, a short presentation 
about cancer in general and this study in particular was 
delivered using simple visual aids, then volunteers were 
invited to participate. A medical technologist was brought 
to each group so that the blood sample could be drawn 
immediately and with the least inconvenience to the 
volunteer. Participants signed the consent form, the blood 
was drawn, and then each was given a questionnaire to be 
completed at home, and an addressed, stamped envelope for 
its return.
The questionnaire.
The questionnaire for this study (Appendix A) was 
designed to assess variable personal attributes and 
behaviors, which are thought to impact the immune system and 
to affect one's susceptibility to lung cancer, such as 
ethnicity, socioeconomic status, geographic area of 
residence, familial history of cancer, occupational history, 
exposure to certain chemicals and metals, diet, and smoking 
practices. The majority of the questionnaire, in particular 
the dietary section, was an adaptation of the Health Habits 
and History Questionnaire (HHHQ), version 02, designed by 
Gladys Block of the National Cancer Institute (Block et al.
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1986).* The software used to estimate nutrient intake was 
the 1989 version 2.2.
The questionnaire borrowed some life-style items (with 
permission) from a questionnaire designed by Dr. Marise 
Gottlieb specifically for case/control studies of cancer in 
Louisiana. Questions concerning the relevance of current 
dietary habits to those which were practiced some years 
ago2, about medications, about recent illnesses and history 
of atopy or autoimmune disease, and about a second 
occupational history were the additions of this author. By 
using mostly items which had already been used successfully 
in questionnaires, the issue of pretesting was largely 
circumvented. The final version was, however, given to 4 
individuals with characteristics similar to those of the 
study subjects, to be sure that there were no problems of 
clarity and to estimate the time that was required to 
complete it (45-60 minutes).
A subject was given 2-3 weeks to return his 
questionnaire before being reminded by telephone. Subjects 
who were delinquent were contacted at least twice. If a 
patient became too ill or died before completing his
Available along with the companion nutrient analysis 
software for use in any study from Gladys Block, PhD., 
Epidemiologist, Applied Research Branch, Division of Cancer 
Prevention and Control, National Institutes of Health, 
Bethesda, MD 20892.
2It is commonly recognized that the development of 
cancer usually involves a period of latency of 5-20 years 
following the initial event.
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questionnaire, his spouse or next of kin was asked to 
complete it.
Questionnaires were coded and keyed into files using 
the Statistical Analysis System3 (SAS) program editor. To 
verify data entry, the data files for each subject were 
printed and visually compared, byte by byte, with the coded 
columns on each questionnaire. Additionally the letter 
codes, which are card codes in the original HHHQ, were 
retained in the data stream to serve as markers for specific 
positions in the data records and used to check for 
misalignment of the data via a character left out of or an 
extraneous character inserted into the input stream. The 
appropriate food-frequency data were abstracted from the 
questionnaire file and formatted into 12 80-column records 
as required by the diet analysis software. Dietary analysis 
was conducted using the options in Table 2.
The Block dietary analysis software incorporates 
strategies for detecting possibly invalid data. The main 
criteria for flagging a subject were (1) too many items were 
skipped, (2) no serving size was used, (3) the number of 
different foods eaten daily was too small, (4) the frequency 
of eating a particular food was too high, or (5) too many 
items were coded with the same serving size. This software
3SAS Institute Inc., SAS Circle, Box 8000, Cary, NC 
27512-8000.
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DIET
OPTION 
Addfats = Yes
Addfib = No
Addsalt = Yes
Advise = No 
Bigfat = No
Carotfib = Yes
Codecer = Yes
Colapsxl = No 
Cutoff = 4 
Darkques = No 
Dietques = Yes 
Dropfood = 0
TABLE 2
ANALYSIS OPTIONS IN EFFECT
INTERPRETATION
Use information on fats used in 
cooking and added to vegetables.
Add fiber if response to 'raw 
foods' question.
Increases sodium according to 
response to 'add salt at the 
table' question.
Do not print advice for subject.
Allocates medium rather than large 
portion of butter added in 
cooking.
Produce an output file containing 
intakes of specific carotenoids 
and fiber.
Allows type-specific nutrient 
contributions from the kind of dry 
cereal consumed.
Did not use extra-large portion 
sizes.
Include nutrient values even of 
foods eaten very infrequently.
Applies to question not asked in 
Version 2.
Includes data on special-diet 
question.
Allows exploration of effect of 
leaving 1 or more foods out of the 
analysis.
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TABLE 2 - Continued
OPTION 
Frtadj = Yes
Htwtques = Yes 
Illadj = No
Keep = Original
Leanques = No
Medonly = No
Morefds = 0 
Moreinfo = Yes
Oldadj = No
Omit = 2
Pillques = Yes
Portions = Agesex
INTERPRETATION
Allows use of 'How many 
f r u i t s / w e e k ? ' t o  p r e v e n t  
overestimation of vitamin C, 
fiber, and carotenoids.
Utilizes the information on
height, weight, age, and sex.
Do not adjust portion size
downward if subject lost 15 lbs. 
or more.
No recalculation using all medium 
portion sizes.
Applies to question not asked in 
Version 2.
Changes all portion sizes to medium 
for all subjects.
No additional foods were added.
Print out nutrients/1000 calories, 
nutrients/kg body wt., nutrients/g 
of solid food, and dietary 
variability indices.
Do not assume that oldest people 
chose too small a portion size.
Written-in foods only considered 
if eaten more than once/week.
The vitamin supplement question 
was asked.
Portion sizes 
specific.
are age/sex-
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TABLE 2 - Continued
OPTION INTERPRETATION
Recalc = No
Restadj = Yes 
Someall = All 
Sources = No 
Versionq = 2 
Study =
Subfruit = Yes
Todo = 99 
Toskip = 0 
Tunaques = No
Vegadj = Yes 
XI = No
Yearcol =0.01923
Do not change all portion sizes to 
medium and recalculate for 
comparison.
Include foods eaten in 
restaurants.
Analyze all files, rather than 
specific ID's.
Do not want contribution of each 
food to each nutrient calculated.
Using Version 
questionnaire.
of the
(These files were all from the 
same study.)
Avoids double counting of fruits 
mentioned in two places on 
questionnaire.
Look for up to 99 subject files.
Process all respondent files.
Applies to question not asked in 
Version 2.
Allows use of 'How many 
vegetables/week?' to prevent 
overestimation of vitamins A and C 
and fiber.
Did not use extra-large portion 
sizes.
Used year as largest time-period 
option.
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was utilized to determine the quality of the subjects' 
dietary data.
Selection of Lymphocyte Markers.
Markers to be used in this study were selected 
primarily on the basis of their relevance to immune status 
as it might relate to susceptibility to cancer. Most of 
the reagent antibodies were harvested from clones available 
from the American Type Culture Collection (Rockville, MD; 
ATCC); some were purchased from commercial sources as 
indicated below.
Most labelling was by the indirect method with 
fluorescein-isothiocyanate(FITC)-conjugated goat anti-mouse 
IgG as the second antibody. Only three determinations were 
done by direct double labelling with a FITC-conjugated 
antibody and a phycoerythrin-(PE-)conjugated antibody: 
CD4/CD45R, CD4/CD29, and CD8/CD11. Basic information about 
each of the antibodies used in this study was provided above 
and is summarized in Table 3. Antibodies to CD16 (Leu-llb, 
IgM) , and CD22 (Leu-14, IgG2b) were purchased from Becton 
Dickinson (San Jose, CA) as were FITC-conjugated CD4 (Leu- 
3a, IgG,) , FITC-conjugated CD8 (Leu-2a, IgG,) , and PE- 
conjugated CDllb (Leu-15, IgG2a) antibodies. Coulter 
Immunology (Hialeah, FL) was the source for CD25 (IL-2R1, 
IgG2a) , CD56 (NKH-1, IgG,), PE-conjugated CD45R (2H4, IgG,) 
and PE-conjugated CD29 (4B4, IgG,) antibodies. Clones which
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TABLE 3 
MARKERS UTILIZED
Marker M.W.fkd> Clone Taraet Subset
CD3 26,20,16 0KT3* Mature T-cells
CD7 40 3A1 T-cells, NK
CD29 59 0KT4 Helper T-cells
CD45R 135 4B4 Memory subset of 
CD4+ T-cells
CD8 32,33 OKT8 Suppressor/cytotoxic 
T-cells, NK subset
CD11/CD18 155/95 Leu-15 Suppressor subset of 
CD8+ T-cells
- 43 W6/32 All leukocytes
HLA-DR 34,28 L243 Monocytes, B-cells, 
activated T-cells
CD71 200(95) OKT9 Dividing cells
CD25 55 IL-2R Monocytes, B-cells and 
activated T-cells
CD14 55 63D3 Monocytes
- - MMA Monocytes, Granulocytes, 
and activated T-cells
CD22 130,140 Leu-14 B-cells
CD56 220/135 NKH-1 NK
CD16 50-65 Leu-llb NK, neutrophils
OK antibodies 
Pharmaceutical Co.,
originally developed by Ortho 
Raritan, NJ.
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produced the antibodies 0KT3 (CD3, IgG^), T3-3A1 (CD7,
IgGj) , OKT4 (IgG2b) , OKT8 (IgGjJ , OKM1 (CDllb, IgG2b) , W6/32 
(IgGj,) , L243 (IgGjJ , OKT9 (IgGj) , 63D3 (CD14, IgGj) , and MMA 
(IgM) were obtained from ATCC.
The hybridoma cell lines from ATCC were cultured at 37° 
in roller bottles to a maximum volume of 500 cc in DMEM, 
Iscove medium, or RPMI-1640 (GIBCO, Grand Island, NY) as 
specified by ATCC. The media were buffered with NaHC03, 
supplemented with 10% fetal bovine serum (Hyclone, Logan, 
UH) , 2mM L-glutamine (GIBCO) , 20 /xM 2-mercaptoethano 1 
(Sigma), and 50 ''Vmi gentamicin sulfate (Schering Corp., 
Kenilworth, NJ) . When viability dropped to <20%, the 
mixtures were centrifuged and the supernates passed through 
45 micron filters. They were concentrated to a volume of 
20-30 cc under 5-10 lbs. of nitrogen pressure in a Novacell 
150™ with a membrane permeable to molecules of <100 kd and 
0.1% sodium azide was added as a preservative. Each 
concentrate was then titrated using human leukocytes (or 
human tumor-cell lines HSB-2 and MT-2 for the transferrin- 
receptor antibody) to determine the optimal dilution, that 
is, that dilution at which a 50 (Ml aliquot added to 5-7.5 x 
10s leukocytes in 50 jlxX of PBS yielded the maximum 
fluorescence intensity. The antibodies purchased from 
commercial sources were reconstituted as recommended by the 
manufacturer and their concentrations were adjusted by 
dilution with PBS so that a 50 /x 1 aliquot would contain the
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appropriate concentration of antibody to label 5-7.5 x 10s 
cells.4 Small stocks of diluted antibodies were prepared 
before sample collection and stored at 4°C until needed.
FITC-conjugated goat anti-mouse IgG (amFITC), 
preadsorbed with human serum proteins to reduce non-specific 
binding to monocytes and B cells, was obtained from Sigma 
Chemical Company. The solution provided by Sigma was 
separated into 50-/li1 aliquots and stored frozen in the dark 
until used. It was diluted 1:100 with phosphate-buffered 
saline (PBS)5 at the time of labelling. Optimal 
fluorescence was obtained using 100 fil of diluted amFITC per 
5-7.5 x 105 cells. Irrelevant mouse antibodies, of the 
IgGl, IgG2a, IgG2b, and IgM isotypes, used as isotype- 
specific, negative controls were also purchased from Sigma.
Subject kits.
The materials needed for the collection of data from 
each subject were pre-assembled and labelled with the 3- 
digit study number for that subject, beginning with 001, 
002,...., and consecutively. The study number was prefaced 
with a P for patient or a C for control. Included in each 
kit were the questionnaire, an addressed, stamped, return 
envelope, a consent form (see Appendix B) , a 3" x 5" card
4Using a volume of 50 fil increased volume measurement 
and dispensation precision.
5137 mM NaCl, 2.78 mM KC1, 7.89 mM Na2HP04, 1.47 mM
KH2P04 ; pH=7 . 2-7 . 4 .
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for the subject's name and phone number (for follow-up on 
questionnaires) , and all of the tubes and storage vials 
required for the collection, processing, and labelling of 
the blood sample. The kits for patients also included a 
medical information form (see Appendix B) , which defined the 
histologic type, stage, and location of the subject's tumor 
and was to be completed by the patient's radiologist.
Phlebotomy and processing of blood specimens.
A licensed phlebotomist was employed to obtain the 
samples. Blood was drawn from an antecubital vein into two 
10 cc, green-top vacutainers (BD) containing lithium heparin 
and stored at room temperature until processing. Processing 
was done on the same day that the samples were collected and 
was begun within 12 hours of collection in all cases.
Samples from 1 to up to a maximum of 12 subjects were 
processed at one time. The work-up was completed, to the 
point of fixing the labelled cells, within between 4 hours 
for one subject and 13 hours for 12 subjects. For each 
subject 4.3 cc of blood were aseptically removed from one 
heparinized vacutainer and 4.0 cc transferred to a 
borosilicate test tube for preparation for FACS analysis. 
From the blood remaining in the pipette, two slides were 
prepared for staining for a manual differential count and 
duplicate capillary tubes were filled for obtaining a micro 
hematocrit determination. The remaining blood in the
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vacutainers was centrifuged at 500 x g for 10 min.6 at room 
temperature (RT). The plasma, erythrocytes, and buffy coat 
cells were cryopreserved for future study.
The 4 ml sample which was reserved for FACS analysis 
was centrifuged. The buffy coat was transferred to a 15 cc, 
polystyrene centrifuge tube. Fourteen milliliters of 
freshly prepared lysing buffer7 were added and the contents 
of the tube mixed immediately by inversion until the mixture 
clarified (3-5 min.). The leukocyte suspension was 
centrifuged and the supernatant solution decanted. The 
pellet was dispersed in 1 cc of cold, isotonic PBS with a 
Pasteur pipette, another 13 cc of PBS were added, and the 
cell suspension mixed by inversion. The mixture was 
centrifuged and the pellet resuspended in enough 
refrigerated PBS with 10% complement-inactivated goat serum8 
(PBS/G) to adjust the cell concentration to between 0.5 to 
1 million cells per 50 /zl aliquot (1.5 to 3 cc of PBS/G). 
A control containing cells exposed only to the goat amFITC 
second antibody was included in the panel for each subject 
to detect any residual non-specific binding.
‘’Unless otherwise indicated, all centrifugation was 
done at 500 x g for 10 min.
7100 ml of distilled H20 added to 829 mg NH4C1, 109 mg 
KHC03, 3.7 mg Na2H2(CH3C02)4C2N2 (ethylenediaminetetraacetic
acid, disodium salt) just prior to use.
8The purpose of the goat serum was to block protein 
binding sites on the cells, especially any receptors for 
goat immunoglobulins.
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Differential.
A manual differential was done on a stained slide for 
each subject. One hundred cells were classified as 
lymphocytes, monocytes, eosinophils, basophils or 
neutrophils. All differential determinations were carried 
out by the same ASCP medical technologist.
Fluorescence labelling.
Appropriately labelled 12x75 mm Falcon tubes for each 
subject were set in an ice bath. A 50 ijlI aliquot of the 
leukocytes in PBS/G was pipetted into each tube. The first 
antibody (50 jul) was added to each of the samples to be 
indirectly labelled. Both antibodies, for example, CD4-FITC 
and CD29-PE, were added at the same time to those samples to 
be doubly labelled. The samples were vortexed, covered with 
aluminum foil, and allowed to incubate on ice for 1 hr. 
Then 3 cc of PBS were added to each tube and the mixtures 
were centrifuged in the cold. The cells which had been 
directly labelled were fixed at this time.
For those samples indirectly labelled, the PBS wash was 
decanted, 100 /zl of amFITC was added to the cell pellet, the 
tube contents were well mixed by vortexing, and the mixtures 
incubated on ice in the dark for 30 min. The cells were 
then diluted with 3 cc of cold PBS and the mixtures 
centrifuged. The PBS was decanted, the cells were 
resuspended in the residual drop (@ 50 jil) of supernate by
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vortexing, and 50 n 1 of cold 1% paraformaldehyde9 was added 
to each of the tubes, on ice, with vortexing. For each 
subject the following negative controls were prepared and 
fixed: cells + amFITC only, and cells + irrelevant antibody 
of isotypes IgGl, IgG2a, IgG2b or IgM + amFITC. The samples 
were covered and stored in the refrigerator for 4-24 hours, 
then diluted with 100 /zl of PBS. Again, they were stored at 
4°C until analyzed on the cell sorter. In nearly all cases, 
the FACS data were collected on the day after labelling.
Instrumentation.
The Fluorescence-Activated Cell Sorter was a BD FACS- 
440 equipped with an argon laser used at 200 mWatt, with a 
488 pm primary emission line. Green fluorescence was 
detected with the primary photomultiplier tube with a 530/30 
band pass filter. Red fluorescence was detected with the 
secondary photomultiplier tube with a 585/42 band pass 
filter. All fluorescence signals and 90° scatter were log 
amplified. Sheath fluid was 0.2/i-filtered deionized water. 
The cell sorter interfaced with Consort 40 software (Becton 
Dickinson) on a Micro-VAX II workstation from Digital 
Equipment Corporation (Westminster, MA) . Formaldehyde-fixed 
chicken erythrocytes were used to align the sorter on 
scatter and green fluorescence each day that samples were
9Two grams of paraformaldehyde were heated in 100 cc 
PBS at 7 0°C until dissolved. The solution was stored at 4°C. 
It was diluted 1:2 with cold PBS just prior to use.
run. A threshold was set on forward scatter such that all 
lymphocytes were retained but residual erythrocytes, 
platelets, and debris were excluded as completely as 
possible. The flow rate was adjusted to the fastest rate 
achievable without sacrificing resolution on forward and 
side scatter; usually 500-1000 cells per second. To check 
for instrument drift, the 2-dimensional scatter displays of 
the first sample and the last sample for each subject were 
overlaid. If substantial drift had occurred, that 
individual's samples were rerun. Where the subject had a 
normal lymphocyte:granulocyte ratio, 15000 events were 
collected, (except that 20000 events were collected for the 
CD22, CD56, CD4/CD29, CD4/CD45R, and CD8/CD11 samples
because the proportions of cells expected to be positive for 
those markers were small). For those subjects with relative 
granulocytosis, some of whom had only 5-10% lymphocytes, 33- 
100% more events were collected with the goal of obtaining 
data on at least 2000 lymphocytes.
No electronic compensation10 was done on red-green 
doubly labelled samples. Compensation did not help to 
discriminate the positive from the negative subgroups and 
completely destroyed the normality of the distributions, 
which would have made it impossible to use Gaussian curve-
10The cell sorter is equipped with an electronic 
compensation mechanism which is supposed to correct for 
spillover of the red emission into the green detector and 
vice versa.
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fitting strategies to estimate the components of the 
mixtures. Data were stored on magnetic tape for later 
analysis.
A novel method for FACS data processing.
Forward- by side-scatter displays of the first and last 
samples from each subject were overlayed. Contours which 
enclosed all of those coordinates for which n events were 
recorded were drawn for n=3 and n=10 in order to define the 
leukocyte distributions. A rectangular window on forward 
and side scatter was set to enclose all of the cells with 
the scatter properties of lymphocytes, while excluding as 
many non-lymphocytic events as possible (Figure 2) . The 
events within this window were selected for further editing.
The following paragraphs describe a new method which 
was invented to achieve percentage estimates on lymphocyte 
subsets from the raw data generated by the cell sorter.
For each event (cell), an integer ranging in value from 
1 to 256 and corresponding to relative intensity or scatter 
angle of the light detected was recorded for each of the 
four parameters. List mode FACS data in this system are 
coded in unsigned binary integers (Dean et al. 1990). 
Analysis of the data with a multidimensional approach 
required conversion of the data to ASCII files so that they 
could be manipulated in SAS. Software which accomplished
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Figure 2. Setting a rectangular window on lymphocytes.
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this, FCSLST V01-03, was obtained from Dr. Robert F. 
Murphy11. Short programs in BASIC12 were then written, 
which compressed the ASCII files to about half the length of 
the file output from FCSLST and truncated large files at 
2500 events.
All processing to this point was conducted on a VAX 
8200. The files were then transferred to an IBM 3090 
mainframe for further editing and analysis.
A probability sample of events from the crudely edited 
data was selected for designation as the lymphocyte 
population in the following way. Based on the assumption 
that lymphocytes were at least approximately homogeneous in 
their scatter properties and that events were normally 
distributed in the 2 scatter channels (see the histographic 
data display in Figure 3) , a bivariate mean vector and 
covariance matrix for sample lymphocytes were estimated from 
the coordinates of the events within the rectangular edit 
window. The number of points used to estimate the mean 
vector and covariance matrix was large compared to the 
dimensionality (2) , therefore the estimates were considered 
to be very close to the true parameter values and the 
standardized squared distance of any sample point from the 
mean of a bivariate normal distribution was considered to be
uDr. Robert F. Murphy, Center for Fluorescence Research 
in Biomedical Science, Carnegie Mellon University, 4400 
Fifth Ave., Pittsburgh, PA 15213.
12Program written by Mrs. Cindy Fort, Systems Analyst.
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distributed as a x2 with 2 degrees of freedom (DF; Johnson
and Wichern 1988, 145) . To decide if a particular event 
was likely to belong to the population of lymphocytes, the 
standardized squared distance of that point from the 
estimated mean (SSD)13 was compared to the 95th percentile 
X\ =5.99:
X,i-Xt
X2i-X2 SiS2
SjS
s
1°2
2 1
Xii-xf
x2i-x2
X2
If the SSD was less than the x2» the event was considered to
be a lymphocyte; otherwise it was rejected.
In order to compensate for the distortion of the 
estimates of the mean vector and covariance matrix by 
outliers, the parameters of the lymphocyte distribution were 
reestimated after the outliers were excluded and the revised 
estimates used to retest the events within the original 
rectangle. In subjects with granulocytosis, for whom 
outliers were relatively numerous compared to lymphocytes, 
the first cut was made at 90%, so that a better second 
estimate of the parameters was obtained. The editing 
process is diagrammed in Figure 4. It was programmed using 
SAS steps and procedures (Appendix C) . An example of a 
selected lymphocyte sample is shown in Figure 5.
13Standardized squared distance is analogous to the 
univariate Z statistic squared: [ (x-ju) / s]2.
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Figure 3. The distribution of leukocytes on scatter and 
fluorescence.
Determination of the proportion fluorescence positive
was made in the following way. Fluorescence intensity, on 
a logarithmic scale, of events of each subset was assumed to 
be normally distributed (Figure 3) , that is, the 
autofluorescence of the negative subpopulation was normally 
distributed as well as the brightness of the positive 
subpopulation(s). As mentioned previously, scatter 
properties were also considered to follow a Gaussian 
distribution. A Fortran algorithm for fitting Gaussian 
distributions to data (McLachlin and Basford 1988) was 
customized to the requirements of this study to estimate up
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Figure 5. A selected probability sample of lymphocytes.
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to 6 distributions in 2 dimensions and to accommodate data 
on up to 6000 events.
The program required that initial values for the mean 
vector, the covariance matrices, and the relative 
proportions of events in each subset be provided. In order 
to achieve data-based initial values for the parameters SAS 
Proc Fastclus14 was used to group events into 2-6 clusters 
(depending on the particular antibody) on the basis of the 
two fluorescence or fluorescence and scatter data on each 
event. The mean vector, covariance matrix, and proportion 
that a cluster of events were of total events were 
calculated for each cluster and appended to the crude data 
for input to the normal-mixtures program. The latter then 
provided final estimates of percentages of cells in each 
group for each subject.
Lymphocytes, especially NK, vary somewhat in their 
properties (Figure 6) . Therefore side scatter was chosen as 
a second dimension for discrimination where only one 
fluorescent antibody marker was employed. In the situation 
where double-labelling was done, the analysis dimensions 
were red and green fluorescence and side scatter was 
ignored, since subsets within subsets of lymphocytes would 
not differ appreciably on side scatter.
14This clustering method is based upon a nearest-cluster 
criterion for assignment of events and does not utilize 
available frequency distribution information as the normals- 
mixture approach does.
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Figure 6. NK cells exhibit higher sidescatter than other 
lymphocytes.
Because the method was new and previously untried some 
care was taken to evaluate and assure the quality of the 
results. The output from each file was compared with 
scatter plots of the data and expected ranges for the 
percentages and fluorescence means and variances to insure 
that convergence of the normals-fitting program was to 
appropriate means and covariances and that the estimates of 
subset percentages were reasonable. Estimates with 
excessively large variances were not accepted to avoid 
assigning events to the population with the large variance 
when they did not belong there.
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A subset of 25 subjects were selected using a table of 
random numbers. Their 63D3 (monocyte marker) files were 
analyzed by the new method to estimate the extent of 
contamination by monocytes in the probability sample of 
lymphocytes.
The performance of the new FACS data processing method 
was compared with the conventional method. The estimated 
percentages for CD3 + , CD4 + , CD8+bright, and CD8+dim for 27 
subjects were compared with estimates for those subsets made 
using conventional analysis procedures.
The master data set.
Non-dietary data from the questionnaire data file, the 
nutrient estimates produced by the dietary analysis 
software, data from the patients' medical forms, hematocrit 
and differential counts, and the lymphocyte subset 
proportion estimates were combined into a master data file, 
coded in ASCII, for statistical analyses.. The codebook for 
the master data set is Appendix D.
The lymphocyte profile.
The estimates of subset proportions were based upon the 
analysis of a large number of lymphocytes, therefore the B- 
cell, T-cell, and NK proportions can be considered to be 
continuous data and looked upon as elements of a lymphocyte 
composition. All of the information necessary to define a 
mixture of n components can be expressed in n-1 proportions,
pu since pn = 1 - pj - p2 - p^. A profile is then
represented as n-1 variables of the form p^ p,,, p2-=-pn/ • • • /P(„- 
ij-j-p,, (Aitchison 1 9 8 6 ,  2 6 )  . The information which fully
described the B-cell/T-cell/NK lymphocyte profile was 
summarized with two terms, the ratios of proportions 
CD3-rCD22 (T-rB) and C D 5 6 ^ C D 2 2  (NK-s-B) . A logarithmic 
transformation of the ratios CD3-S-CD22 and CD56-rC D 22  
normalized their distributions and allowed the components of 
the profile to be simultaneously regressed upon a linear 
combination of putative effector variables. SAS Proc GLM 
with the MANOVA request accomplished the mathematics 
required to estimate the probability that any particular 
independent variable was not a determiner of the outcome 
profile.
Independent variables were added, one at a time, to the 
model, beginning with variables for which there was prior 
evidence of association. The first 3 variables that were 
incorporated were age, disease, and smoking, followed by 
terms summarizing the time of day when the sample was 
collected and the month of the year when the sample was 
collected.
"Rhythm” implies a movement with periodicity, cyclic 
variation. Therefore whatever variation that was due to 
time of day or time of year would be expected to display a 
cyclic and continuous pattern. Circadian rhythms have 
commonly been modelled with a cosine function (COSINOR
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method; Reinberg and Smolensky 1983). Parameters aj are 
estimated for the nonlinear regression model:
Y(tj) = a0 + ajcosf (2pi-ra2) t‘ + a3], where 
t; = time (when blood drawn) , 
a0 = mesor (or mean), 
at = amplitude, 
a2 = period, and 
a3 = acrophase (phase).
Software exists which will estimate all of the parameters aj 
given the data. In this case, however, the function of time 
had to be constructed so as to permit incorporation into a 
larger, linear model. Therefore if a cosine function was to 
be used, it was necessary to estimate a value for period and 
one for acrophase and assume those to be constant. The 
mesor then is incorporated into the intercept of the larger 
model and the amplitude is the estimated parameter of the 
model for that time function. A starting estimate of the 
period and one of the phase for each cosine term were easily 
determined from inspection of data plots. The phase was 
verified and estimated more precisely with the NLIN 
procedure in SAS (SAS Institute, Inc. 1988, 675-712).
Variables were screened for effect on the lymphocyte 
profile by regressing the residuals from the current model
on them (semi-partial plots15) . The assumption was made, at 
this stage that there was no covariance between the 
independent variable being tested and the other variables 
already in the model. In the absence of prior definitive 
data on patterns of circadian and circannual rhythms, the 
data were used to decide upon tranformations for hour-of-day 
and month-of-year from longitudinal variables to cyclic 
variables. If a variable was found to contribute toward the 
residual variance, the residual means by categories of the 
variable were plotted to determine the best modelling 
strategy for the variable. Then it was entered into the 
model. Each time that a variable was added to the model, 
the model was reassessed by backward elimination of the 
interaction terms from a full model with all 2-way and 3-way 
interactions (Kleinbaum, Morgenstern, and Kupper 1982, 451). 
Terms were eliminated in order of least significance, 
starting with the 3-way interactions. With models 
containing 7 or 8 main effects, 3-way interaction terms were 
added in groups of 5 or 6 and removed at once if P(>F) > 
0.50. Once all of the 3-way interactions had been tried 
with the exclusion criterion of 0.50, those remaining in the 
model were excluded in order of least significance in the
15In partial regression, both the dependent variable and 
the independent variable are adjusted for the other 
variables in the model and the relationship of the residuals 
examined. In semi-partial regression, the dependent 
variable is adjusted for other variables in the model, but 
the independent variable is assumed to have no covariance 
with other independent variables.
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usual manner. The criterion for remaining in the model was 
an approximate16 F statistic with a probability of 0.05 or 
less. After new variables were added to the model, 
variables previously excluded were retested against the new 
residual variance.
Isolation of single effects.
Adjustment of the data for a factor or a combination of 
factors was conducted in the following way. The data were 
modeled as a linear combination of factors F;:
Ln (CD3-T-CD22) , Ln (CD56-H2D22)
= Mean0 + Ft + ... + Fn.j + Fn + R„17 
= Predicted + R„
Data adjusted for factors Ft - Fn were simply 
[Ln (CD3-S-CD22) , Ln (CD564-CD22) ]adju8ted 
= Mean0 + R,j
The effect of Fn was estimated as the Predicted from the 
model which included Fn minus the Predicted from the model 
without Fn.
F„ = [Mean0 + Ft + ...+ F^ + FJ
- [Mean0 + Ft + ...+ Fn_i]
16Since division of a covariance matrix by a covariance 
matrix does not yield a scalar quantity, test statistics for 
multivariate analysis are constructed from the determinates 
or traces or eigenvalues of the hypothesis and error 
matrices and have nearly an F distribution (Barker and 
Barker 1984).
17R represents the residual or "error" variance element.
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To isolate the effect F0 of a variable B which was involved 
in an interaction,
Ln(CD3-T-CD22) ,Ln(CD56-KTD22)
= Mean0 + FA + F„ + FAxB + R„, 
the data were adjusted for the effect FA of A, then further 
adjusted for the effect FAxB, of AxB estimated from the full 
model as described above, and the doubly adjusted data 
examined by levels of B.
Other tests.
For correlations and tests involving a proportion, 
rather than a ratio of proportions, a logit transformation 
(ln[p^-(l-p) ]) was used to normalize the distributions 
(Rothman 1986) . The SAS procedures MEANS and CORR were used 
to conduct paired t-tests and to test correlations.
Ternary diagrams.
It was often useful to make a visual representation of 
a three-component mixture on a two-dimensional ternary 
diagram (Aitchison 1986), an equilateral triangle on which 
each apex represents 100% of a particular component and the 
opposite side is 0% of that component (Figure 7). The legs 
which extend from an apex are scaled linearly from 100% to 
0% for that component. Any point which falls on the straight 
line which connects X% on one leg to X% on the other 
contains X% of that component. Therefore the percentage of 
a component can be read from the sides of the triangle by
1 0 2
100% T'S
2 0 2  T 'S
100% B'S 100% NK’S
Figure 7. The ternary diagram.
projecting a line, parallel to the 0% base from the point to 
either side. To plot the profile points using existing SAS 
software the percentage of T-cells was aligned with the Y 
axis, and the 100% B-cell apex was placed at (0,0), then the 
lymphocyte composition profile was plotted on a rectangular 
coordinate system using the following transformation:
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Y = % CD3+,
X = 100 - (% CD3+-^ 2) - % CD22 +.
The printing of the rectangular coordinates was suppressed 
and a triangular grid was overlaid for reference (Figure 8) .
The leukocyte profile
The leukocyte profile was examined in manner similar to 
that used for the lymphocyte profile. Dependence on 
disease, age, smoking, month of year, and hour of day was 
tested. The composition was represented by four logratios 
of neutrophils, monocytes, eosinophils and basophils to 
lymphocytes:
ln(NEUT-rLYM) , ln (MONCK-LYM) , ln(EOS-^LYM), and In(BAS-KLYM) . 
Where the count of one of the numerator subsets was 0, the 
count was set to 0.25, in order to preclude calculating 
ln(0) as a datum.
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Figure 8. Plotting a ternary diagram in rectangular 
coordinates.
RESULTS
Study subjects.
Since patients with small-cell (oat-cell) carcinomas 
were almost always treated with chemotherapy prior to any 
radiation treatment, this major cell-type was not 
represented in the patient population. Similar numbers of 
patients with the other three major histologic types of lung 
cancer were enrolled. Seventy new white male patients with 
primary lung cancer of the 3 histologic types eligible for 
the study entered treatment at PCC between January 29, 1988 
and January 6, 1990. Of these 25 of 26 (96%) with squamous­
cell carcinoma, 20 of 24 (83%) with large-cell carcinoma 
and 19 of 20 (95%) with adenocarcinoma18 volunteered to
participate. There was no evidence of differences in 
smoking history among the three histologic groups. In fact 
of those with the least smoking-related histotype, 
adenocarcinoma, only 4 of 17 (23.5%) were ex-smokers of over 
a year, whereas 52% of those with squamous cell and 47% of 
those with large cell carcinoma reported having quit the
18The proportion representing each histologic type 
should not be taken as representative of incidence for the 
geographic area which Mary Bird Cancer Center serves since 
radiation therapy is not necessarily appropriate for the 
same proportion of patients from each group.
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habit more than 1 year ago, but the differences were 
statistically non-significant.
The origins of comparison subjects are detailed in 
Table 4. In all 219 comparison subjects were enrolled.
TABLE 4
ORIGIN OF COMPARISON SUBJECTS
Group Number
American Assn. of Retired Persons 26
Council on Aging 7
Kiwanis International 34
Lions Clubs 10
American Legion 61
Amer. Leg. Veterans Home, Jackson, LA 24
Veterans of Foreign Wars 10
Salvation Army 6
University Baptist Church 8
Knights of Columbus 3
Referred by third party 4
Brochure, other publicity 15
Acqua intances 11
219
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Response to questionnaires.
Of the total number of subjects enrolled, 16 controls 
and 4 patients failed to return questionnaires even after 
repeated reminders.
The dietary data for five controls and one patient were 
considered unusable because of too many items skipped and 
failure to indicate portion sizes. In most cases, missing 
portion sizes were recoded to "medium11 since examination of 
the questionnaires indicated that the respondents were 
otherwise diligent in completing them. No one was 
eliminated for eating too few or too many different foods on 
a daily basis, because their questionnaires indicated that 
they ate an unremarkable variety of food items overall and 
seemed merely to have difficulty in estimating how often 
they ate certain foods. Of those who returned
questionnaires 244 (55 patients and 189 controls) had usable 
dietary data. Of these 147 were considered to have no 
problems, 22 had what were judged to be miscellaneous minor 
errors, 64 had marked too high a percentage of the items 
with a medium or a small portion size, and 11 indicated too 
many or too few foods daily.
Comparisons of patient and control groups on age, 
parish of residence, income per person in the household, and 
education are presented in Figures 9-12. The age range of 
patients was well represented in the control group. There 
were subjects among the controls, but not among patients,
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who were in their fourth decade. A majority of the conti-ols 
(54%) and nearly half of the patients (46%) reported 
residence in East Baton Rouge Parish. The controls who 
resided in East Feliciana Parish came from the War Veterans' 
home in Jackson and presumably did not live the majority of 
their lives there, but had resided in other parishes. When 
household income was calculated on the basis of the number 
of individuals who shared it, 85% of the patients reported 
less than $10,000 per year per person whereas only 45% of 
the controls fell into that category. Controls also 
reported more education than patients: 73% of the controls 
had at least finished high school compared to 50% of 
patients. Eighteen percent of the patients reported less 
than an eighth grade education compared to 4% of controls. 
Nevertheless there were representatives in the control group 
of every subgroup of patients with respect to income and 
education such that control for these measures of 
socioeconomic status was possible.
The subjects grouped according to disease and smoking 
characteristics as illustrated in Figure 13. No patient was 
a life-time non-smoker. One individual had smoked only a 
pipe but had that exposure for 45 years. He was not 
included in the analysis. Despite efforts to recruit 
smokers, only 63 of the comparison subjects were current 
smokers. Smokers in the older age groups proved least 
available.
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Figure 9. Age distribution of patients and controls.
Sample-to sample spillover.
CD3 samples were run in duplicate in order to get an 
estimate of sample-to-sample variability. However evidence
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Figure 10. Income classification of patients and 
controls.
was found that in some cases not enough time had been 
allowed between running of sequential samples on the FACS 
and that the first CD3 sample in some subjects was
Ill
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Figure 11. Parish of Residence for Patients and Controls.
contaminated with residual control cells. A subsample of 
subjects (n=112) was analyzed. The paired differences for 
the proportion positive in the second sample minus that of 
the first averaged to 0.0152 (SE=0.0045) and was
1 1 2
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F i g u r e  12. Educational status of patients and controls.
significantly different from 0 at PCO.OOII. If the paired 
differences were graphed, the largest group of individuals 
clustered around 0 and 10 individuals formed a broad tail on 
the positive end of the difference distribution. Without
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DISEASE
Yes
(61)
SMOKING
NO
(203)
SMOKING
Ever
(160)
Never
(43)
Current Quit Former 
(21) <1 yr. (25)
(14)
Current Quit Former Never 
(63) <1 yr. (94) (43)
(3)
Figure 13. Characterization of subjects on disease and 
smoking.
the 10 outliers, the averaged paired differences were not 
different from 0 and the estimate for the standard deviation 
in determinations from the two samples per 102 individuals 
was 2.7%. When the rest of the samples were considered 
separately, virtually identical results were obtained, with 
a mean difference of 0.015 caused by 12 individuals in the 
tail of the distribution. Since the first samples of at 
least 22 individuals were contaminated, the estimate from 
the second sample was used for analysis for everyone.
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Only one other problem with spillover from the previous 
sample was observed. The HLA-DR samples were preceded by 
the antibody W6/32 to a common leukocyte antigen and 20 
files were seen to be contaminated. By going back to the 
original data which contained all leukocytes, an estimate of 
the percentage of contamination could be made by determining 
the percentage of granulocytes which displayed green 
fluorescence above background. Corrections were applied to 
the HLA-DR estimates.
Performance of the new data analysis method.
An average of 2 041 (±376) lymphocytes were selected and 
analyzed. Only two of 25 randomly selected subjects had 
greater than 1% contamination with monocytes as identified 
by the antibody 63D3 (CD14).
Occasionally extraneous events (doublets, for instance) 
occurred at a distance from the minor component on 
fluorescence or small numbers (<20) events grouped at 0 
fluorescence and influenced estimation of the distributions. 
The normal-mixtures-fitting routine treated each event as 
though it belonged to one of the specified subsets and 
adjusted parameter estimates to accommodate it. Where 
difficulties arose, such obviously irrelevant events were 
edited out of the data so that estimates would converge to 
realistic values.
In some instances the curve-fitting routine seemed to 
'detect' the presence of more subpopulations than were
115
theoretically there. For instance with the CD4+CD29+ 
doubly-labelled cells, there seemed to be more than 4 
distinguishable populations. In particular, there were 
small numbers of cells which labelled very brightly on red 
fluorescence (CD29-PE). In 11 cases, 5 groups were needed 
to fit the data and in 22 cases, 6 groups were needed. The 
proportions positive in both groups were summed to give a 
total estimate for CD29-bearing CD4+ lymphocytes.
Cells which labelled with HLA-DR formed a broad peak of 
low amplitude. A more satisfactory solution was obtained if 
two distributions were fitted to the positive cells in the 
majority of cases. This was taken as an indication that 
distinct subgroups of lymphocytes express the class II major 
histocompatibility antigen at different densities. However, 
for the purposes of this study, the proportions were 
combined as one positive population. In 81 cases, a single 
positive distribution fitted better than 2.
Beginning around subject 205, a small (1-2%), third 
population of cells appeared in the samples labelled with 
CD56, the NK marker. These cells exhibited brighter 
fluorescence than those presumed to be the NK, but had the 
side-scatter characteristics of average lymphocytes. Their 
percentage was estimated and because of their side-scatter 
characteristics added to that of non-NK. The brightness of 
the NK was also diminished in these later samples.
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TABLE 5
FAIRED DIFFERENCES OF ESTIMATES BY TWO METHODS
Mean Standard
Marker Difference Error
CD3 -0.0044 0.024
CD4 0.0116 0.032
CD8bright 0.0168 0.028
CD8dim -0.0282 0.028
The estimates of CD3 + , CD4 + , CD8+bright, and CD8+dim done by 
the conventional method for 27 subjects were compared with 
estimates for those subsets done by the new method. The 
paired differences (Table 5) were not different from 0, 
indicating that both methods gave the same estimates 
overall. The standard deviation on an individual 
difference, however, was 0.14 or 14 percentage points, which 
caused the standard error of the mean difference to be on 
the order of 3%. Therefore a mean paired difference of 
even 6% would not have been considered significant. In 
other words the power of this comparison of 27 subjects to 
detect a difference in estimated mean percentage positive of 
6% was only 50%.
The standard deviations of estimates by both methods 
for the group of 27 subjects are presented in Table 6.
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TABLE 6
VARIABILITY OF ESTIMATES WITHIN METHOD
Old Method 
Marker Std. Dev.
CD3 0.095
CD4 0.109
CD8bright 0.084
New Method 
Marker Std. Dev.
CD3 0.081
CD4 0.113
CD8bright 0.090
Although the variances of the estimates appear to be the 
same, the estimates from the old method were based on an 
average of 2990 (±1330) events, whereas the longer files
were truncated in the new method and the estimates were 
based on 2 041 cells on the average. Therefore the new 
method was somewhat more precise in estimating the 
percentage positive.
Lymphocyte subsets.
Of the 17 lymphocyte markers measured, the eight 
indicated in Figure 14 were selected for first stage 
analysis on the basis that (1) they are commonly estimated 
markers, (2) they are relevant to possible immune defenses 
against cancer, and (3) the positive and negative 
populations, with the exception of the 2H4 and 4B4 subsets 
of CD4-positive cells, were relatively easily discriminable,
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CD3 ------  CD56   CD22 HLA-DR
(T-cells) (NK) (B-cells) (Class II)
CD4 CD8
(Help/Ind) (Cyto/Sup)
CD45R CD29
(Naive) (Memory)
Figure 14. Subsets chosen for first-stage analysis
therefore more accurately estimable. As one can see from 
Figure 14, some markers define subsets of sets. For 
example, nearly all cells which carry CD3 also bear CD4 or 
CD8. Likewise most CD4+ lymphocytes are considered to carry 
either 2H4 or 4B4 although some 15-30% have been reported to 
carry neither (Morimoto 1985). T-cells, B-cells, and 
natural killer cells are the component subsets of 
lymphocytes. The only lymphocyte commonly recognized as 
carrying the Class II major histocompatibility marker HLA-DR 
is the B-cell, however activated T-cells and monocytes 
express HLA-DR as well. Therefore the following
relationships between the proportions of cells having 
particular markers were expected to hold:
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CD4+ + CD8+ = CD3+
CD45R+ + CDw2 9+ < CD4 +
CD3+ + CD22+ + CD56+ = 1.00 
HLA-DR+ >= CD22+
These relationships were probed utilizing all subjects for 
whom there were data. The distributions of estimated 
proportions were normalized by employing a logit 
transformation, ln[p-r (l-p) ].
Relevant statistics for the above subsets and 
combinations of subsets are presented in Table 7. The mean 
proportions and confidence intervals were determined using 
the logit-transformed variables and back-transformed. The 
Pearson correlation coefficients R are given for appropriate 
comparisons among the transformed variables and Pr(>jRj) 
under the hypothesis that there is no correlation was 0.0001 
for each case.
The paired differences corresponding to the 
relationships above were tested for equality to zero and the 
results are presented in Table 8. The sum of the 
proportions of cells CD3-, CD56-, and CD22-positive
accounted for all lymphocytes, that is, they summed to 1.00 
as would be expected if the 3 antibodies do indeed label 
mutually exclusive subsets of lymphocytes and each labels 
100% of its specific subset. The differences (1 - PCD3- Pcd56 
- PCD22)i were not normally distributed, due predominantly to 
kurtosis (the distribution was symmetrical); the mean was
1 2 0
TABLE 7
STATISTICS FOR SELECTED SUBSETS
MARKERS N MEAN 95% C.I. R
CD4+CD8! 277 0.659 0.46-0.82
[ln{p/(l-p)}] [0.661] [-0.17-1.49]
0.71
CD3 275 0.709 0.48-0.86
[ln{p/(l-p)}] [0.892] [-0.07-1.85]
0. 68
CD4+CD8j+CD82 2 7 6 0 . 75 1 0 . 55 - 0 . 88
[ln{p/(l-p)}] [1.105] [0.18-2.03]
CD4 279 0.431 0.23-0.65
[ln{p/(l-p)}] [-0.248] [-1.19-0.60]
CD45R+CD29 223 0.356 0.17-0.60
[ln{p/(l-p)>] [-0.592] [-1.60-0.42]
CD3+CD56+CD22 276* 1.003 0.80-1.20
CD22 279 0.090 0.03-0.26
[ln{p/(l-p)>] [-2.311] [-3.55+1.07)]
HLA-DR 279 0.182 0.09-0.34
[ln{p/(l-p)}] [-1.504] [-2.35-(-0.66)]
0.77
0.43
Six subjects with values below 0.75 were excluded.
1 2 1
TABLE 8
TESTS OF SUBSET EQUIVALENCE HYPOTHESES
HYPOTHESIS STUDENT'S t Pf>!tM
CD3-(CD4+CD81+2)=0 -10.330 0.0001
CD3-(CD4+CD8!)=0 10.01 0.0001
CD4-(CD42H4+CD44B4)=0 16.31 0.0001
1-(CD3+CD56+CD22)=0 0.515 0.607
(HLA-DR)-CD22=0* 31.52 0.0001
* [logit(HLA-DR - CD22+0.08)-logit(0.08)=0]
0.003, standard error of the mean (SEM) was 0.0058 
indicating that the estimate was precise, and the median of 
the differences was 0.001, indicating that the distribution 
was symmetrical and that the mean was an adequate measure of 
central tendency.
There were at least 2 subsets of lymphocytes which bore 
CD8, one at high density and another at lower density. The 
proportions of lymphocytes which were CD4+ or CD8+ 
(including both dim and bright cells with CD8) summed to a 
total greater than the proportion CD3-positive (mean paired
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difference = -0.045, p(>|t|) < 0.0001). If the dim cells 
are considered to be CD3' natural killer cells (Ault 1988) 
and only the brighter cells were summed with CD4 then the 
proportion (CD4+ + CD8bright+) was less than the proportion CD3 + 
(mean paired difference = 0.044, p(>|t|) < 0.0001), implying 
that there were some T-cells present which had neither CD4 
nor CD8bright. Likewise, the CD45R+ and CD29+ subsets of 
CD4-positive cells did not sum to the proportion estimated 
as CD4-positive by independent labelling (0.36 v. 0.44). 
The correlations of CD3+ with CD4+ + CD8+totaj, CD4+ + CD8+bright, 
and of CD4+ with CD4+4B4+ + CD4+2H4+ were high, (0.68, 0.71 
and 0.77, respectively).
The logit transformation normalized the distributions 
of proportions positive for HLA-DR and CD22. It was 
necessary to transform the quantity (HLA-DR+ - CD22+) by 
adding the constant 0.08 before logit transformation so 
that the difference was a positive number for all subjects. 
The distribution of this logit was normal except for 2 
outliers whose logit(difference) were greater than 3 
standard deviations below the mean and 9 individuals who 
clustered around a value 2.7 standard deviations above the 
mean (Table 9) . It was assumed that the outliers were 
individuals for whom something had gone awry in the data 
collection or analysis process and they were deleted in this 
comparison. The equivalent of the hypothesis that HLA-DR+ - 
CD22+ = 0 for the transformed difference was H0: logit (HLA-
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DR+ - CD22+ + 0.08) = logit(0.08) = -2.442. The mean of the 
transformed difference, even with outliers excluded, was - 
1.70 (t168=31. 52, P(>t) <0.0001) . The proportion of cells
expressing HLA-DR, then, exceeded the estimated proportion 
of B-cells by an average of 7.6%. Furthermore ANOVA showed 
that the patients, with 11.7% more HLA-DR+ cells than B- 
cells, had a significantly greater excess of HLA-DR+ 
lymphocytes (Fj274=46.75, P<0.0001) than controls (6.6 % more 
HLA-DR+ cells than B-cells).
The lymphocyte profile.
The first variables to enter the regression model were 
disease, age, smoking, hour-of-day, and month-of-year. 
Modelling decisions with respect to the last 3 were data- 
based.
It was reported in the literature that the effects of 
smoking on the immune system resolved within less than a 
year after quitting. Profile logratio means for each of 
five categories of smoking status are shown in Figure 15. 
Those who had stopped smoking at least 1 year were very much 
like those who had never smoked, while those who had stopped 
within the year in which the sample was drawn, clustered 
with current smokers. Therefore subjects were dichotomized 
on smoking.
Estimation of and adjustment for circadian and 
circannual variation in the lymphocyte profile within the
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TABLE 9
SUBJECTS DELETED BECAUSE OF 
EXTREME VALUES OF (HLA-DR) - (CD22)
SUBJECT HLA-DR CD22 DIFFEREN
C099 0.451 0.083 0.368
P006 0.411 0.045 0.366
C256 0.431 0.110 0.321
P120 0.472 0.159 0.313
P005 0.321 0.011 0.310
P051 0.348 0.046 0.302
C184 0.346 0.047 0.299
C114 0.363 0.080 0.283
P092 0.387 0.105 0.282
C143 0.256 0.289 -0.033
C277 0.035 0.107 -0.072
constraints of a linear model required the transformation of 
longitudinal time units into cyclic variables. Inspection 
of plots of the profile logratios In (CD3-i-CD22) and 
In (CD56-s-CD22) , adjusted for age, disease, smoking, and an 
age-by-smoking interaction (Figures 16 and 17) , suggested 
that cosine functions of the time units could be utilized in 
constructing effective transformations. Therefore two 
cosine functions with different periods were used to model
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Figure 15. Profile adjusted for age and disease, by 
smoking.
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Figure 16. Means of adjusted profile logratios by month 
of year.
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day.
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the effect of each of the time variables month and hour and 
the transformation consisted of a linear combination of the 
two functions. The adjusted-logratio plots were used to 
estimate periods for the circannual variation and those for 
the circadian variation; these were assumed to be constant 
throughout the year and day respectively. Proc NLIN in SAS 
(SAS Institute, Inc. 1988, 675-712) was utilized to estimate 
the acrophase for each cosine function and the acrophase was 
also assumed to be constant over the day or year for the 
component with the shorter period. The residuals of the 
profile logratios adjusted for other factors in the model 
were then regressed on the linear combination of the two 
cosine functions and an interaction term for the two 
functions to estimate the appropriate coefficients for the 
best linear combination. The transformations used were 
T(month) = 0.545cos[ (27T-T-12) (month-5.17) ]
+ 0.967cos[2TT-j-4) (subyear-1.7) ]
+ 3.9lcos[ (27T-4-12) (month-5.17) ]cos[ (27t-:-4) (subyear-1.7) ], and 
T(hour) = 0.102cos [ (27T-S-24) (hour-8.3) ]
+ 0.123cos[ (27T-T-6) (subday-2.45) ].
An interaction term did not contribute significantly to the 
fit of residuals to cosine functions of hour, but seemed 
important for the transformation of month.
Residuals from the 5-factor model including age, 
disease, smoking, T(month), and T(hour) were regressed on 
weekly vegetable intake (VEG) and VEG contributed to the
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explanation of the residual variance at the 0.05 level. The 
distribution of VEG was examined and 2 outliers were 
detected at 72 per week and 97 per week. Since these were 
unlikely to reflect true consumption rates and it was 
undesirable for them to have undue influence on the 
contribution of VEG to the model, the values for these 
individuals were recoded to 55 per week, a value just above 
the highest value for the other subjects. Furthermore when 
one categorized VEG: 0-6, 7-14, 15-20, 21-27, 28-34, and >34 
per week, a threshold effect was suggested with the break 
point at 14 per week. The dichotomous VEG contributed at a 
higher level of significance than continuous VEG toward 
explaining the variance of the profile adjusted for the 
other variables, therefore VEG was considered to be 
dichotomous.
Similarly FAT intake as percent of daily calories was 
an important determiner of lymphocyte profile and performed 
better as a dichotomous variable with the breakpoint at 28% 
of daily calories, than as continuous variable.
Finally alcohol (ALC), expressed as the percent of 
daily calories which come from alcoholic drinks, was found 
to be important to explain variation in the lymphocyte 
profile. Eight effects in all were found which accounted 
for significant portions of the variance of the profile: 
disease, age, smoking, hour-of-day, month-of-year, vegetable 
intake, fat intake, and alcohol intake.
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As variables were added to the model the 
transformations of month and hour were reevaluated. When 
T (month) was left out and a model built containing the other 
7 effects disease became a non-significant contributor and 
a very simple model resulted:
Ln (CD3-S-CD22) , Ln (CD56-5-CD22) = AGE SMOKING VEGETABLES FAT
ALCOHOL T(hour) AGE-by-SMOKING.
Yet when T(month), modelled as the linear combination (of 2 
cosine terms and their interaction) above was added, the 
model suddenly expanded to include 3 3-way interaction terms 
and 14 2-way interaction terms, beyond the 8 main effects. 
This suggested that month was being overmodeled. 
Examination of a partial-partial plot, that is, a plot of 
the data adjusted for the above model (excluding T(month) 
and disease) against month adjusted for the same variables 
(Figure 18) , a transformation involving only a cosine of 
month with a 12-month period was suggested. Thus the 
transformation of month was revised to
T(month) =cos[27T-j-12 (month-4.93) ].
When the residuals from the above model (excluding month and 
disease) were regressed on T(month), T(month) "explained" 
36% of that variance of the residual ln(CD3-J-CD22) by month 
and 72% of that variance of the residual ln(CD56-rCD22) by
Ln(T/B) MEANS BY ADJUSTED MONTH
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Figure 18. The adjusted data against adjusted month.
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month19 which could be accounted for by regression on 
categorical month. Using this revised transformation of 
month, a final 8-factor model was derived (Table 10) . This 
model "explained" 28% of the variance in ln(CD3-j-CD22) and 
43% of the variance in In(CD56-5-CD22) . If one adjusts for 
the degrees of freedom contained by the model (Neter, 
Wasserman, and Kutner 1985, 241),
Ra2 = 1 - [(n-l)-s-(n-p) ] (1 - R2)
= 1 - [233-5-223] (1-R2)
= 1.045(R2) _ o.045,
the adjusted R2's are 25% for ln(CD3-rCD22) and 40% for 
In (CD56-5-CD22) .
No subject who had missing data on any of the 
independent variables or on any of the components of the 
lymphocyte profile could be used in the analyses based on 
the 8-factor model. The model building used the data from 
234 subjects. They did not differ appreciably from the
19The denominator for determining the proportion of 
residual variance assignable to T(month) was the proportion 
of total residual variance that could be attributed to the 
means of the residuals by month. The proportion of the 
total variance which was the variance of the monthly mean 
residuals from the overall mean residual was determined by 
regressing the residuals on categorical month, i.e. a 
perfect fit of the model to the monthly means:
■^cd3/cd22 / Rcd56/cd22 = Mean + Ef f (mo) jld_f_ + ResidB
■^cd3/cd22 / ^cd56/cd22 = Mean + T (month) + ResidA + ResidB
T(month)/Eff(mo)Udf = proportion of monthly variance 
attributable to T(month).
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TABLE 10
FINAL MODEL FOR THE LYMPHOCYTE PROFILE
TYPE III TESTS. POF)
EFFECT Ln(CD3/CD22) Ln(CD5 6/CD2 2) MANOVA
DISEASE
AGE
SMOKING
VEGETABLES
FAT
ALCOHOL
MONTH
HOUR
DISEASE-by-
VEGETABLES
DISEASE-by-
MONTH
AGE-by-
SMOKING
0.0052
0.0009
0.7492
0.0060
0.0001
0.0003
0.2912
0.0004
0.0385
0.0053
0.8543
0.0253
0.0001
0.0237
0.0001
0.0175
0.0058
0.0080
0.0001
0.0069
0.0029
0.0026
0.0169 
0.0001 
0.0067 
0.0001 
0.0004 
0.0013 
0.0219 
0.0001
0.0237
0.0061
0.0003
R'2« _ 0.281 0.431
fii,222 statistics for Wilk's Lambda, Pillai's 
Trace, and Hotelling-Lawley Trace were all equal
’Uncorrected
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composition of the larger group on age, income, parish of 
residence, or education (Figures 19-22) .
Circadian variation.
A linear combination of two cosine functions with 
different periods was needed to model the circadian 
variation. The data spanned only 16 hours of the day so 
there was no information about variation between 11 p.m. and 
7 a.m. The data suggested that there might be a post­
prandial association; maxima occur near 8:30 a.m., 2:30
p.m., and 8:30 p.m. There did not seem to be any 
confounding of the hour-of-day term with other variables in 
the final model. Means of logratios adjusted for all other 
factors in the model were computed for the 3 maxima and 2 
minima spanned by the data and the corresponding profiles 
were plotted in Figure 23. There is more variation from 
"maximum" to "minimum" than one would expect for a three- 
hour period. For instance, B-cells more than double, from 
6.9% to 15.4% between 2:30 p.m. and 5:30 p.m.
The modeling of the circadian or hour-of-day effect on 
the lymphocyte profile as the linear combination of two 
cosine functions of hour of day performed well in accounting 
for the variance of the logratios with hour-of-day (Figure 
24) . When the profile logratios were adjusted for all 
effects except hour, T(hour) could claim 57% of the variance 
of the adjusted ln(CD3-rCD22) means by hour and 81% of the
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Figure 19. Distribution of subjects in the 8-factor model
by age.
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Figure 23. Circadian variation in the lymphocyte profile.
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Figure 24. The circadian variation of the lymphocyte 
profile logratios.
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variance of the adjusted ln(CD56-rCD22) means by hour20. 
Furthermore no interactions with T(hour) were significant 
when T(hour) was added to the model.
The T(month)-by-disease interaction.
Confounding arises in consideration of circannual 
variation in the lymphocyte profile and the difference in 
the lymphocyte profile between lung cancer patients and 
controls because subject composition with respect to disease 
varied with month of year (Figure 25) . This might be the 
reason that the effect of disease was not apparent in the 
model which excluded month. Furthermore there is a 
significant T(month)-by-disease interaction effect, i.e. the 
patients' profile varies differently over the year from the 
controls' profile. The interaction term in the model can 
be visualized as a correction factor of sorts. The data 
means adjusted for all effects in the model except the 
interaction term for T(month)-by-disease are plotted by 
month in Figures 26 and 27. Notice the almost complementary 
distribution of adjusted logratio means of patients by 
month, compared to the T(month) incorporated into the model 
(see 'predicted' curves in Figures 32 and 33) . The
predicted (in Figures 26 and 27) are the predicted from the 
full model minus the effects of all of the components of the
“Calculated in the same manner as the proportion 
attributable to T(month); see previous footnote.
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F i g u r e  26. Ln(CD3/CD22) : The interaction between T(month) 
and disease.
WS
^Z
d 
►- 
W
S
^
Z
d
144
Ln(NK/B) MONTH BY DISEASE EFFECT. CONTROLS
> > « 95*  C. Limit
A A A  P re d ic te d  Meons 
0 0 0  A d jus ted  M eans1.6
1.4
1.2
1.0
80.
0.6
0.4
0.2
0.0
JAN FEB MAR APR MAY JUN JUL AUC SEP OCT NOV DEC
MONTH SAMPLE COLLECTED
Ln(NK/B) MONTH BY DISEASE EFFECT, PATIENTS
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
■ .  ■ 95x  C. Limit 
A A A  p re d ic te d  M eans 
0 0 0  A d ju s ted  M eans
■ ■ 1 ■ I ' ■ ' 1 I ' i ■ ■ | ■ | ■ ■ ■ ■ I ■ ■ 1 ■ I » ■ ■ ■ I ■ ■ ■ 1 I ■ ■ ' | »
FEB HAR APR HAY JUN JUL AUC SEP OCT NOV DEC
MONTH SAMPLE COLLECTED
Figure 27. Ln(CD56/CD22): The interaction between
T(month) and disease.
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Figure 28. Ln(CD3/CD22) adjusted for all effects,
including disease and disease-by-vegetable, except
T(month) and T(month)-by-disease.
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Figure 29. Ln(CD56/CD22) adjusted for all effects,
including disease and disease-by-vegetable, except
T(month) and T(month)-by-disease.
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model except T(month)-by-disease, in other words, Mean0 +
r
*  T(month)-by-discasc •
Without T(month) the disease-by-vegetable interaction 
is significant at only p<0.0567 and disease is significant 
as a main effect at p<0.02. When the disease-by-vegetable 
interaction is removed, the effect of disease becomes non­
significant. But if one retains both the main effect of 
disease and the disease-by-vegetable interaction in the 
model without T(month) or the T(month)-by-disease 
interaction and plots the data adjusted for this model by 
month (Figures 28 and 29) one definitely observes a 
different month effect for patients than for controls. 
Patients seem to experience maxima in September and minima 
around the first of April. It is somewhat difficult to 
identify trends in the patient data, however, because of the 
wide confidence intervals on the estimates.
Because the monthly variations of profiles for patients 
and controls are about 180° (6 months) out of phase, one 
would expect that the difference between patients' and 
controls' profiles would be maximal around May and November. 
If one adjusts the data for all variables except month and 
disease, one can see in Figure 30 that the profiles of 
patients and controls are indeed widely separated. The 
profile logratios are plotted in Figure 31. There was only 
one patient in November who had all of the data to be
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data to be included in the profile analysis, so there is no 
confidence interval on that profile.
Circannual variation.
If one isolates the effect of month by adjusting for 
all effects in the model except month and T(month)-by­
disease, then subtracting the effect of T(month)-by-disease 
(estimated as the predicted from the full model minus the 
predicted from the model without the month-by-disease term) , 
then plots the adjusted means by month, one sees the plots 
in Figures 32 and 33. The 'predicted' is that from 
regressing the adjusted data on T(month). Both logratios 
exhibit maxima in late April and minima in late October. 
The adjusted data for patients also fit the pattern seen in 
controls because of the adjustment for T(month)-by-disease. 
It is difficult to graph profiles by month on a ternary 
diagram because there are so many points, but four points 
representing the maximum, the minimum, and a point midway 
between on either side of the maximum were graphed (Figure 
34) to illustrate the cycle. The profiles represent the 
mean adjusted profiles for January and February, April and 
May, July and August, and October and November. The ternary 
plot also illustrates how deceptive and inadequate the 
logratio plots are for interpreting changes.
These data would suggest then that the lymphocyte 
profile does vary with month of year and that Caucasian men 
with lung cancer experience a cycle which is about 180° out
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Figure 32. Ln(CD3/CD22) adjusted for all effects except
month, including the estimated T(month)-by-disease effect.
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Figure 33. Ln(CD56/CD22) adjusted for all effects except
month, including the estimated T(month) -by-disease effect.
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of phase with that of Caucasian men who do not have lung 
cancer.
The disease-by-vegetable interaction.
Patients' and controls' lymphocyte profiles seem to 
respond to vegetable intake differently. The classical 
statistical interaction between 2 dichotomous variables is 
seen in Figure 35. The magnitude of the effect, on both 
logratios, of low vegetable intake seems to be much greater 
for patients than for controls. Figure 36 illustrates how 
that interaction is translated into the effect on the 
composite lymphocyte profile. Patients who say that they 
consume more than 14 vegetables per week have lymphocyte 
profiles very similar to those of the controls. However the 
profiles of those who have a low vegetable intake are 
affected more severely than those of controls. Patients 
with low intake have 21.7% NK compared to 17.2% for those 
with high intake, whereas the controls with low intake only 
have 19.8% NK. The difference in NK is evenly distributed 
among T-cells and B-cells among controls, whereas patients 
have predominantly a relative loss of B-cells.
The vegetable effect.
When the vegetable effect was isolated (Figure 37), it
looked not much different from the control effect, which is
what one would expect. When the adjusted logratio means
were plotted against vegetable intake category, the
VEGETABLE BY DISEASE INTERACTION, ln(T/B) Means
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Figure 37. The isolated vegetable effect.
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Figure 38. The isolated vegetable effect, by vegetable 
intake category.
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threshold effect which caused vegetable consumption to be 
dichotomized can be seen (Figure 38). If the model without 
disease effects was fitted to controls only, the vegetable 
contribution was non-significant (Manova F statistics = 
1.53, p<0.22). Therefore the vegetable effect was large 
only among patients.
Lung cancer effect.
The disease effect isolated from the effects of the two 
interactions is presented in Figure 39. Statistically the 
difference is not likely to have been found by chance 
(p<0.017), but it is questionable whether there is any 
meaningful or interpretable biological difference here.
The age-by-smoking interaction.
Throughout the modeling process the age-by-smoking 
interaction was an important effect. The importance of the 
interaction persists among controls alone, (as one would 
expect since the significance of the interaction in the full 
model among all subjects is calculated as a Type III sum-of- 
squares). The logratio plots (Figures 40 and 41) are not 
especially informative about the changes in the actual 
profile. If one groups subjects by age such that V 4 fall 
into the "young" category, V 4 fall in the "old" category and 
the other 50% form the "middle" group, as in Figure 40, the 
relationship of logratio to smoking category appears to be 
linear. If one categorizes smoking by 10-year age groups,
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Figure 40. The logratios by smoking category by three age 
groups.
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however, the linear relationship does not seem to hold at 
the higher age groups. There appears to be a plateau effect 
or even a decline in logratios at the oldest levels. 
Because the numbers are small in these uppermost age groups, 
however, it is not possible to draw any conclusions about 
the behavior of the upper tail. Note that there were no 
current smokers in the over 80 age group.
If one appraises the ternary plot in Figure 42, a 
dramatic difference is seen in the maturation of the 
lymphocyte profiles among smokers compared to non-smokers. 
As non-smokers age from less than 51 to older than 68, their 
percentage of NK rises from 14% to 24%. Their T-cells drop 
from 74% to 68% while B-cells are reduced from 11% to 7%. 
The profiles of smokers, however do not mature.
Consumption of alcoholic drinks.
The percentage of daily calories which come from 
alcoholic drinks seems to affect the lymphocyte profile. If 
one plots the profile logratios adjusted for the other 
variables in the model against alcoholic drink consumption 
in 5% increments (Figure 43), one can see a general linear 
trend, but the means estimated are not very precise since 
74% of the subjects fall in the lowest two categories. If 
one categorizes alcoholic drink intake in 3 groups such that 
the 62 subjects who get over 5% of their daily calories from 
alcoholic drinks are divided evenly in the upper two 
categories, a linear trend is more apparent (Figure 44) .
ALCOHOL CONSUMPTION. ln(T/B) Means
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Figure 43. The effect of intake of alcoholic drinks on 
profile logratios.
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The lymphocyte profiles of the three groups by low, 
moderate, and high intakes of calories from alcoholic drinks 
are plotted in Figure 45. The meaning of the changes seen 
here is unclear. Moderate drinkers have increased T-cells 
with roughly equal relative decreases in B-cells and NK. 
The heavy drinkers, however, have the same proportion of T- 
cells as the light- or non-drinkers, but increased NK at the 
expense of B-cells.
Consumption of fat.
The lymphocyte profile was affected by reported level 
of fat intake. There was an unmistakable threshold effect 
on the profile logratios, that occurred at 28% of daily 
calories in fat (Figure 46). The effect on the lymphocyte 
profile was not only highly significant (Manova F tests, 
p<0.0004), but substantial as well, there being a 5 
percentage point rise in the proportion T-cells among those 
with a high-fat diet, accommodated by a 4% decrease in B- 
cells and 1% fewer NK (Figure 47).
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Other factors tested.
Other variables were tested for influence on the 
lymphocyte profile by regressing the residuals from the 8- 
factor model on each of them individually. None of the 
following made a significant contribution toward explaining 
the variance of the residuals: parish of residence, income 
per person in household, education category, percent of 
daily calories in sweets, weekly fruit intake, weekly citrus 
intake, intake of green and yellow vegetables, total 
carotene intake, or B-carotene intake. Total vitamin C
intake was significant at p<0.048. Variables representing 
the sum of occupational exposures to potentially
carcinogenic materials and the sum of exposures of a year or 
more to occupations associated with higher incidence of lung 
cancer also failed to contribute toward explanation of the 
residual variance.
The effects of the vegetable- and fruit-related dietary 
items above were also tried on the residuals from a model 
which excluded the vegetable and vegetable-by-disease 
effects. None of them, including total vitamin C, made a 
significant contribution toward explaining the variance of 
the residuals.
Patients and controls on fat intake.
While modelling the lymphocyte profile, it was found 
that all 3-way interactions involving disease-by-fat had 0
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DF. On investigation, it was discovered that only one 
patient out of the 48 in the model-building process reported 
a low fat intake, compared to 21 of 166 controls (x2 = 0.51,
likelihood ratio X2 = 0.025). If fat intake was categorized
by quartiles of intake among controls, patients were under­
represented in the lowest category and over-represented in 
the highest category (p<0.005, Table 11).
TABLE 11
FAT INTAKE BY DISEASE
Controls
Patients
Fat Intake, % of Calories 
<32.6 32.6-38.1 38.1-41.8 >41
46 47 46 47
3 12 10 23
p(>X ) < 0.005
Disease and exposure to substances or occupations.
When subjects were dichotomized according to whether or 
not they had been exposed for a year or more to any of the 
substances associated with higher incidence of lung cancer
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TABLE 12 
OCCUPATIONAL EXPOSURES
In your work, have you ever been exposed for a 
year or more to any of the following?
Asbestos
Radiation
Welding
Coal tar, soot, pitch, 
creosote, asphalt
Mineral, cutting or 
lubricating oil
Benzidine, J3- 
naphthylamine
Benzene
Isopropyl oil
Dyestuffs
Arsenic
Iron foundry
Nickel smelting
Underground mining
Lumber industry or 
heavy wood dust
Rubber or cablemaking 
industry
Chemical or plastics 
industry
Pesticides, herbicides
Mustard gas
Chromium
Cadmium, beryllium, 
vinyl chloride
(Table 12) , patients were more likely to have reported 
exposure (35 of 48 patients compared with 86 of 186 
controls; p(>X2) < 0.002). When the number of exposures was
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categorized by quartiles of controls (more than 50% of 
controls reported 0 exposures so that there were only 3 
categories) and the patients' distribution across categories 
was examined, the patients were significantly differently 
distributed (p < 0.004; Table 13). However, patients did 
not report having engaged in the occupations associated with 
higher incidence of lung cancer more often than controls.
TABLE 13
EXPOSURES TO CARCINOGENIC SUBSTANCES
Number of Exposures 
0 1 >1 
Controls 100 44 42
Patients 13 16 19
P(>X 22) < 0.004
Leukocyte subsets.
A differential leucocyte count of 100 cells was done 
for each subject. The mean percentages measured among the 
subjects are presented in Table 14, along with the expected 
ranges for adults (Wintrobe et al. 1974, 1794). The values
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TABLE 14 
DIFFERENTIAL LEUKOCYTE COUNTS
NORMAL PERCENTAGES
Mean 95% Ranae
Neutrophils 53 34.6 - 71.4
Lymphocytes 36 19.6 -52.7
Monocytes 7.1 2.4 - 11.8
Eosinophils 3.2 0.0 - 7.8
Basophils 0.6 0.0 - 1.8
CONTROLS PATIENTS
Mean Std.Err. Mean Std.Err.
Lymphocytes 37.24 0.78 24.45 1.39
Monocytes 1.87 0.49 2.43 0.27
Neutrophils 58.78 0.76 69.91 1. 51
Basophils 0.97 0.49 0.38 0. 09
Eosinophils 3.14 0.50 2.78 0.39
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observed for monocytes are suspect. The mean percentage of 
monocytes over all of the subjects in the study was 1.6%, 
whereas the expected value was 7.1% (2.4-11.8%). No
monocytes were observed among 100 cells for 85 of 286 
individuals (30%) while if the expected percentage of 
monocytes were 7%, the probability of counting 100 cells 
without seeing at least one monocyte is only 0.0007 
([0.93] 10°) . The mean values found for the other 4 subsets 
agree with reported ranges.
A leukocyte profile was constructed of the logratios of 
neutrophils, monocytes, eosinophils, and basophils to 
lymphocytes in a manner analogous to the construction of the 
lymphocyte profiles. The leukocyte profile among these 
subjects was not influenced by smoking or by the hour of the 
day when the sample was drawn. The final quadrivariate 
model included disease, age, month of year, and the age-by- 
month interaction.
The eosinophils, basophils, and monocytes together 
comprised only about 4% of the leukocyte composition. In 
the above quadrivariate model there was only one non-zero 
eigenvalue for the quotient matrix [SSCP],.^ ,.'1 [SSCP]model, 
indicating that the minor components of the leukocyte 
profile were not discriminated by the model. If the 
leukocyte profile was represented by the two logratios 
ln(neutrophils-Mymphocytes), In(other-Mymphocytes), the same 
independent variables were significant determiners and were
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TABLE 15 
THE LEUKOCYTE PROFILE
P (>F), Manova F Tests
DISEASE
AGE
MONTH
AGE-by-MONTH
Quadrivariate 
Model____
0.0001
0.0157
0.047
0.040
Bivariate
Model
0.0001
0.0074
0.0114
0.009
more highly significant (Table 15). After adjustment for 
age and month in which the sample was drawn, the subjects 
had less than 1% difference in their mean percentages of 
monocytes, eosinophils and basophils, but patients had an 
average of 25.3% lymphocytes and 71.0% neutrophils, while 
the controls had 36.0% lymphocytes and 60.7% neutrophils. 
Nearly all of the disease effect, then, was reflected in the 
differing proportions of lymphocytes and neutrophils.
Adjustment for age, month, and age-by-month decreased 
the intergroup difference in the mean logratio of 
neutrophils to lymphocytes by 15%, while not reducing the 
intragroup variances at all. However it did remove 
confounding; an exaggerated patient-control difference due
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to different age and month distributions among the two 
groups.
DISCUSSION
Study subjects.
The patient population in this study should not be 
considered to be representative of all Louisiana lung cancer 
patients with respect to histologic type since selection 
processes associated with treatment were operant. The 
relative prevalence of the major types of lung cancer varies 
geographically and with time, but most studies find that 
large-cell carcinoma is less common than adenocarcinoma, and 
adenocarcinoma less common than squamous cell carcinoma. In 
this study there were very similar numbers of the three 
types. The composition of the patients may reflect a 
greater use of radiation therapy among cases of large-cell 
carcinoma than among other types.
One would expect to find never-smokers or long-time ex­
smokers among the men with the least smoking-related type of 
lung cancer, adenocarcinoma, but there were no life-time 
non-smokers at all among patients21. If 95% of lung cancer 
among men is associated with having been a smoker, the 
probability of observing no non-smokers among 64 lung cancer
21If 95% of lung cancer cases among men are associated 
with having smoked, the probability of observing no non- 
smokers among 64 patients is 0.0375. About 1 in 25 samples 
would contain all current smokers or ex-smokers.
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patients is 0.0375 ( Q.9564 ), which means that about one in 
25 samples would contain all smokers or ex-smokers. The 
proportion of ex-smokers among the adenocarcinoma group was 
actually smaller than in other histologic types, but the 
difference in distribution was non-significant. Perhaps 
non-smokers who get carcinomas of the lung and especially 
those who get adenocarcinomas are less likely to receive 
radiation treatment for it.
Although all of the patients had smoked at some time, 
6 of the patients (10.2%) reported that it had been 20 years 
or more since they had quit smoking. It is commonly 
believed among epidemiologists, that an ex-smoker's risk of 
lung cancer drops to that of a non-smoker after 15 years. 
This observation could be meaningful in terms of identifying 
alternative or auxiliary causes, however the in-depth 
analysis of the characteristics of these men was beyond the 
scope of the present phase of analysis.
The controls compare reasonably well with the patients 
in terms of demographic characteristics. Selection of 
volunteers from local civic groups like Lions and Kiwanis 
and even AARP tended to raise the average socioeconomic 
level of the controls. Each resource group tended to be 
different from the other in the socioeconomic 
characteristics and also in the age range represented, but 
this heterogeneity was unavoidable, since random-digit 
dialing or driver's license resourcing were not feasible for
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this study. The veterans' organizations were the most 
balanced in terms of the characteristics for which 
similarity was desired among patients and controls, e.g. 
age, parish of residence, and socioeconomic indicators. It 
was difficult to find volunteers in their late 70's or 80's, 
however, and particularly difficult to find elderly smokers. 
Attempts to gain access to residence facilities for senior 
citizens for the purpose of recruiting volunteers were 
unsuccessful. The prevalence of smoking appears to decline 
as a birth-cohort22 ages, either through attrition of the 
habit or biological selection. It was fortunate that former 
smokers of at least one year were much like never-smokers in 
their lymphocyte profiles, or there would have been no "non- 
smokers" among patients. The empty cell would have created 
difficulties in the statistical analysis.
The questionnaire.
The questionnaire was relatively long. A large 
proportion of the time and effort required to complete it 
was due to the dietary portion, in which the food frequency 
questions on 99 requested estimates of both portion size and 
frequency. The overall response of the subjects was good 
given the length of the instrument. If subjects 
inadvertently skipped pages, these were sent to them for 
completion. A number of subjects placed check marks instead
22A birth cohort is a group of people born in the same 
year or span of years.
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of numbers in the food frequency boxes. Those also had to 
be mailed back for correction. Two patients could not read 
or write. For one patient, this problem was identified 
while the man was still at PCC and a nurse helped him to 
complete the questionnaire. The other patient became a 
'non-responder'. It is unknown if any of the controls did 
not return the questionnaire because they were illiterate.
Dietary data.
The 3 dietary associations that were found with the 
lymphocyte profile suggest that the dietary data obtained in 
this study is meaningful, at least on a group level (Block
1982). If the food-frequency method used had been 
inadequate, one would expect reduced chances of finding 
differences among subgroups due to non-differential 
misclassification of subjects by nutrient intake (Rothman 
1986, 87) . The possibility exists, of course, that patients 
were more motivated to complete the questionnaire accurately 
than controls, but there is no reason to suspect that they 
would report higher consumption of any particular food than 
controls because of their diligence, or because of their 
disease status. When compared to controls on the overall 
quality of their dietary data, patients were no more likely 
than controls to have dietary data with none of the flaws 
flagged by the Block software. A major advantage of using 
the Block dietary questionnaire is that the dietary results
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on this group of subjects will be comparable to the results 
of other studies which have used this instrument.
The laboratory method.
In deciding upon a method for to isolating the 
leukocytes of interest, 3 options were considered. Many 
investigators prefer to work with lymphocyte populations 
isolated on density gradients, but some investigators have 
demonstrated that certain subsets, in particular subsets of 
CD8+ cells, can be lost (Renzi and Ginns 1987; Green and 
Stelzer 1988). Ficoll preparations are not quantitatively 
lymphocytes, either; substantial numbers of monocytes remain 
in the preparation. Monocytes are also the most difficult 
to exclude on the flow cytometer (Green and Stelzer 1988). 
Because of the fear of biasing their results due to selec­
tive loss of subsets on density gradients, many researchers 
do whole blood lysis. The problem with that approach is 
that considerable debris from the lysed erythrocytes remains 
behind. It is difficult to exclude such debris on the 
cytometer without also excluding small lymphocytes. By 
collecting the buffy coat, most of the erythrocytes are 
eliminated and clean samples can be obtained.
Sample to sample spillover occurred despite vigilance 
against it. Fluorescence histograms of each sample were 
monitored in the instrument's display window, and data 
acquisition by the computer was not begun until equilibrium
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in the histogram was attained. The transport of a sample to 
the point where it passes through the laser beam involves 
passage through approximately 12 inches of plastic tubing, 
which can cause an effect much like hysteresis. It should 
be considered a flaw in the design of the instrument.
An unforseen problem arose with the labelling of total 
leukocytes because with the Consort 40 software, one cannot 
avoid collecting data on granulocytes. In some individuals 
lymphocytes constituted only 5-6% of the total leukocytes. 
This meant that in order to collect data on even 2000 
lymphocytes, a total of 40,000 events had to be recorded. 
This created a problem with data storage and handling, and 
resulted in collection of fewer lymphocytic events than were 
desired. Handling large data files was difficult given the 
computer-to-computer transfers which were required for data 
processing as well, and the longer files were truncated at 
2500 sampled lymphocytes. Thus an average of only 2 000 
lymphocytes per sample were actually analyzed. The usual 
sample size in previous reports in the literature was 
between 5000 and 10000 lymphocytes. The analysis of 
relatively small samples was probably the reason that sample 
overlap constituted a serious problem. When a sample was 
truncated, the first 2500 recorded events were kept; it 
would have been preferable to have retained the last 2500 
since the events carrying over from the previous sample
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would have occurred much more frequently at the beginning of 
the current sample than at the end.
The new method for editing and processing the FACS data.
The only means of analyzing the cell sorter data which 
was available with the Consort 40 software, was to display 
a sample on the computer monitor in the two dimensions of 
scatter, visualize the leukocyte subpopulations by 
displaying contours (boundaries within which were 
coordinates which had been recorded at least n times), and 
draw an arbitrary polygon around the lymphocyte population 
with the mouse to select the lymphocytes. The sample could 
then be replayed on green fluorescence and side scatter, and 
the fluorescence-positive population isolated with the aid 
of the mouse in the same way. The computer would then 
provide the statistics for the selected population. If the 
positive and negative populations overlapped in 
fluorescence, the Consort 40 software provided a one­
dimensional normal curve-fitting routine to assist in their
separation.
The most immediate problem with using the available 
method was that it was extremely labor-intensive and time- 
consuming and therefore inadequate for processing a large 
number of files. It would have been impossible to monopo­
lize the computer for the time required since it was needed 
for operating the FACS. Secondly the method was too subjec­
tive. If one were to reanalyze the same file without having
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recorded the coordinates of the polygon used before, it was 
unlikely that one would select the same polygon. Visual 
estimation of the boundaries of the two-dimensional 
lymphocyte distribution is not accurate enough. Further­
more, one either had to create a new polygon for each sample 
from a subject, or ignore fluctuations in machine (stream) 
alignment which can cause the mean of the lymphocyte popula­
tion on scatter to shift somewhat from sample to sample. An 
automated, objective method was needed which processed each 
sample in the same way, while being flexible enough to 
respond to variations in scatter properties among samples.
The conventional method for determining the percentage 
fluorescence positive was not entirely satisfactory either. 
There is no difficulty in discriminating the fluorescence- 
positive cells from negative populations when the two are 
completely separated but can be difficult when the 
difference of the mean fluorescence of the two is not at 
least 4 standard deviations. It has been standard practice 
to set a cut-off point at that channel above which only 5% 
of the unlabelled control cells fall (Lanier et al. 1983). 
The number of cells of the sample which fell above this 
channel, less 1 /19 x the number of negative cells, are 
considered the positive population. No consideration was 
given to the possibility that some of the events recorded in 
the "positive" domain might not belong to the subset of 
interest, or to those situations where there could be more
than one positive subset having differing densities of 
marker expression. Another problem with this method was 
that positive cells which fell below the cutoff were counted 
as negative and therefore the proportion positive was 
variably biased depending upon the true proportion that was 
positive, and upon the proportion of the positive cells that 
lay below the cutoff channel. The 95th percentile for 
negative cells was rarely the 5th percentile for positive 
cells and the antigen density, which determines the mean 
brightness of positive cells, can vary from individual to 
individual, as well. Consider a hypothetical situation in 
which 50% of lymphocytes label with a marker antibody and 
the 95th percentile for control or negative cells is the 
20th percentile for positive cells. Rounding to whole 
numbers, the above method would conclude that only 37% of 
the cells were positive! Furthermore it cannot be 
determined what percentage of positive cells fell below the 
95th percentile for negative cells, unless one assumes 
normality of the distributions, finds the mode of the 
positive cells, assums that the mode is the mean, and 
estimates the variance from the upper half of the positive 
distribution. If that approach were taken, however, fitting 
Gaussian curves to the fluorescence histogram would have 
been preferable. Indeed this has been another approach for 
estimating each population (Mann, Hand, and Braslawsky
1983). BD software includes software which will fit up to
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five Gaussian curves to a fluorescence histogram, but it can 
be applied in only one dimension at a time.
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Figure 48. Comparison of Bonferroni simultaneous C.I. to 
bivariate 95% estimation ellipse.
The current study not only took advantage of the 
normality assumption, but also used the advantage that data 
are recorded in multiple (in this case, four) dimensions. 
Considering multiple dimensions simultaneously, which is the 
essence of multivariate statistics, increases the precision 
and accuracy of estimation (Johnson and Wichern 1988) . For 
instance, if one were to estimate a confidence interval for 
a variable in each of two dimensions separately but using a 
Bonferroni alpha-j-2 adjustment for making multiple (two)
interval estimates, then plot the confidence limits in two 
dimensions, the result would be a rectangular confidence 
area with dimensions of Mi ± 2.24 and having an overall 
confidence level of 95%. However if one considered both 
dimensions simultaneously and used the information contained 
in the covariance matrix, the boundary of constant 
statistical distance would be an ellipse with axes equal to 
Mi ± 2.448 CT; for a joint confidence level of 95%. The 
confidence area so defined is 94% of that of the rectangle 
(Figure 48) . Note that the 95% range of values of x2 
depends upon the value of Xj and vice versa even though in 
this example the variables are orthogonal, that is, their 
covariance = 0. This arises from the joint improbability of 
both variables" having extreme values at the same time. 
Thus multivariate analytical techniques use more of the 
information in data such as that collected in this study and 
yield more precise and accurate estimates. The method 
invented for this study and described in "Materials and 
Methods," then, improved upon several aspects of the 
analysis of FACS data.
Estimation of the scatter mean of lymphocytes from the 
crudely edited cells worked well in most cases. Problems 
did arise in samples that were relatively lymphocytopenic in 
that a large percentage of contaminating, outlier cells 
compared to the actual lymphocytes were present and had undo 
influence in the estimation of the mean. In a few cases,
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the first elliptical cut had to be made at 75% in order to 
exclude influential outliers.
The clustering technique for achieving starting values 
for the normal-curve-fitting routine which estimated the 
percentage of positive cells worked well. Using more 
clusters than actual subsets was helpful since the density 
of events with particular coordinates only indirectly, 
influences the clustering process; primarily the distance 
from the mean coordinates of each cluster is the criterion 
for assignment of an event to a cluster.
Because the group estimates on each parameter were as 
precise as those for the old method, and the new method 
sampled 33% fewer events, the new method seems to be 
actually more precise. Another way to visualize that is to 
realize that if as many events were sampled in the new 
method as in the old method the experimental variance 
component would have been reduced and the group estimates 
would have had smaller variances than those made by the old 
method. Whether the estimates from the new method differ 
from those produced by the old, is still an unanswered 
question, since the comparision of 27 subjects could show 
that they were different only if the mean paired difference 
was 6% or more!
The computerized method could be improved. No attempt 
was made in the data processing to assess residual 
contamination of the lymphocyte population by monocytes.
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Roughly 8% of the subjects might have had more than 1% of 
monocytes in the selected elliptical confidence window, 
therefore biasing estimates of lymphocyte subsets in the 
negative direction. One could use the monocyte marker to 
flag those subjects with more than X% monocytes, for 
reediting. Alternatively, (or additionally) one could 
correct for the estimated number of monocytes in the 
selected lymphocyte window.
The latter procedure might be the preferred one, since 
tightening the window would begin to bias the estimation of 
NK because of their higher mean side scatter. Another 
source of variation in the overlap of lymphocyte and 
monocyte populations was day-to-day variation in degree of 
resolution on scatter which was achieved in aligning the 
instrument. While there did seem to be some interpersonal 
variation in the relative scatter properties of lymphocytes, 
monocytes, and granulocytes, observed among subjects run on 
the same day, the focus of the populations was directly 
affected by instrument alignment on a daily basis. The FACS 
440 is not as easy to operate as, for instance, an 
ultraviolate spectrophotometer. Better results on these 
samples might have been obtained by a better-trained, more 
experienced operator.
For the last approximately 75 subjects, a small 
population (on the order of 1%) of lymphocytes apparently 
positive for the NKH-1 marker appeared at a higher mean
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fluorescence than that of the majority of positive cells, 
and the mean fluorescence of the presumed NK declined 
slightly from what it had been in earlier samples. The 
brighter population was too small to be seen while 
collecting the data and became apparent only during the data 
processing. Because the NKH-1 antibody used was all of the 
same lot number and the aberration occurred during the last 
quartile of subjects, aging of the antibody solution was 
suspected to be the cause.
A perspective on analysis.
There were 2 possible approaches to the analysis of 
these data. The epidemiologic approach would have 
disease/no disease as the outcome of a function of multiple 
variables, including lymphocyte profiles, in a logistic 
regression model. The immunologic approach is to look at 
lymphocyte subset profile as the outcome variable and 
disease as one of the modifying characteristics. In this 
phase of the analysis, the immunologic approach was chosen.
One of the difficulties in evaluating differences in 
numbers and proportions of various leukocyte subsets is that 
the blood compartment is a closed system. Modifications in 
particular subset levels necessitate that other subsets are 
modified as well. Some researchers speak of "numbers" of 
cells with a particular phenotype (per mm3 of blood); others 
prefer to operate in the context of relative proportions of
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one cell type to another. To say that the number of T-cells 
is reduced in the blood of lung cancer patients (e.g. Ginns 
et al. 1982) without consideration of whether total 
lymphocytes are also reduced among such patients is of 
limited value. For instance, persons with granulocytosis 
could have an expanded blood volume and therefore the same 
number of T-cells in the total peripheral blood compartment 
as those with normal levels of granulocytes, yet the number 
of T-cells per cubic millimeter of blood would be reduced. 
Therefore the relative proportions of subsets are more 
meaningful. Even then a particular subset should not be 
taken out of the context of the total composition if 
possible; alterations in one subset do not occur without 
compensation among other subsets. A profile approach in 
treating compositional data is a more comprehensive and 
therefore more meaningful perspective in analysis.
Subset balances.
Estimates of proportions will be nearly normal in their 
mid-range, but since they are constrained to vary between 0 
and 1, for low proportions or high proportions distributions 
of estimates become asymmetrical. Therefore, if one is to 
make meaningful estimates of central tendency and variation 
of estimates, a transformation is necessary to "normalize" 
the distributions. Either logit (log-odds) or arcsin 
transformations work very nicely; the logit transformation 
was chosen for these data merely because it was similar in
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nature to the logratio transformations which were used for 
compositional analysis. Essentially it is the logratio 
representation of a two-component composition.
In considering both dimly and brightly CD8+ lymphocytes 
their sum is greater than the total number of cells which 
are CD3+. Although one group (Blue et al. 1985) found an 
average of 3% CD4+CD8+ cells in T-cells from normal donors, 
only activated, proliferating populations of T-cells have in 
general been found to contain meaningful numbers of cells 
expressing both CD4 and CD8 (Creemers 1987) . In fact in 
Blue's work, cells were isolated by rosetting with sheep red 
blood cells and may have been activated in that process. 
Binding of the Til (CD2) sheep erythrocyte receptor has been 
shown to activate thymocytes to express interleukin 2 
receptors (IL-2R, Fox 1985) . Thus overestimation of CD4 + 
plus CD8+ cells from counting doubly positive cells twice is 
an unlikely explanation for the excess.
The cells which express CD8 at low density are probably 
a subset of NK cells, which do not express CD3 (Perussia 
1983; Ault 1988). There is also evidence that a small 
percentage of CD3+CD8+ cells are dimly CD8+ (Wonigeit et al. 
1988) , which would mean that part of the population of 
lymphocytes which express CD8 at low density could account 
for the difference between CD3+ and CD4+ + CD8+bright. Some 
extraneous CD4 reactivity could also be due to contaminating 
monocytes but this is unlikely; monocytes carry CD4 at low
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density and only brightly labelled CD4+ cells were counted 
as positive. Also the sum of CD4+ and bright CD8+ is 5% 
less than CD3+, a difference too large to be accounted for 
by contaminating monocytes. Landay states that some CD3+ 
cells expressing y/S T-cell receptor genes carry neither the 
CD4 nor the CD8 antigenss (Landay 1990) which, along with 
putative CD8+dim T-cells, would help to explain why the sum 
of CD4+ and bright CD8+ cells was less than CD3+ cells and 
allow the dimly CD8-labelled NK cells to account for the 
excess in total CD8+ + CD4+.
The excess of HLA-DR+ cells over the number of B-cells 
presumably represents activated T-cells (Evans et al. 1978) . 
Transplant recipients show increased expression of HLA-DR on 
CD8+ T-cells (Henny it al. 1986). Henny et al. found that 
expression of HLA-DR by CD8+ cells correlated with lower 
expression or steric hinderance of the CD8 epitope recog­
nized by the Leu-2a anti-CD8 antibody, but did not affect 
the epitope recognized by 0KT8. The lung cancer patients 
averaged a 5% greater excess of HLA-DR expression than 
controls. Since we have data on samples double-labelled 
with Leu-2a FITC and CD11 PE, the findings of Henny et al. 
could be tested among our subjects. If patients showed a 
greater difference in proportions of cells labelled with 
0KT8 and Leu-2a than controls and that difference correlates 
with higher HLA-DR+ - CD22+ percentage, there would be 
indirect evidence that more CD8+ T-cells in patients are
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expressing HLA-DR than in controls. This might be 
postulated as evidence of an ongoing anti-tumor immune 
response.
For the purposes of this analysis, the 11 individuals 
in Table 10 were considered to have erroneous estimates for 
either HLA-DR or CD22 or both. For instance, subject C143 
had an estimated 29% B-cells which is an unlikely percentage 
in a normal individual. However it is possible that these 
individuals did indeed differ from the rest of the 
population in terms of their HLA-DR+ and/or CD22+ 
lymphocytes.
The CD45R+ and CD29+ subsets of CD4-positive cells did 
not sum to the proportion estimated as CD4-positive by 
independent labelling (0.36 v. 0.44). These non­
equivalencies could be due to a bias in the estimation of 
the subsets involved, but others have found that cells 
CD45R+ and CD29+ do not account for all CD4+ lymphocytes 
(Morimoto et al 1985a; Coulter product bulletins) , that 16- 
32% of CD4+ T-cells express neither. Our results, 18% CD29' 
C45R', agree with these estimates.
No analysis of CD45R+ and CD29+ subsets has yet been 
done aside from verifying that the 2 subsets do not account 
for all CD4+ lymphocytes. That the correlation between the 
sum of CD4+CD45R+ and CD4+CD29+ with CD4+ was as high as 
0.77 could be interpreted to suggest that the CD4+CD45R'CD29' 
cells are a relatively stable percentage of total CD4+
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lymphocytes. Investigation of the subsets of CD4+ 
lymphocytes will be conducted from the perspective of the 
CD4+ profile, that is, the natural logs of CD29+ + CD45R' 
CD29' and CD45R+ -r CD45R'CD29' will be used to summarize the 
information about CD4+ T-cells. In this way the 
uncharacterized subset (s) of CD4+ T-cells will not be 
ignored.
The proportions CD3+, CD22+, and CD56+ summed to 1.00. 
Although the distribution of the difference 1 - CD3+ - CD22 + 
- CD56+ was not normal, it was symmetrical in that the mean, 
median, and mode were nearly identical. The mean, then, was 
a meaningful quantity. In any case, the distribution of the 
mean itself, is likely to be normal (by the Central Limit 
Theorem) . To test its difference from 0 using the paired t- 
test was, then, appropriate. That the profile sums to 1.00 
implies that CD3, CD22, and CD56 label exclusive and
complementary subsets. Sources differ as to the percentage 
of B-cells which carry CD22 and the percentage of NK which 
carry CD56, but nowhere has it been suggested that overlap 
of the three markers occurs. Furthermore no one has 
previously reported characterization of lymphocytes with 
this particular set of markers. Triple-labelling
experiments with a dual-laser instrument and 3 fluorochromes 
could verify the exclusivity of the markers and their 
comprehensiveness.
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The lymphocyte profile model.
Mathematical modelling was the method of choice for 
these data. Some of the variables of interest, especially 
the outcome variables, are continuous. Stratified analysis 
(contingency table analysis) necessitates the categorization 
of all of the variables (Kleinbaum, Kupper, and Morgenstern 
1982, 321) and when one categorizes a continuous measure, 
information is almost always lost. Furthermore, when one is 
exploring many factors, observations rapidly become too 
thinly spread among categories and precision in estimation 
is lost (Rothman 1986). In addition, the purpose here was 
to examine the effect of study factors, including lung 
cancer, on the lymphocyte profile as a whole, rather than on 
each component separately, and multivariate, multivariable 
regression23 is the only available analysis strategy which 
can accommodate all of these features of the study 
variables.
The partitioning of the variance of the lymphocyte 
profile among study factors was more successful than the 
univariate logratio R2s would indicate. Measurement of 
lymphocyte subsets involves substantial experimental error. 
Even duplicate CD3 determinations on aliquots of the same
23Researchers often refer to regression of one variable 
on several other variables as 'multivariate' whereas the 
better term is 'multivariable', reserving 'multivariate'to 
describe simultaneous regression of more than one outcome 
variable on one or more independent variables.
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buffy-coat isolate had an estimated standard deviation of 
2.7%. It was not possible to estimate any portion of this 
major source of variability since replication was not 
feasible, so it all remains in the total unexplained 
variation. Under these circumstances, it was remarkable 
that 25% of the variance of the CD3-^CD22 logratio and 40% of 
the variance of the CD56-j-CD22 logratio were assigned to the 
independent variables studied.
Circadian variation.
There is little known about the variation of relative 
proportions of lymphocyte subsets over hour-of-day (Levi et 
al. 1985; Ritchie et al. 1983; Kidd and Vogt 1989; Giorgi 
1986) , or month-of-year (Abo et al. 1984; Levi et al. 1988) . 
Subsets have been considered separately and not in the 
context of their membership in a composition. Insufficient 
numbers of subjects were assessed at time intervals too 
widely spaced to estimate the pattern of fluctuation, for 
example, the study of four individuals at 4-hour intervals 
to assess the circadian variation of T-, B-, and K-cells 
(Abo et al. 1981). Levi et al. (1985) measured 5 
individuals, also at 4-hour intervals, then estimated the 
parameters (mesor, amplitude, and acrophase) for each 2 
cosine functions with periods of 12 hrs. and 24 hrs. from a 
total of 30 data points, without properly accounting for the 
degrees of freedom in the model, and not taking into 
consideration that they were estimating 6 parameters from
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measurements at 6 values of the independent variable time 
(over-parameterization) . Finally other factors which affect 
the balance of lymphocyte subsets were not considered. 
Therefore there was no credible, previously proposed 
function which could be used in modeling and controlling for 
variation of the lymphocyte profile over time.
Abo and coworkers (1981) assessed the levels of T- 
cells, and immunoglobulin-bearing cells (B-cells) among 4 
individuals at 4-hour intervals throughout the day. He 
found minima for both subsets at 8:00 a.m. and maxima at 
midnight. Those subjects whose blood was sampled between 
5:00 and 6:00 p.m. in the current study had the lowest 
percentages of B-cells and the patterns of fluctuation in 
these data simply do not agree with theirs. That this study 
measured different individuals rather than the same 
individuals throughout the day may have had some influence 
on the results, although sex and race were controlled and 
the hourly logratio means were adjusted for 7 other profile 
modifiers including smoking, age, and disease status, thus 
removing much of the interpersonal variation. Since these 
were data-based transformations, degrees of freedom were 
'•used" in estimating the parameters of the linear 
combination of cosine functions, but the consequences would 
be negligible in the context of a total of 233 DF. Of 
course the only way that the proposed hourly pattern can be 
supported or refuted is through testing with another data
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set. Since there were no data for 8 nighttime hours, the 
daytime pattern cannot be projected to include that third of 
the day.
The magnitude of the circadian variation in the 
lymphocyte profile was unexpected. During the one 3-hour 
period, B-cells increased 9% (Figure 23) . Examining the 
profile logratio graphs, maxima are observed at 1.5 to 2 
hours after what would be mealtimes, suggesting that there 
might be a post-prandial effect. Studies of the same 
individuals sampled at 2- or 3-hour intervals throughout the 
day, on several days with mealtime schedules deliberately 
modified on each day, would show whether or not lymphocyte 
profiles were correlated with mealtimes. Lack of such 
cycling during the sleeping hours would also support a post­
prandial influence.
The peripheral blood accounts for only a small 
percentage of the total population of lymphocytes, the rest 
being sequestered in various tissues and in the lymph. 
Lymphocytes migrate through the blood, lymph, and the
tissues by means of surface molecules specific for ligands 
on high endothelial cells which line venules (Chin,
Sackstein, and Cai 1991) . It is plausible that the
digestive process induces the release of factors which cause 
expression of subset-specific ligands on the venule
endothelium in gut-associated tissues such as the Peyer's 
patches and removes lymphocytes from the peripheral
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circulation for a period of time, then allows them to 
return. The up-regulation of such ligands on cultured high 
endothelial venule cells by the cytokines TNF-a, 7- 
interferon, and granulocyte-macrophage colony-stimulating 
factor has been demonstrated (Cai 1991). To my knowledge, 
there is no data available on circadian patterns in 
lymphocyte migration.
The linear combination of two cosine functions of hour, 
even with the simplification of fixed periods and 
acrophases, accounted for the major portion of the variation 
of logratio means with hour of day. The remaining variation 
might still be due a more complex relationship of lymphocyte 
profile to hour of day, but it might also represent 
confounding of some other, as yet undetermined variable with 
both hour and lymphocyte profile.
The circannual variation.
There was a good deal of covariance between month of 
the year in which the samples were drawn and the other 
variables in the model. The partial-partial plot (Figure 
18) , with adjustment for 7 variables, reveals a simpler 
pattern of profile variation with month of year than was 
seen at first. The cosine of month function with a 12-month 
period was moderately successful in modelling the residual 
variance of the lymphocyte profile with month, accounting 
for 36% of the CD3-rCD22 logratio variance and 72% of the 
CD56-j-CD22 logratio variance. A better fit might have been
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possible if the period and acrophase had not been fixed, but 
those constraints were necessary for incorporating a 
nonlinear function into a linear model. Also some of the 
remaining variance with month could be due to confounding 
with attributes of the subjects, which were either not 
measured in this study or were not discovered in the model- 
building process.
The variation of lymphocyte profile over the year as 
illustrated in Figure 34 is modest, especially when compared 
to the fluctuation of profiles throughout the day. It is 
possible that the variation is due, in part, to seasonal 
variation in exposure to pathogens, or to seasonal 
modulation in climate. If the latter were a factor, then 
one would expect patterns of variation to differ 
geographically, particularly with latitude of residence.
T(month)-by-disease interaction.
The nature of the variation in lymphocyte profile with 
month is better characterized for controls than it is for 
patients because of the relatively low numbers of patients, 
but these data indicate, at least, that patients' profiles 
do not fluctuate in the same pattern that controls' do. A 
cosine function about 180° out of phase with controls' fits 
the data, but would only be just one of multiple patterns 
which would fit data with as much variation as the 
patients'. One explanation is that the disease effect 
merely overwhelms the circannual effect on lymphocyte
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profiles, but if one looks at Figures 28 and 29, there does 
seem to be a maximum for patients at about September and a 
minimum around March, which is nearly the reverse of the 
behavior of the controls's profiles. Actually, the data as 
plotted in Figures 28 and 29 suggest that patients's and 
controls's profiles are more nearly 120° or 4 months out of 
phase, but a variation in acrophase was not allowed for in 
the transformation of month used in this model.
The disease-by-vegetable interaction.
One can speculate about what the disease-by-vegetable 
interaction means. For instance, if substances in 
vegetables protect against initiating events, perhaps 
patients suffer more initiating events than controls given 
the same deficit in dietary protection and hence have a 
requirement for a greater expansion of NK. In a sense, 
then, patients as a group are more vulnerable to the 
negative effects of deficient diet. This could possibly be 
an effect which precedes the development of cancer in these 
people. Unfortunately the magnitude of the difference is 
probably not great enough for it to be used as a 
discriminator and it would only be useful for prediction 
among those people who happen to eat less than 14 vegetables 
per week in any case. The difference in lymphocyte profile 
between those who eat more than 14 vegetables per week and 
those who eat fewer is significant only among patients.
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The disease effect.
The differences between lymphocyte profiles of lung 
cancer patients and controls are contained for the most part 
in the disease-by-T(month) and disease-by-vegetable-intake 
interactions. If one adjust for both of those effects, the 
remaining difference is small (Figure 39) and probably not 
physiologically meaningful.
Age-by-smoking interaction.
These results with respect to smoking and age agree 
with those of Abo, Cooper, and Balch (1982) in that the 
proportion of lymphocytes with a NK phenotype increases with 
age. They also agree with Tollerude's findings of lower 
percentages of NK in smokers (Tollerud et al. 1989). 
Tollerud also found reduced percentages of cells with the NK 
phenotype among ex-smokers, whereas this study did not; ex- 
smokers' profiles in this study "caught up" with those of 
never-smokers. The finding of lower levels of
immunoglobulins G, A, and M in the blood of smokers (Johnson 
et al. 1990) would not be attributable to lower percentages 
of B-cells among smokers, because the differences in B-cell 
levels among smoking and non-smoking subjects in these data 
are quite small and probably not meaningful in a 
physiological sense. Smokers' profile logratios adjusted 
for all other effects in the model do not exhibit a 
significant linear age trend within the age range of these 
subjects (Manova F-tests: p<0.12).
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Consumption of alcoholic drinks.
It is unlikely that the alcohol effect seen in these 
data is due to chance since it is highly significant (Manova 
p<0.0013), but whether it has implications for health status 
is unclear. The pattern of change in the lymphocyte profile 
seen in Figure 43 is not readily interpretable. Part of the 
difficulty may lie in the manner in which the lymphocyte 
profile is modelled; what does a linear relationship with 
the logarithms of ratios of proportions have to do with the 
behavior of the subset proportions themselves? With respect 
to the age effect on non-smokers, there was a clear 
transition from status "young" to "old" with the middle-aged 
group falling inbetween. There is no such "trend" in the 
profiles of consumers of alcohol, but then it must be 
remembered that in ternary diagram, we are not dealing with 
2 dimensions, as we are accustomed to do, but with 3. The 3 
dimensions also bear the constraint that they must sum to 
1.00. It would have been helpful to have had CBC data to 
see if the individual subset concentrations are affected by 
consumption of alcoholic beverages.
Consumption of fat.
It is interesting to note that the lymphocyte profile 
is affected by intake level of fats , but even more 
intriguing is the unmistakable threshold effect (Figure 47) . 
Not only is there a threshold effect, but it occurs at an 
intake level of about 28%. This is quite close to the 30%
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recommended by the National Research Council (1989), and a 
number of health-related organizations, as the upper limit 
for percentage of calories in the diet from fats. The 
effect itself appears to be substantial, as well, having a 
magnitude of 5% in T-cells, about 4% in B-cells and 1% in NK 
(Figure 49) . One estimate of the 5th percentile to 95th 
percentile range for T-cells is 59-81% (Giorgi 1986) , 
therefore a 5% difference is relatively large. The 
particular subsets of T-cells which are increased would be 
of interest and might contribute to interpretation.
Another interesting finding with respect to fat intake, 
is that only one patient of 48 in the analysis fell into the 
low-fat intake category compared to 11% of the controls 
(p<0.036). The difference holds even if never-smokers are 
eliminated from the control group. The categorization of 
fat intake was based on the effect of fat intake on 
lymphocyte profile and entirely independent of patient/ 
control status, therefore it is likely that the finding of 
higher reported fat intake among patients is real.
That only 11% of controls report <28% of daily calories 
in fat reflects dietary habits in Louisiana in general. A 
high intake of fats has been associated with cancers of the 
colon, breast and prostate, but never before associated with 
lung cancer. Dietary factors, however, are not independent 
of one another, and perhaps fat in this situation serves as 
a surrogate for low 6-carotene intake or low fruit intake,
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both of which have been associated with lung cancer. 
However when B-carotene intake was divided into quartiles 
and then the distribution of patients and controls among 
quartiles was compared, there was no evidence that patients 
differed from controls in intake of B-carotene intake. Nor 
did they differ from controls in weekly intake of fruit, 
weekly intake of citrus, total carotene intake or total 
vitamin C intake. It is also possible that patients have 
modified their diets since their diagnosis of cancer to 
include more fruits and vegetables but did not reduce their 
fat consumption.
Other factors tested.
It would not be expected that demographic factors would 
affect the lymphocyte profile except perhaps indirectly 
through dietary habits. Neither would a history of 
exposures to carcinogenic substances be expected to have 
affected the lymphocyte profile, although current exposures 
could have an effect. It was interesting that weekly 
vegetable intake was important in modelling lymphocyte 
profiles, but specific nutrients such as B-carotene were 
not, and intake of green and yellow vegetables, in 
particular, was not. The potential of total vitamin C to 
contribute has yet to be explored.
Vitamin C intake did not appear to be important in the 
earlier models of the lymphocyte profile, which illustrates 
that model building is a dynamic and in a sense an iterative
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process. The remodelling of month of year underscores this 
fact, as well.
Usefulness of FACS data for diagnosis.
Unfortunately the contribution of measurement error to 
the variance of the profile estimation could not be 
quantitated. From the variance present in the replicate CD3 
samples, it is thought that the experimental variance is 
large. The precision with which the lymphocyte profile for 
an individual can be determined would be enhanced if 
replicate samples were prepared and more lymphocytes 
analyzed per sample. The usefulness of FACS data for 
classifying individuals depends directly upon the variance 
of individual estimates. Adjustment for factors which 
contribute to interpersonal differences in FACS measures are 
helpful if they reduce intra-group differences to a greater 
extent than they do inter-group differences, but the 
precision with which one can estimate group means is 
irrelevant for prediction of group membership for an 
individual unless one can estimate the individual's profile 
with precision.
The leukocyte profile.
During the data gathering phase of the study, patients 
seemed to be relatively lymphocytopenic compared to 
controls. This was verified in the analysis and is the 
major difference in the leukocyte profiles of patients and
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controls. Pulmonary bacterial infections are common among 
persons with lung cancer which could explain the relative 
granulocytosis. Smoking was not a significant determinant 
of the relative number of lymphocytes and neutrophils, which 
agrees with the observations of Miller et al. (1982). On 
the other hand, they reported no association with age 
whereas age was an important modifier in this study. The 
leukocyte profile was not explored as assiduously as was the 
lymphocyte profile, and other modifiers remain to be 
identified.
Adjustment for age and month of year in which the 
sample was collected reduced the difference between patient 
and control means by 15% while not reducing the intragroup 
variance at all. Still a control would have less than a 17% 
chance of having a neutrophil to lymphocyte ratio higher 
than the estimated adjusted mean for patients. It would 
also not be difficult to improve the individual estimate of 
the percentages of lymphocytes and neutrophils by counting 
more leukocytes, thereby reducing that component of the 
intragroup variance. Combining this indicator with 
similarly improbable measures could identify an undiagnosed 
patient.
Disease and fat intake and occupational exposures.
Preliminary evidence was found in this study that lung 
cancer patients were more likely to consume higher levels of 
fat than controls and were more likely to have reported
occupational exposures to potentially carcinogenic 
substances than controls. Evidence of the former 
association has not been found previously for lung cancer. 
Both associations will be explored in the context of 
potential confounders when the data is examined from the 
epidemiologic perspective. It is quite possible that the 
difference in occupational exposures might be explained by 
the differences in socioeconomic status between patients and 
controls. On the other hand, the differences in specific 
exposures could be quite meaningful in interpreting the high 
incidence of lung cancer in Louisiana.
SUMMARY AND CONCLUSIONS
The purpose of this study was to measure lymphocyte 
subsets among lung cancer patients and controls to determine 
whether (1) there were significant differences between the 
two groups after adjustment for other modifiers, and (2) to 
project whether those differences could be exploited, 
particularly in terms of earlier diagnosis of the disease. 
Realizing the complexity of the cancer phenomenon, wide- 
ranging, detailed data were gathered so that appropriate 
controls and adjustments could be made in the analysis.
In the process of the study a new method for automating 
the analysis of cell sorter data was invented. It removed 
a great deal of the subjectivity involved in other methods, 
and therefore should reduce intraanalyst bias and 
interanalyst variance. Certainly the method needs 
refinement, however the proof that it worked well for this 
study is that meaningful differences among subset profiles 
were found by other variables assessed. A comparison of 
subset estimates with determinations using a conventional 
method indicated that the new method gave estimates 
indistinguishable from those of the other method but was 
more precise than the old one. In addition to being more
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objective, the method designed in this study was automated 
and therefore labor-saving as well.
The first phase of the analysis was confined to 8 of 
the 17 subsets or subset combinations actually measured. 
The analysis is ongoing and the results presented here, 
aside from the lymphocyte profile analysis, included only 
some general observations of the relationships among the 
subsets analyzed. The major focus of these results is the 
modelling of the lymphocyte profile, the relative balance of 
CD3+ T-cells, CD22+ B-cells, and CD56+ natural killer cells, 
as a log-linear function of variables recorded about the 
subjects in the study. By summarizing the 3-component 
profile with 2 variables and regressing these simultaneously 
on the independent variables, a holistic view of the effect 
of involved variables on the lymphocyte composition was 
achieved. With the help of ternary diagrams, one profile 
can be visually compared to another, as well. The effects 
of 8 factors on the profile have been estimated from these 
data and presented for verification or refutation in future 
research.
Previously reported results with respect to differences 
in relative proportions of lymphocyte subsets between 
persons with lung cancer and those without have been 
conflicting. It is likely that the disagreement has been
due to failure to adjust for the many factors which 
influence lymphocyte balance. In the process of building
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this model, it was demonstrated that disease effect could be 
masked by confounding with another variable, that is, with 
the month of year in which the sample was collected, also 
with weekly vegetable intake. Differences between patients 
and controls in lymphocyte profile were predominantly within 
the disease-by-month and disease-by-vegetable-intake 
interactions.
Although previous research has demonstrated that 
lymphocyte subsets vary with circadian and circannual 
rhythms, data to date has been insufficient to describe the 
patterns of variation. With the data of the current study, 
cosine functions with periods of 6 and 24 hours model a 
large proportion of the variance of lymphocyte profile with 
hour of the day. There appear to be maxima at 8:30 a.m., 
2:30 p.m. and 8:30 p.m. Similarly the profile seemed to 
vary as the cosine of month with a period of 12 months and 
maxima for the logratios in May. The profile of patients 
appeared to be 6 months out of phase with that of controls.
The relationship of lymphocyte profile with age, 
between the mid-forties and the early eighties appeared as 
a consistent trend for non-smokers on the ternary plot 
across 3 categories of age , with the most dramatic 
difference being the increase of natural killer cells from 
14% to 20% to 24% of the composition. Smokers retain the 
lymphocyte profile of younger men which may not serve them 
well as their bodies age. The effects of smoking seem to be
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reversed in as little as one year after quitting, but are 
not instantaneously reversed.
Low vegetable intake in patients had a greater effect 
on their lymphocyte profiles than on the profiles of 
controls. There was a significant variation in lymphocyte 
profile with moderate (>5% of daily calories from alcoholic 
drinks) and heavy (>12%) drinking, but its meaning is an 
enigma at this point. The effect of a high-fat (>28% of 
daily calories) diet was surprisingly substantial, amounting 
to a shift of +5% in T-cells. It is interesting that the 
threshold effect of fat falls very near the upper limit 
recommended by specialists in nutrition for the daily 
dietary intake of fat. The dietary effects on components of 
the immune system observed in this study have not been 
reported previously and should offer fertile ground for 
further research.
Whether these findings concerning the lymphocyte 
profile could be useful in predicting a case of lung cancer 
prior to conventional diagnosis is doubtful. The difference 
between patients and controls is not large even after 
adjustment for other variables and the intragroup variance 
of the estimates remains substantial. A large component of 
that variance is the experimental error in the individual 
measurement. Until that can be reduced, the usefulness of 
FACS data for individual diagnosis will be limited.
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Perhaps when the analysis is completed patients will be 
found to be different from controls on enough indices, 
including but not limited to FACS data, that a composite 
differentiation scale can be constructed. Potentially 
useful differences have been found in the leukocyte profile 
and in the proportion of cells HLA-DR+ which are not B- 
cells. Patients were found to average 11% fewer lymphocytes 
and 10% more neutrophils than controls and 5% more HLA-DR 
expression that was independent of that of B-cells. In 
addition, patients reported exposure to suspected 
carcinogens more frequently, and had less of a tendency than 
controls to eat low-fat diets.
In conclusion, patients did display differences in 
their CD3-CD56-CD22 profiles from those of comparable 
controls, but the differences found were mostly contained in 
the differing patterns of circannual variation and more 
extreme effect of low vegetable intake. Difference in 
lymphocyte profile, then, would be an unlikely discriminator 
for lung cancer. A major difference in lymphocyte-to- 
neutrophil balance was found, however, that has potential as 
a component for a screening battery and a role for the 
relative excess of HLA-DR expression among patients has not 
been excluded, if the adjustment for confounders does not 
decrease the intergroup difference more than the intragroup 
variability and if the experimental variability in
individual estimates of subset percentages could 
controlled.
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LOUISIANA LUNG CANCER STUDY
Louisiana State University 
Mary Bird Perkins Cancer Center
HEALTH HABITS AND HISTORY QUESTIONNAIRE
This fo rm  asks you a varie ty  o f questions about you r background, env ironm en t, and habits, w h ich  m ay 
affect o r  be related to you r health. The in fo rm a tion  you p rov ide  w ill he lp  scientists to  understand m ore about 
the  causes o f disease.
T h is questionnaire w ill take about 40 m inutes to complete. Please f i l l  in  the in fo rm a tio n  requested, or 
place a check in  the appropria te  space. A  few  questions may be s im ila r to  ones you have answered before, 
b u t please do  n o t sk ip  any questions fo r th is  reason. I f  you are not sure about an answer, please estimate.
I f  you have any questions o r w ou ld  like  help f illin g  it  ou t, please call Joan Blackmon____________
at _388— 1213 Please re tu rn  th is  questionnaire b y __________________________________ We thank  you
fo r yo u r tim e and you r con tribu tion  to th is  research.
T'
lx. In WHAT STATE or COUNTRY were you born?
(Circle correct response.)
ALabama IowA New Jersey VermonT
AlasKa KanSas New Mexico VirginiA
ArlZona KentuckY New York WAshlngton
ARkansas LouislAna N. Carolina W. Virginia
CAlifornia Main® N. Dakota Wisconsin
Colorado MarylanD OHlo WYomlng
ConnecTicut Massachusetts. OKlahoma
DEIaware Michigan ORegon. Puerto Rico
D. of C. MiNnesota PennsylvAnia Virgin Islands
FLorida Mississippi Rhode .Island GUam
GeorgiA Missouri S. Carolina CaNada
Hawaii MonTana S. Dakota CUba
IDaho NEbraska TeNnessee MeXico
ILlinois NeVada TeXas Rest of World
INdiana New Hampshire UTah UNknown
2x. With respect to your PRESENT home,
in what PARISH do you reside? (Circle correct response.)
AsCension 
Assumption 
E. Baton Rouge
E. Feliciana Pointe Coupee W. Baton Rouge
IBerville St. Helena W. Feliciana
Livingston TAngipahoa
is your neighborhood (Check one. )
  URBAN?
  SUBURBAN?
  RURAL?
  OTHER?
what is your sip code? _____
Office Use 
X U  _ _
X13
X15
XI6
-1-
243
PERSONAL INFORMATION, HABITS
1. When were you bom?  I I_____
Month Day Year
2. How old are you?  years I 18
3. Sex: 1  Male 2 ___ Female ! 20
4. Race or ethnic background:
1 —  White, not of Hispanic orgin___4 __American Indian/Alaskan native
2 —  Black, not of Hispanic orgin 5 __Asian
3 —  Hispanic 6 __Pacific Islander
5. Please circle the highest grade in school you have completed:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 +
6. What is your marital status? 1_Single 3  Widowed
2 __Married 4  Divorced/Separated j 24
7. How many times have you moved or changed residences in the last ten years?  times 25
3x. Is the total income, before taxes and other deductions, of 
your household (the TOTAL income of ALL members of the 
household) (Check one.)
lacfiDS j *21
  Under S10,000/yr? I 1
  $10,000 - $19,999/yr? I 2
  $20,000 - $29,999/yr? I 3
  $30,000 - *39,999/yr? 4
  $40,000 - $49,999/yr? 6
  Or over $50,000/yr? I 6
  I don’t wish to answer. | 9
4x. Bow many persons are there in your household?   | X22
5x. For how many of the last 30 years did you live in a
RURAL AREA?..................  yrs I X24
I
SUBURBAN AREA?   yrs [ X26
URBAN (DOWNTOWN) AREA? .....  yrs , X28
-2-
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6x. Bave you ever lived within a mile of an industry which 
emitted DOST or ODORS or IRRITATING GASES?
No
Yes
Don’t Know
If YES,i
Tell me which plant you lived close to for the LONGEST 
period of time.
KIND OF PLANT? 
HOW LONG? ____
TYPE OF EMISSION? (Chefck one.)
Dust
Odors
Irritants
Other
Next longest? 
KIND OF PLANT? 
HOW LONG? _____
TYPE OF EMISSION?
  Dust
  Odors
  Irritants
  Other
Third longest? 
KIND OF PLANT? 
HOW LONG? ____
TYPE OF EMISSION?
  Dust
  Odors
  Irritants
  Other
Fourth longest? 
KIND OF PLANT? 
HOW LONG? ____ _yrs
TYPE OF EMISSION?
  Dust
  Odors
  Irritants
  Other
X30
0 
1 
9
1 X31
I
| X43
I X4S
1 
2 
3 
9
X46
| X58
! X60
1 
2
3
4
X61
X73
X75
1 
2
3
4
X76
1X68
X90
1
2
3
4
-3-
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8. Have you smoked at least 100-cigarettes in your entire life? 1  No 2 — Yes
IF YES: About how old were you when you first started smoking cigarettes fairly regularly? 
 years old
On the average of the entire time you smoked, how many cigarettes did you smoke per day?
 cigarettes per day
Do you smoke cigarettes now? 1  No 2  Yes
IF NO: How old were you when you stopped smoking?  years old
IF YES: On the average, about how many cigarettes a day do you smoke now? cigarettes
9. Have you ever smoked a pipe or cigars regularly? 1  No 2  Yes I f  Yes,
---------------------------T---
IF YES: For how many years?  years
About how much?  pipes or cigars per ,
(day or we«k) 1 2
27 —
2 8 ___
3 0 _____
32 _
3 3 _____
35 _____
37 _
3 8 _____
4 0 ________
If you have NEVER smoked, skip to question 1 x  
If you are a CURRENT or FORMER smoker
%
Since you began smoking, how many years were there, 
altogether, when you did not smoke? ______.
Bow many years did you smoke non-filter cigarettes?
How many years did you smoke filter cigarettes?  
Thinking about how you USUALLY smoked, would you say that
you (Check one.)
  DIDN’T INHALE
  DREW SMOKE INTO MOUTH &  THROAT ONLY
  INHALED DEEPLY INTO CHEST
  INHALED AT DIFFERENT LEVELS
  CAN’T DESCRIBE
Usually, how long was the butt when you put the cigarette 
out? Was it (Check one.)
  Was it more than 1/2 the cigarette?
  1/3 to 1/2?
  1/4 to 1/3 ?
  less than 1/4?
When you were not drawing on it, did you usually
  PUT THE LIGHTED CIGARETTE ON AN ASHTRAY?
  KEEP IT IN YOUR MOUTH?
  HOLD IT IN YOUR FINGERS?
  OTHER?
X91
X93
X95
X97
1 
2
3
4
5
X98
1 
2
3
4
X99
1 
2 
3 
9
-4-
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7x. Did either of your parents (or the people who raised you) 
smoke?
X100
  NO
  MOTHER (or mother-substitute)
  FATHER (or father-substitute)
I
Ox. Have you lived with a spouse or roommate who smoked?
  NO
  SPOOSE
  ROOMMATE
  OTHER
9x. For how many years altogether did you live with 
a smoker? _________yrs
0 
1 
2
X101
0
1
2
5
X102
10. During the past year, have you taken any vitamins or minerals?
1 —  No 2 —  Yes, fairly reeularlv 3  Yes. but not reeularlv I f  Yes,'
What do you take fairly regularly? #  o f PILLS per DAY, WEEK,
M ultip le Vitamins etc.
One-a-day type p ills  p e r
Stress-tabs type p ills  p e r
Therapeutic, Theragran type p ills  p e r How many milligrams
Other Vitamins or IUs per pill?
Vitamin A p ills  p e r r _____ IU per p ill
Vitamin C p ills  p e r _____ mg per p ill
Vitamin E p ills  p e r _____ IU per p ill
Calcium or dolomite p ills  p e r __ _____ mg per pill
Other (What?) 1 __ Yeast 2 ___ Selenium 3 __ Zinc 4 __ Iron 5 __ Beta<arotene
6 __ Cod liver oil 7 Other
Please list the brand of multiple vitamin/m ineral you usually take:
43
44
47
50
53 
57 
61 . 
65
FOR OFFICE USE
Q 10, mg or IU: 1=50-100 2 = 200-250 3 =  400-500 4 =  1000 5 =  5000 6=10,000 7 = 20,000-25,000 8 =  50,000 9 = Unk.
-5-
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11. Are you on a special diet?
1 ___ No 2  Weight loss 3  For medical condition
6 ___ Low cholesterol 7 _____Weight gain
. Vegetarian 5  Low salt
12. How often do you eat the following foods from restaurants or fast food places?
RESTAURANT FOOD
l
Almost 
every day
2
2-4 times 
a week
3
Once a 
week
4
1*3 times 
a month
5
5-10 times 
a vear
6
1-4 times 
a year
7
Never, or less 
than once a year
Fried chicken
Burgers
Pizza
Chinese food
Mexican food
Fried fish
Other foods
13. This section is about your usual eating habils. Thinking back over the past year, how often do you 
usually eat the foods listed on the next page?
First, check ( / )  whether your usual serving size is small, medium or large. (A small portion is" 
about one-half the medium serving size shown, or less; a large portion is about one-and-a-half 
times as much, or more.)
Then, put a NUMBER  in the most appropriate column to indicate H O W  OFTEN, on the average, 
you eat the food. You may eat bananas twice a week (put a 2 in the "week" column). If you never eat 
the food, check "Rarely/Never." Please DO NOT SKIP foods. And please BE CAREFUL which col­
umn you put your answer in. It w ill make a big difference if  you say "Hamburger once a day" 
when you mean "Hamburger once a week"!
Some items say "in  season." Indicate how often you eat these just in  the 2-3 month time when that 
food is in season. (Be careful about overestimating here.)
Please look at the example below. This person
1) eats a medium serving of cantaloupe once a week, in  season.
2) has ’/ i  grapefruit about twice a month.
3) has a small serving of sweet potatoes about 3 times a year.
4) has a large hamburger or cheeseburger or meat loaf about four times a week.
5) never eats w inter squash.
E X A M P LE :
M edium
Serving
Your
Serving
Size
S M L
Cantaloupe (in season) '/«medium ✓
Grapefruit <W) ✓
Sweet potatoes, yams I*  cup ✓
Hamburger, cheeseburger, meat loaf 1 m edium
W inter squash, baked squash ‘/ ic u p
>4m
D
H o
jt 
V
s
AT Of
£co
2
en?
>
*55
DC Z
1
3
4-
OFFICE USE 
70 ___
72
73
74
75
76
77
78
£_ 
79 80
PLEASE CO TO NEXT PACE
S-l No. Da-1
M-2 Times Wk-2
1-3 Mo-3
NS-9 NS-99 Yr-4
Nev-5
NS-9
FOR OFFICE USE 
On the fo llow ing tw o  pages, 
code the four characters for each 
food as follows:
If respondent places a checkmark in the "H o w  often" columns, 
do not im pute "01", once. Instead, code "99", Not Stated. If 
respondent does not check a portion  size, do not im pute 
medium, but code "9".
-6-
248
| Your ■ 1 How often?
Serving
,Serving 
) Size
! i
1 v. ft
X
c ">NW
1 FRUITS &  JUICES iS ;m . l i D 2 >
<1 *t
fiCZ
| EXAMPLE -  Apples, applesauce, pears (1) o r '4 cup ' Y\ 4 *
Apples, applesauce, pears (1) o r ‘4  cup ] | 1
Bananas 1 medium \ i i
Peaches, apricots (canned, frozen or dned, whole year) (1) or *4 cup 1 i
Peaches, apncots. nectarines (fresh, in season) 1 medium | T—
Cantaloupe (in  season) V* medium j
Watermelon (in season) 1 slice 1
Strawberries (fresh, in season) '4 cup
Oranges 1 medium
Orange juice o r grapefru it juice 6oz. glass
Grapefruit m
Tang, Start breakfast drinks 6 oz. glass
O ther fru it juices, fo rtified fru it drinks 6 oz. glass
A n y  other fru it, includ ing  berries, fru it cocktail ■4 cup
v e g e t a b l e s  1 s M L Da W k M o Yr Nv
String beans, green beans •4 cup
Peas *4 cup
C hili w ith  beans 3/4CUp
Other beans such as baked beans, pintos, kidney beans, limas 44 cup
Com *4 cup
W in te r squash, baked squash ■4 cup
Tomatoes, tomato juice ( l)o r6 o z .
Red ch ili sauce, taco sauce, salsa picante 2 Tblsp. sauce
Broccoli ■4 cup
C auliflow er o r brussei sprouts l4 c u p
Spinach (raw) % cup
Spinach (cooked) •4 cup
Mustard greens, tu rn ip  greens, coilards ’4  cup
Cole slaw, cabbage, sauerkraut •4 cup
Carrots, or mixed vegetables contain ing carrots 14 cup
Green salad 1 med. bow!
Salad dressing, mayonnaise (includ ing  on sandwiches) 2 Tblsp.
French fries and fried potatoes V4cup !i |
Sweet potatoes, yams •4 cup
— j..,
rt 1
O ther potatoes, includ ing boiled, baked, potato salad ( l ) o r  ‘4  cup i
Rice V«cup
Any other vegetable, including cooked onions, summer squash 14 cup
Butter, margarine or.other fa t on vegetables, potatoes, etc. 2 pats
M E A T, FISH, POULTRY &  M IX E D  DISHES s M L Da W k M o Yr Nv
Hamburgers, cheeseburgers, meat loaf 1 medium
Beef— steaks, roasts 4 oz.
Beef stew o r pot pie w ith  carrots, o ther vegetables I cup
Liver, inc lud ing  chicken livers 4oz. I
Pork, includ ing  chops, roasts 2 chops o r4 o z .
Fried chicken 2 sm. or 1 Ig. piece i
Chicken or turkev, roasted, stewed or broiled 2sm. or 1 Ig. piece I I
Fried fish or fish sandwich 4oz. o r 1 sand. l
Tuna fish, tuna salad, tuna casserole '4  cup 1
Shell fish (shrimp, lobster, crab, oysters, etc.) (5) % cu p o r3 o z .
O ther fish, broiled, baked 4 oz.
Spaghetti, lasagna, other pasta w ith  tomato sauce 1 cup j
Pizza 2 slices |
M ixed dishes w ith  cheese (such as macaroni and cheese) 1 cup I
-7-
! OFFICE USE
II_____
1 5 _______________
1 9 _______________
2 3 _______________
2 7 _______________
3 1 _______________
3 5 _______________
3 9 _______________
■13_______________
4 7 _______________
5 1 _______________
5 9 _______________
6 3 _______________
6 7 _______________
15_____
1 9 _______________
2 3 _______________
3 5 _______________
3 9 _______________
7 5 _______________
1 5 _______________
1 9 _______________
2 7 _______________
3 5 _______________
3 9 _______________
6 3 _______________
3
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M edium
Serving
Your 
Serving- 
Size I
LUNCH ITEMS S M  L I
L iverw urst 2 slices 1
! H o! dogs 2 dogs
j Ham, lunch meats 2 slices
j Vegetable soup, vegetable beef. minestrone, tomato soup 1 med. bowl |
‘ O the r soups 1 med. bowl : 1
BREADS / SALTY SNACKS I SPREADS I S M L
Biscuits, m uffins, burger rolls (ind . fast foods) 1 med. piece ! 1
W hite bread (including sandwiches), bagels, etc., crackers 2 slices, 3 cracks 1
D ark bread, inc lud ing  whole wheat, rve, pumpernickel 2 slices
C om  bread, com  m uffins, com tortillas 1 med. piece
Salty snacks (such as chips, popcorn) 2 handfuls 1
j Peanuts, peanut butter 2 Tblsp. i
Butter on bread o r rolls 2 pats j
M argarine on bread o r rolls 2 pats i
Gravies made w ith  meat dripp ings, o r w hite  saiice 2 Tblsp. !
BREAKFAST FOODS : s M L
H igh  fiber, bran or granola cereals, shredded wheat 1 med. bowl | 1
H igh ly  fortified cereals, such as Product 19, Total, or Most 1 med. bowl 1 i
O the r cold cereals, such as Com Flakes, Rice Krispies 1 med. bowl 1
Cooked cereals 1 med. bowl !
Sugar added to cereal 2 teaspn.
Eggs | 1 egg *  small, 2 egES = mediumi
Bacon 2 slices
Sausage 2 patties or links
SWEETS i S !M L
Ice CTeam 1 scoop '
Doughnuts, cookies, cakes, pastry 1 pc. or 3 cookies
Pum pkin  pie. sweet potato pie 1 med. slice |
O the r pies 1 med. slice
Chocolate candy small bar, 1 oz. i 1
O the r candy, je lly , honev, brown sugar 3 pc. or 1 Tblsp. 1
D A IR Y  PRODUCTS s M L
Cottage cheese '•5 cup 1
O ther cheeses and cheese spreads 2 slices o r 2 oz.
Flavored vogurt l e u p  i i
| Whole m ilk and bevs. w ith  whole m ilk (not incl. on cereal) 8 oz. glass 1
2% m ilk  and bevs. w ith  2% m ilk  (not incl. on cereal) 8 oz. glass 1 '1—
Skim m ilk , 1% m ilk  or butte rm ilk  (not incl. on cereal) 8 oz. glass
BEVERAGES s M L
Regular soft d rinks 12 oz. can or bottle
D iet soft d rinks 12 oz. can or bottle
Beer 12 oz. can or bottle j
W ine 1 med. glass \
Liquor 1 shot j
Decaffeinated coffee 1 med. cup |
Coffee, not decaffeinated 1 med. cup j 1
Tea (hot o r iced) 1 med. cup
Lemon in  tea 1 teaspn. (
N on-d ia ry  creamer in coffee o r tea 1 Tblsp. i
M ilk  in  coffee o r tea 1 Tblsp. j .
Cream (real) o r Half-and-Half in coffee o r tea 1 Tblsp. ! i 1
Sugar in  coffee or tea 2 teaspn.
A rtifica l sweetener in coffee o r tea 1 packet |
Glasses of water, not counting in coffee or tea 8 oz. glass j
How o f
L l a  
, £  ! !  ! !
en?
<%
>
•5s
£ > i  *
1 ;
i r
i 1
1i
i
1 Da W k M o Yr Nv
1
Da W k M o Yr Nv
*
j ]
i !
; I i
i 1 i
|D a W k M o Yr Nv
1 |
! i
1
|
1
Da W k M o Yr j Nv
Da W k M o Yr Nv
1
1
OFFICE USE
- 8- | 67 jL jL J -J L
2 7 _________
3 1 _________
3 5 _________
3 9 _________
4 3 _________
4 7 _________
5 1 _________
5 5 _________
5 9 _________
6 3 _________
6 7 _________
71 ._________
7 5 _________
1 1 _________
1 5 _________
1 9 _________
2 3 _________
2 7 _________
3 1 _________
3 5 _________
3 9 _________
4 3 _________
4 7 _________
5 1 _________
5 5 _________
5 9 _________
6 3 _________
0  6 9
IL_
79
G _
79 8. '
H  _
79 80
79 00
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14. Think about your diet over the last vear and the responses you have just made on this questionnaire. Are there any 
foods not mentioned which vou ate at least once a week, even in small quantities, or ate frequently in a particular 
season? Consider other meats, breakfast foods, catsup, green chilies or |alapenos. avocado (guacamole), Mexican 
dishes, Chinese or other ethnic foods, other fruits or vegetables, as well as nutritional supplements (bran, etc.). 
Please take a look at the list of toods at the bottom of the page. .
FOOD Your
Serving
Size
S M I L
Ht
Oft
Day
>w
en?
Week
15. How often do you eat the skin on chicken?
How often do you eat the fat on meat?
How often do you add salt to your food?
How often do you .add pepper to your food?
16. How often do you use fat or oil in cooking?
For example, in frying eggs, meat or vegetables? . . times p e r .
day, week, month
17. What do you usually cook with? 1___Don't know or don't cook 2  Soft margarine
3  Stick margarine 4  Butter 5  Oil 6  Lard, fatback, bacon fat
7  Pam or no oil
18. What kind of fat do you usually add to vegetables, potatoes, etc?
1  Don't add fat 2  Soft margarine 3 ___ Stick margarine 4 .
5  Half butter, half margarine 6  Lard, fatback, bacon fat
19. If you eat cold cereal, what kind do you eat most often?___________
. Butter
vegetables day, week
20. Not counting salad or potatoes, about how many 
vegetables do you eat per day or per week?
21. Not counting juices, how many fruits do you 
usually eat per day or per week?
fru its day, week
22. Have you gained or lost more than five pounds in the past year? (You may check more 
than one answer.)
1 —  No 2 —  Lost 5-15 lbs. 3 ___Lost 16-25 lbs. 4  Lost more than 25 lbs.
5 —  Gained 5-15 lbs. 6  Gained 16-25 lbs. 7  Gained more than 25 lbs.
per
per
\  2 3
Seldom/Never Sometimes Often/Alwavs
OFFICE USE 
Code Amounts
11________
2 3 _______________________
2 9 _______________________
4 1 _______________________
54
56
58
67
9  9
DO YOU EAT THESE ONCE A WEEK?
veal. lam b 01 pancakes. w affles 21
*o fu  03 instant breakfast, metrecal 22
m ixed  d ish  w /m e it 04 p u d d in g  23
m ixed d ish  w /chicken 05 m ilkshake 24
Chinese dishes 06 o ther d u ry  p roduc t 25
Mexican dishes 07 o the r dessert, sweet 26
seafood creole 0B sour cream, d ips 31
re in e d  beans o r bean bum ios  IW d ie t salad dressing 32
P o lish  o r Ita lian  sausage 10 catsup 33
cream  soups ] |  green chilies. talapenos 34
noodles |2
on ions 41 H i-C 63
sum m er squash 42 cranberry  |utce cocktail t>4
asparagus 43 grapes 65
sweet green peppers 44 mangoes 66
sweet red peppers 45 papayas 67
bean sprouts 46 honevdew  o r cassaba melon 68
avocado, guacam ole 47 lem ons o r  lem on tuice 69
beets 48 nu ts  and seeds 70
ptneapple o r  p ineapp le  tuice 61 bran 71
prunes o r prune (ukt 62 o the r vegetab le 'fru it 
o th e r no t m entioned here
79
88
lOx. Think about the way you used to eat ABOUT 20 YEARS AGO. Has 
it very different from the way you have been eating in the 
past year? j X104
  NO | 0
  YES | 1
  CAN’T SAY j 9
I
llx. Please write MORE, i 2
LESS, or . 1
THE SAME j 0
to describe how much of the following foods you ate 20 years 
ago compared to now.
I
___________  Total calories? I X105
I
___________  Charcoal-broiled meat? } X106
____________  _ Butter and oil? j X107
-----------  Fruit? j X108
___________  Vegetables? | XI09
___________  Vitamin Supplements? j XI10
12x. Do you take any precription drugs as often as everyday or
almost every day? j XI11
  NO I 0
  YES I 1
  OTHER ' 9
If YES,'
Hhat is the most important or strongest medicine that
you take? __ (Name of drug or "Unknown")
Hhat is the next most important? ____________________
j XI12 
I XI24
13x. Have you had a cold, the flu, or another viral illness within
the past three weeks? I XI36
I
  NO | 0
  YES I 1
  POSSIBLY 2
  OTHER I 9
14x. Have you taken antibiotics (like penicillin, erythromycin, etc.)
within the last three weeks? j X137
  NO | 0
  YES I 1
  POSSIBLY I 2
  OTHER 9
-10-
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MEDICAL INFORM ATION
23. In  the  past fiv e  years. H ow  m a ny  tim es have yo u  been hosp ita lized?  
( i f  fem ale , o m it c h ild b ir th s )   tim es
OFFICE USE
24. Have you ever had any of the following
tests or treatments?
X-ray treatments for acne, ringworm, 
enlarged tonsils, adenoids, thymus . . .
Treatment w ith  radium, cobalt, or other 
radioactive isotopes ..........................
Upper GI series (x-ray o f stomach after 
drinking white l iq u id ) .............................
Lower GI series (Barium e n e m a ).............
NO
2
YES
Jtf IF YES,
H O W  M A N Y  AGE AT FIRST 
TIMES? TREATMENT
25. Have you ever been told by a doctor that you had any of the following conditions?
NO
2
YES
P O N 'T
K N O W
Heart disease or angina
Heart attack
H igh blood pressure
Stroke i
Tuberculosis
Chronic bronchitis or 
emphysema
Asthma :
Hav fever
D iverticuiosis
Rectal/coion polyps
Chronic colitis
Diabetes |
Thyro id condition I
1
NO YES
D O N 'T
KNOW
Kidnev disease
Bladder disease
Liver cirrhosis
Hepatitis
Stomach ulcers
Rheumatoid
arthritis
O ther arthritis
Osteoporosis
Fractured h ip i
Prostate trouble T "
Abnormal Pap smear i
Skin cancer
Leukemia |
O ther cancer
If yes to leukemia, skin, or other cancer, fill in below:
What kind of cancer? (Lung, breast, etc.) Year 1st Diagnosed
What kind of cancer? (If you had a second) Year 1st Diagnosed
26. In the past year, have you had i
N O
Bleeding or sore g u m s ...........................
Bruise easily ...........................................
N oseb leeds.................................. ..........
PLEASE GO  TO  N E X T  PAGE
2
YES
l
NO
2
YES
Difficulty seeing in the dark 
Frequent or chronic fever . . 
Frequent constipation or 
hem orrho ids.....................
7!_____
7 5 _________________L
ib____
5 0 _____________
(See codes 
below)
FOR OFFICE USE 
Ca Yr
01— Bladder 09—  L ive r
02—Bone 10— Leukem ia
03— Brain I I — Lung, bronchus
0 ^ -B re a s i 12— Lvm phom a, in c lu d in g  H odgkins
05— C ervix 13— M o u th , oral
0b—C o lon  \4 _ Q v a rv
07— Esophagus 15— Pancreas
OB— K idnev 16— Prostate
- l i -
17— Rectum
IB—Skin-M elanom a
19— S km -N o t melanoma (Basal or squamous)
20—S kirv-N ot specified
21— Stomach
22—T hyro id
23— Uterus
24—O th e r
253
15x. Has a doctor ever told you that you had:
an AUTOIMMUNE DISEASE, where your body makes antibodies to your
own tissues? I X138
I
  NO I 0
  YES . 1
  NOT SURE ! 9
If Y B S , ^
............. ■ i .1 1.1 ii i i .  —     —  -..  -in.
What kind? ______________________  ! X139l
(Name of disease or "Unknown")
aplastic anemia? • X151
  NO I 0
  YES | 1
  NOT SURE j 9
food allergy? X152
  NO I 0
  YES I 1
  NOT SURE | 9
dust allergy? ' X153
  NO I 0
  YES I 1
  NOT SURE | 9
pollen allergy? i X154
  NO | 0
  YES | 1
  NOT SURE 9
allergy to animal hair? I X1S5
  NO | 0
  YES 1
  NOT SURE 1 9
allergy to insects? ■ X156
  NO 0
  YES I 1
  NOT SURE | 9
drug allergy? X157
  NO 1 0
  YES | 1
  NOT SURE j 9
other allergy? | X158
  NO I 0
  YES I 1
  NOT SURE I 9
-12-
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OCCUPATIONAL INFORM ATION OFFICE USE
27. What is your current employment status? Check the one that applies to the greatest percent of 
your time.
1 —  Employed 4 ___Disabled, unable to work 7 ___ Other
2 —  Homemaker 5  Unemployed
3 —  Retired 6 ___Student
28. What has been your usual occupation or job — the one you have worked at the longest?
(For example, carpenter, executive, salesman, foreman, waitress, truck driver)
Job/occupation .
Years in this job .
In your work, did you spend more time 1  indoors 2  outdoors? (Please check one.)
29. In your work, have you ever been exposed for a year or more to any of the following?
i 2 D O N 'T
N O  YES KN O W
Asbestos
Radiation
W elding
Coal tar, soot, pitch, 
creosote, asphalt
M ineral, cu tting  or 
lubricating o il
Benzidine, beta- 
naphthvlam m e
Benzene
Isopropyl oil
Dyestuffs
Arsenic
i
N O
2 D O N 'T  
YES KNOW
Iron foundry
Nickel smelting
Underground mining
Lumber industry, or 
heavy wood dust
Rubber ot cablemaking 
industry
Chemical o r plastics 
industry
ii
Pesticides, herbicides I
Mustard gas i
Chrom ium
Cadmium, beryllium, 
v inv i chloride
16z. Hhat was your second longest occupation or job?
(Job name or "None") 
If you worked at a second occupation ^
*003 many years did you do that work? yrs
Has the work mostly INDOORS or OUT OF DOORS?
INDOORS
OOT OF DOORS
BOTB
___ CAN’T SAY
70
72
73
75
77
11
13
15
17
19
21
K_
79 SO
2 3 ___
X159
X171 
XI73
1
2
3
9
-13-
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17x. Have you ever worked for a year or more in the following '
industries: I
I
shipbuilding industry? i X174 _
  NO I 0
  YES 1
  NOT SORE 1 9
construction industry? | XI75
  NO | 0
  YES 1
  NOT SORE I 9
fishing industry? 1 I X176
  NO | 0
  YES . l
  NOT SORE | 9
lumber, wood, furniture manufacturing, or paper industries? . X177
  NO 0
  YES I l
  NOT SORE | 9
petrochemical industry? I X178 _
  NO 0
  YES 1 1
  NOT SORE I 9
other chemical industries? . X179
  NO I 0
  YES I l
  NOT SORE | 9
metal refining, manufacturing, polishing, or plating indus- '
tries? I X180
  NO | o ”
  YES , 1
  NOT SORE I 9
I
sugar cane farming? i X181
  NO o "
  YES 1
  NOT SORE 1 9
mining industry? I XI82
  NO i 0
  YES I 1
  NOT SORE | 9
insulation manufacturing or installation? i X183
  NO 0 "
  YES I i
  NOT SORE I 9
-14-
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(Continuation of question 17x.)
asbestos manufacturing or manufacturing of products containing 
asbestos?
  HO
  YES
  NOT SOKE
cement manufacturing?
  HO ,
  YES
  NOT SORE
demolition industry?
  HO
  YES
  NOT SORE
cook?
  HO
  YES
  NOT SORE
gas station attendent or auto mechanic?
  HO
  YES
  HOT SORE
FAMILY HISTORY
30. Have any close relatives had cancer? 1  No 2  Yes
IF YES. please f ill this out for each blood relative who had cancer. Include your natural parents, 
sisters and brothers, daughters and sons, grandparents.
One RELATIVE per 
line  (Mother, 
son, etc.)
Circle one 
1 2
If  A live, 
give 
age
IfDead, 
give age 
at death
Type o f Cancer
Age at
Diag-
nosis
A live Dead
A live Dead
A live Dead
A live Dead
A live Dead
PLEASE CO TO NEXT PACE
XI84 _
0
1
9
X185
0
1
9
XI86
0
1
9
X187 _ 
0 
1
9
XI88 _
0
1
9
25
26 See below
FOR OFFICE USE
M *l Sn*5 D is .c o d n :
F-2 D t-6 Set p. S
B-3 GF-7 
S-« G M -fi
N u At/
Rel. Rel. Dd Age D is  Age
26
-15-
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18x. In your work or hobbies, have you ever been exposed I
FOR A YEAR OR MORE to any of the following: |
petroleum refining? X188 _
  SO I 0
  YES I 1
  NOT SORE j 9
smoke: wood, oil, sugar cane? X190 _
  NO ' 0
  YES I 1
  NOT SORE | 9
gasoline/motor oil? i X191 _
  NO 0
  YES * 1
  NOT SORE I 9
x-rays, fluoroscopic equipment, or radio isotopes? XI92 _
  NO 0
  VES | 1
  NOT SORE 9
coke oven gases? I XI93 _
  NO | 0
  YES I 1
  NOT SORE 9
OTHER HEALTH FACTORS I office use
I
31. How tall are you?  fee t inches 32. How much do you weigh?  pounds I _________
I 43
33. What is the most you have ever weighed?  pounds i v> ____
34. About how many times have you gone on a diet to lose weight? I
ID (2) 0) <41 (5) (6| I
—  Never ___1-2  3-5____ 6-8  9-11  12ormoretimes I 52
35. How many hours of sleep do you usually get at night? I
(I) (2) (3) (4) I
 6 hours or less _7 hours______ __ 8 hours _9 hours or more I 53
36. How often do you feel under stress which makes you tense or worried, or causes physical '
problems such as stomach or back trouble or headaches? I
(I) (2) (3) (4) (51 I
—  Everyday  Several times  Several times  Several times  Rarely or I 54
a week a month a year never ‘
-16-
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37. Here is a list of active things that people do in their free time. How often do you do any of 
these things? 1 2 3 4 5
MORETHAN ABOUT A FEW A FEW RARELY
ONCE A ONCE A TIMES A TIMES A OR
WEEK WEEK MONTH YEAR NEVER
Active s p o r ts ...............................  ...............  ...............  ...............  ...............  ...............
Doing physical exercises ..........  ...............  ...............  ................ ...............  ...............
Jogging or ru n n in g ..................... ...............  ...............  ...............  ...............  ...............
Swimming or taking long walks ._________  _______  _______  _______  _______
Gardening, fishing, hunting . . . _______  _______  _______  _______  _______
Something else_____________   ._________  _______  _______  _______  _______
38. How many close friends do you have? (People that you feel at ease w ith, can talk to about 
private matters, and can call on for help.1)
H) (2) (3) (41 (5)
 None  l o r 2   3to5  6to9  lOormore
How many relatives do you have that you feel close to?
 None  l o r 2   3to5  6to9  lOormore
How many of these friends or relatives do you see or talk to at least once a month?
 None  l o r 2   3 to5  6to9  lOormore
39. How often do you participate in the following groups or activities?
1 2 3 4 5
MORETHAN ABOUT A FEW A FEW RARELY 
ONCE A ONCE A TIMES A TIMES A OR
WEEK WEEK MONTH YEAR NEVER
Go to church or te m p le .............  ...............  ...............  ................ ................ ...............
Participate in group meetings or 
activities (such as clubs, PTA, pro­
fessional, labor or service groups) . _______  _______  _______  _______  _______
19x. Today’s date is 19_
Please take a moment to fill in any questions you may have skipped.
THANK YOU VERY MUCH for taking the time to fill out this information. The answers you have 
given w ill be very useful in interpreting the results of this study, and in helping to understand 
and control disease. Your participation is sincerely appreciated.
Reviewed b y _______________;______________
63
65
X194
Coder:
Version # JL —
5
-17-
IK 
->|R
APPENDIX B
MISCELLANEOUS STUDY MATERIALS
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C O N S E N T  A N D  A U T H O R I Z A T I O N  F O R  V E N I P U N C T U R E  A N D  W I T H D R A W A L  OF B L O O D
L O U I S I A N A  S T A T E  U N I V E R S I T Y  
and
M A R Y  B I R D  P E R K I N S  C A N C E R  C E N T E R
I h e r e b y  c o n s e n t  to h a v e  a b l o o d  s p e c i m e n  o f  a p p r o x i m a t e l y  10 
m i l l i l i t e r s  (1 t u b e) w i t h d r a w n  f r o m  a v e i n  in m y  arm, w i t h  a new, 
s t e r i l e  n e e d l e ,  b y  a f u l l y  c e r t i f i e d  M e d i c a l  T e c h n o l o g i s t .  T h i s  b l o o d  
s a m p l e  wil l be u s e d  in t h e  c o n d u c t  of l a b o r a t o r y  r e s e a r c h  i n v e s t i ­
g a t i o n s ,  a nd I h a v e  been* i n f o r m e d  t h a t  t h i s is the b e s t  m e t h o d  of 
o b t a i n i n g  t he b l o o d  s a m p l e  f o r  t h i s  p u r p o s e .
T h i s  p r o c e d u r e  h a s  b e e n  r o u t i n e l y  u s e d  f o r  m a n y  y e a r s  in c a r i n g  
f o r  p a t i e n t s  an d  is g e n e r a l l y  c o n s i d e r e d  b y  t h e s e  i n v e s t i g a t o r s  and 
o t h e r s  to'i>e of l i t t l e  or no r i s k  to m e. T h e r e  is s o m e  d i s c o m f o r t  and 
t he p o s s i b i l i t y  o f  m i n o r  b r u i s i n g  a nd l e a k a g e  o f  b l o o d  u n d e r  t h e  s k i n  
at t h e  s i t e  o f  b l o o d  w i t h d r a w a l .  T h i s  u s u a l l y  h e a l s  q u i c k l y .  I h a v e 
b e e n  i n f o r m e d  t h a t  a n y  q u e s t i o n s  I m a y  h a v e  c o n c e r n i n g  the p r o c e d u r e s  
i n v o l v e d  wil l be a n s w e r e d .
I u n d e r s t a n d  t h a t  I s h a l l  be a s k e d  to s u p p l y  i n f o r m a t i o n  a b o u t  
a s p e c t s  of m y  p e r s o n a l  h i s t o r y  and h a b i t s  w h i c h  ar e  r e l e v a n t  to the 
h e a l t h  c o n d i t i o n  u n d e r  s t u d y ,  b u t  t h a t  I m a y  c h o o s e  n o t  to a n s w e r  a 
p a r t i c u l a r  q u e s t i o n  o r  q u e s t i o n s .
I u n d e r s t a n d  t h a t  M a r y  B i r d  P e r k i n s  C a n c e r  C e n t e r  w i l l  p r o t e c t  m y  
r i g h t  to p r i v a c y  and wil l n o t  p e r m i t  t h e  r e s e a r c h  p e r s o n n e l  to k n o w  m y  
full n a m e ,  or a n y  i n f o r m a t i o n  w h i c h  w o u l d  i d e n t i f y  me. T h e  r e s u l t s  of 
t h e  a n a l y s i s  o f  m y  b l o o d  s a m p l e  a n d  all q u e s t i o n n a i r e  d a t a  will be 
c o d e d ,  a n a l y z e d ,  a n d  p r o c e s s e d  f o r  p r e s e n t a t i o n  or p u b l i c a t i o n  in s u c h  
a w a y  t h a t  m y  i d e n t i t y  w i l l n o t  be r e v e a l e d .
I h a v e  a g r e e d  to d o  t h i s  o f  m y  o w n  f r e e  wil l a nd w i t h o u t  t h r e a t  
or c o e r c i o n  o f  a n y  k i n d .  I u n d e r s t a n d  t h a t  I wil l n o t  b e n e f i t  
m e d i c a l l y  f r o m  t h i s  p r o c e d u r e ,  b u t  t h a t  it m a y  p r o v i d e  h e l p f u l  
i n f o r m a t i o n  f o r  t h i s  r e s e a r c h .
I h a v e  b e e n  i n f o r m e d  t h a t  I m a y  w i t h d r a w  m y  c o n s e n t  and 
d i s c o n t i n u e  p a r t i c i p a t i o n  at a n y  t i m e  w i t h o u t  p r e j u d i c e  to m y s e l f  or 
loss o f  a c c e s s  to c a r e  at t h i s  f a c i l i t y .
If I h a v e  q u e s t i o n s  at a n y  t i m e ,  I m a y  cal l Dr. M.J . N e w m a n  (346- 
33 2 9) o r  Mrs . J o a n  B l a c k m o n  ( 3 4 6 - 3 3 5 3 ) .
Y O U  A R E  M A K I N G  A D E C I S I O N  W H E T H E R  O R  N O T  T O  P A R T I C I P A T E  IN T H I S  
R E S E A R C H .  Y O U R  S I G N A T U R E  I N D I C A T E S  T H A T  H A V I N G  R E A D  T HE A B O V E  
I N F O R M A T I O N ,  Y OU H A V E  D E C I D E D  T O  P A R T I C I P A T E .
 D a t e
AM
PM T i m e
S i g n a t u r e
S i g n a t u r e  of I n v e s t i g a t o r S i g n a t u r e  o f  W i t n e s s
Study #
M e d i c a l  I n f o r m a t  ion F o r m  
f o r
L u n g  C a n c e r  P a t i e n t s
H i s t o l o g i c  T y p e :
O a t  C e l l  _ _ _ _ _ _
S q u a m o u s  C e l l  _ _ _ _ _ _
A d e n o c a r c i n o m a  _ _ _ _ _ _
L a r g e  C e l l  _ _ _ _ _ _
O t h e r  ( M i x e d ,  S a r c o m a ,  e t c . )  _ _ _ _ _ _ _
A r e a  A f f e c t e d :
M a i n  B r o n c h u s  _ _ _ _ _ _
R i g h t  L u n g  or  L e f t  L u n g
U p p e r  L o b e :  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
M i d d l e  L o b e :  _ _ _ _ _ _
L o w e r  L o b e :I — — . i -  —
O t h e r  o r  n o t  s p e c i f i e d  _ _ _ _ _ _
P r e v i o u s  T h e r a p y :
S u r g e r y  _ _ _ _ _ _
C h e m o t h e r a p y  _ _ _ _ _ _
D r u g  P r e s c r i b e d  _ _ _ _ _ _ _ _ _ _ _ _ _
N o n e  _ _ _ _
S t a g e :
L o c a l  ,_ _ _ _ _
R e g i o n a l  _ _ _ _ _
D i s s e m i n a t e d
Physician
C o - I n v e s t 1 g a t o r s :
J oa n  P. B l a c k m o n ,  M . S . P . H  
L o u i s i a n a  S t a t e  U. 
M a r k  J. N e w m a n ,  P h . D .  
L o u i s i a n a  S t a t e  U. 
K e n n e t h  K. Lo, M . D . ,  P h . D  
M a r y  B i r d  P e r k i n s  
C a n c e r  C e n t e r
VOLUNTEERS
a re
NEEDED
to s e r v e  as 
C A N C E R - F R E E  
c o m p a r i s o n  s u b j e c t s .
262
BRIEF DESC R I P T IO N  
OF THE LSU-MBPCC
L UN G  C AN CE R  STUDY
T h e r e  a re c e r t a i n  c h e m i ­
c a l s ,  c a l l e d  P A H ' s  ( P o l y c y c l l c  
A r o m a t i c  H y d r o c a r b o n s ) ,  w h i c h  
a re p r e s e n t  1n c i g a r e t t e  
s mo k e ,  In c h a r b r o l l e d  m e a t s  
and o t h e r  f o o d s ,  1n p e t r o l e u m  
p r o d u c t s  and e l s e w h e r e  1n the 
e n v i r o n m e n t .  H e  t h i n k  th a t  
t h e y  m a y  p l a y  a r o l e  1n the 
d e v e l o p m e n t  o f  c e r t a i n  c a n c e r s  
In h u m a n s ,  I n c l u d i n g  l u n g  c a n ­
cer . H e  k n o w  t h a t  t h e s e  c h e m ­
ica ls ca n  d a m a g e  g e n e s  1n 
c e l l s  b y  b i n d i n g  to t h e  D N A  
m o l e c u l e s .  S o m e  p e o p l e  a l s o  
m a k e  a n t i b o d i e s  to t h e i r  o w n  
d a m a g e d  P A H - D N A  a nd w e  w o u l d  
l ik e  to k n o w  1f t h i s  p l a y s  a ny 
r o l e  In t h e  l i k l l h o o d  t h a t 
t h e s e  p e o p l e  w o u l d  d e v e l o p
lu n g  can c e r .
A n o t h e r  m a j o r  f o c u s  o f 
t h e  s t u d y  will be an e v a l u ­
a t i o n  of t he I n v o l v m e n t  of
d i f f e r e n t  t y p e s  o f  w h i t e  b l o o d  
c e l l s  1n s p e c i f i c  k i n d s  of
l un g  c a n c e r .  A t  L SU w e  h a v e  
an I n t r i c a t e  p i e c e  o f  m a c h i n ­
ery , called- a F l u o r e s c e n c e -  
A c t i v a t e d  Cel l S o r t e r ,  w h i c h  
c a n  i d e n t i f y  and c o u n t  m a n y  
d i f f e r e n t  t y p e s  o f  w h i t e  b l o o d  
c e l l s  f r o m  a Sma l l s a m p l e  of 
b l o o d .  Y o u r  w h i t e  b l o o d  c e l l s  
are t he a r m y  o f  y o u r  I m m u n o ­
l o g i c a l  d e f e n s e  s y s t e m  a nd It 
is t h o u g h t  t h a t  I m b a l a n c e s  in
t h e  p r o p o r t i o n s  o f  t h e  d i f f e r ­
e n t  t y p e s  o f  c e l l s  m a y  be 
I n v o l v e d  1n w h y  p e o p l e  get 
l un g  c a n c e r  a n d  In w h a t  t y p e  
o f  lun g c a n c e r  t h e y  get.
A l t h o u g h  w e  a re p a r t i c u ­
l a r l y  I n t e r e s t e d  in t h e  a b o v e  
f a c t o r s ,  it Is a l s o  n e c e s s a r y  
to h a v e  I n f o r m a t i o n  a b o u t  
o t h e r  f a c t o r s  k n o w n  o r  s u s p e c ­
t e d  to be I n v o l v e d  w i t h  the 
c a u s a t i o n  of  l u n g  c a n c e r .  Th i s  
a l l o w s  us t o  I d e n t i f y  c o m b i n a ­
t i o n s  o f  c h a r a c t e r i s t i c s  w h i c h  
m a y  p r e d i s p o s e  c e r t a i n  p e o p l e  
to d e v e l o p  c a n c e r .  H e  o b t a i n  
t h i s  I n f o r m a t i o n  u s i n g  a 
q u e s t i o n n a i r e .  T h e  q u e s t i o n ­
n a i r e  c o v e r s  a w i d e  r a n g e  of 
d e s c r i p t o r s ,  a m o n g  w h i c h  are 
d i e t a r y  f a c t o r s ,  s m o k i n g  h i s ­
t o r y  a nd p r a c t i c e ,  w o r k - r e l a ­
t e d  e x p o s u r e s ,  h i s t o r y  of 
a l l e r g i e s  a n d  f a m i l y  h i s t o r y .
At t h i s  t i m e ,  w e  are 
l i m i t i n g  t h e  s t u d y  to w h i t e  
m a l e s ,  b e c a u s e  t h e y  h a v e  t he  
h i g h e s t  r a t e s  o f  l u n g  c a n c e r .  
H e  wil l s t u d y  m e n  w h o  c o m e  to 
M B P  C a n c e r  C e n t e r  f or 
r a d i a t i o n  t r e a t m e n t  o f  t h e i r  
l u n g  t u m o r s .  T h e  c o m p a r i s o n  
g r o u p  w i l l  c o n s i s t  of w h i t e ,  
m a l e  v o l u n t e e r s  w h o  are 
c a n c e r - f r e e .
T h e  a b o v e  is o n l y  a v e r y  
b r i e f  o v e r v i e w .  If y o u  ha v e  
q u e s t i o n s  o r  w o u l d  l i k e  to 
k n o w  m o r e  a b o u t  t h i s  S t u d y ,  
p l e a s e  c o n t a c t  t he S t u d y  D i ­
r e c t o r  M r s .  J o a n  B l a c k m o n  at 
L S U  ( 3 8 8 - 1 2 1 3 ) .
H e  n e e d
WHITE MEN
w h o  h a v e
NEVER HAD CANCER
( o t h e r  t h a n  s k i n  c a n c e r )  
w h o  a re
OVER 30 YEARS OF AGE
w h o  a r e
SMOKERS, FORMER-SMOKERS,
or
N O N - S M O K E R S
a n d  w h o  a re
R E S I D E N T S  OF
E. B a t o n  R o u g e  
E. F e l i c i a n a  
A s s u m p t i o n  
L i v i n g s t o n  
I b e r v l l l e
H. B a t o n  R o u g e  
H. F e l i c i a n a  
A s c e n s i o n  
T a n g i p a h o a  
St. H e l e n
o r  Po1n.te C o u p e e  p a r i s h e s .
V o l u n t e e r s  w i l l  n e e d  to 
c o m e  t o  M a r y  B i r d  P e r k i n s  
C a n c e r  C e n t e r  to g i v e  a 
S M A L L  S A M P L E  O F  B L O O D  
(0 1 T a b l e s p o o n f u l )  
a n d  to c o m p l e t e  the 
Q U E S T I O N N A I R E  
w h i c h  w i l l  t a k e  0 1 hour. 
E V E N I N G  a n d  W E E K E N D  
a p p o i n t m e n t  t i m e s  a r e  p l a n n e d .
F i l l  o u t  t h e  a t t a c h e d  f o r m  
a nd g i v e  It to t h e  M B P  C a n c e r  
C e n t e r  r e c e p t i o n i s t  
or
cal l M r s .  J o a n  B l a c k m o n  at 
3 8 8 - 1 2 1 3  
t o  a r r a n g e  an a p p o i n t m e n t .
263
264
am
Lo u i s i a n a  St a t e U n i v e rs i ty A N D  AG RIC U LTU R AL A N D  M IX 1 IA N IC A L  COLLEGE
D e a r  M a d a m ,
M a r y  B i r d  P e r k i n s  C a n c e r  C e n t e r  is c o l l a b o r a t i n g  w i t h  
L o u i s i a n a  S t a t e  U n i v e r s i t y  in a s t u d y  t h r o u g h  w h i c h  w e  h o p e  t o  
i d e n t i f y  f a c t o r s  i n v o l v e d  in t h e  c a u s a t i o n  o f  l u n g  c a n c e r .  A 
b r i e f  d e s c r i p t i o n  o f  t h e  s t u d y  is a t t a c h e d .  T h e  s t u d y  g r o u p  w i l l  
c o n s i s t  o f  w h i t e  m a l e s  w h o  c o m e  t o  t h e  C a n c e r  C e n t e r  f o r  t r e a t ­
m e n t  o f  t h e i r  l u n g  c a n c e r .  W e  a l s o  n e e d  a c o m p a r i s o n  g r o u p  o f  
w h i t e  m e n  w h o  d o  n o t  h a v e  l u n g  c a n c e r .  B e c a u s e  c a n c e r  h a s  
t o u c h e d  y o u r  l i f e ,  w e  h o p e  t h a t  y o u  w i l l  h e l p  u s  f i n d  v o l u n t e e r s  
to  s e r v e  as h e a l t h y  c o n t r o l  s u b j e c t s .  Y o u r  b l o o d  r e l a t i v e s  
c a n n o t - b e  e l i g i b l e  b e c a u s e  o f  t h e  t e n d e n c y  f o r  c a n c e r  t o  " r u n  in 
f a m i l i e s " .  B u t  d o  y o u  h a v e  a h u s b a n d ,  i n - l a w ,  n e i g h b o r , ' o r  
f r i e n d ,  w h o  is o v e r  3 0  y e a r s  o f  a g e ,  w h o  h a s  n e v e r  h a d  c a n c e r  
( o t h e r  t h a n  s k i n  c a n c e r ) ,  a n d  w h o  w o u l d  b e  w i l l i n g  t o  c o m e  t o  t h e  
C a n c e r  C e n t e r  t o  1. f i l l  o u t  a q u e s t i o n n a i r e  w h i c h  w o u l d  t a k e  
a b o u t  a n  h o u r ,  a n d  2. g i v e  u s  a s m a l l  s a m p l e  o f  b l o o d  ( a b o u t  1 
t a b l e s p o o n f u l ) ?  W e  w o u l d  b e  g l a d  t o  a c c e p t  as m a n y  g e n t l e m e n  as 
a r e  w i l l i n g  t o  p a r t i c i p a t e .
If y o u  c a n  t h i n k  o f  p e r s o n s  w h o  w o u l d  l i k e  t o  h e l p  u s  t o  
i d e n t i f y  w a y s  t o  p r e v e n t  l u n g  c a n c e r ,  p l e a s e  g i v e  e a c h  o n e  a 
b r o c h u r e  w h i c h  c o n s i s t s  o f  a s t u d y  d e s c r i p t i o n ,  a l i s t  o f  c h a r ­
a c t e r i s t i c s  w h i c h  c o n t r o l  s u b j e c t s  m u s t  h a v e ,  a n d  d i r e c t i o n s  f o r  
v o l u n t e e r i n g .  T h e s e  a r e  a v a i l a b l e  f r o m  t h e  C e n t e r ' s  r e c e p t i o n ­
i s t .  If y o u  w o u l d  p r e f e r  t h a t  w e  c o n t a c t  h i m ( t h e m )  d i r e c t l y ,  
p l e a s e  w r i t e  t h e  n a m e ( s )  a n d  p h o n e  n u m b e r ( s )  o n  t h e  a t t a c h e d  b l u e  
f o r m  a n d  g i v e  it t o  t h e  r e c e p t i o n i s t ;  s h e  w i l l  p a s s  t h e  i n f o r m a ­
t i o n  o n  t o  u s .
T h a n k  y o u  f o r  y o u r  h e l p .  W e  w i s h  y o u  s u c c e s s  in y o u r  
p e r s o n a l  b a t t l e  w i t h  c a n c e r .
BATO N  ROUGE • LO U IS IA N A  ■ 70803-8416
Jinror'fllu
J o a n  P. B l a c k m o n ,  M . S . P . H .  
S t u d y  D i r e c t o r
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B R I E F  D E S C R I P T I O N  O F  T H E  
L S U  L U N G  C A N C E R  S T U D Y
C o - I n v e s t i  g a t o r s  s
J o a n  P. B l a c k m o n ,  M . S . P . H .
L o u i s i a n a  S t a t e  U n i v e r s i t y  
M a r k  J. N e w m a n ,  P h . D .
L o u i s i a n a  S t a t e  U n i v e r s i t y  
K e n n e t h  K. Lo ,  M . D . ,  P h . D .
M a r y  B i r d  P e r k i n s  C a n c e r  C e n t e r
T h e r e  a r e  c e r t a i n  c h e m i c a l s ,  c a l l e d  P A H ' s  ( P o l y c y c l i c  
A r o m a t i c  H y d r o c a r b o n s ' ) ,  w h i c h  a r e  p r e s e n t  in c i g a r e t t e  s m o k e ,  in 
c h a r b r o i l e d  m e a t s  a n d  o t h e r  f o o d s ,  in p e t r o l e u m  p r o d u c t s ,  a n d  
e l s e w h e r e  in t h e  e n v i r o n m e n t .  W e  t h i n k  t h a t  t h e y  m a y - p l a y  a r o l e  
in t h e  d e v e l o p m e n t  o f  c e r t a i n  c a n c e r s  in h u m a n s ,  i n c l u d i n g  l u n g  
c a n c e r .  We  k n o w  t h a t  t h e s e  c h e m i c a l s  c a n  d a m a g e  g e n e s  in c e l l s  
b y  b i n d i n g  t o  t h e  D N A  m o l e c u l e s .  S o m e  p e o p l e  a l s o  m a k e  
a n t i b o d i e s  t o  t h e i r  o w n  d a m a g e d  P A H - D N A  a n d  w e  w o u l d  l i k e  to k n o w  
if t h i s  p l a y s  a n y  r o l e  in t h e  l i k l i h o o d  t h a t  t h e s e  p e o p l e  w o u l d  
d e v e l o p  l u n g  c a n c e r .
A n o t h e r  m a j o r  f o c u s  o f  t h e  s t u d y  w i l l  be an e v a l u a t i o n  o f  
t h e  i n v o l v m e n t  o f  d i f f e r e n t  t y p e s  o f  w h i t e  b l o o d  c e l l s  in 
s p e c i f i c  k i n d s  o f  l u n g  c a n c e r .  A t  L S U  w e  h a v e  an i n t r i c a t e  p i e c e  
of m a c h i n e r y ,  c a l l e d  a F l u o r e s c e n c e - A c t i v a t e d  C e l l  S o r t e r ,  w h i c h  
c a n  i d e n t i f y  a n d  c o u n t  m a n y  d i f f e r e n t  t y p e s  o f  w h i t e  b l o o d  c e l l s  
f r o m  a s m a l l  s a m p l e  o f  b l o o d .  Y o u r  w h i t e  b l o o d  c e l l s  a r e  t h e  
a r m y  o f  y o u r  i m m u n o l o g i c a l  d e f e n s e  s y s t e m  a n d  it is t h o u g h t  t h a t  
i m b a l a n c e s  in t h e  p r o p o r t i o n s  o f  t h e  d i f f e r e n t  t y p e s  o f  c e l l s  m a y  
be i n v o l v e d  in w h y  p e o p l e  g e t  l u n g  c a n c e r  a n d  in w h a t  t y p e  o f  
l u n g  c a n c e r  t h e y  g e t .
A l t h o u g h  w e  a r e  p a r t i c u l a r l y  i n t e r e s t e d  in t h e  a b o v e  
f a c t o r s ,  it is a l s o  n e c e s s a r y  to h a v e  i n f o r m a t i o n  a b o u t  o t h e r  
f a c t o r s  k n o w n  o r  s u s p e c t e d  to be i n v o l v e d  w i t h  t h e  c a u s a t i o n  o f 
l u n g  c a n c e r .  T h i s  a l l o w s  u s  t o  i d e n t i f y  c o m b i n a t i o n s  o f  
c h a r a c t e r i s t i c s  w h i c h  m a y  p r e d i s p o s e  c e r t a i n  p e o p l e  t o  d e v e l o p  
c a n c e r .  T h e  q u e s t i o n n a i r e  c o v e r s  a w i d e  r a n g e  o f  d e s c r i p t o r s ,  
a m o n g  w h i c h  a r e  d i e t a r y  f a c t o r s ,  s m o k i n g  h i s t o r y  a n d  p r a c t i c e ,  
w o r k - r e l a t e d  e x p o s u r e s ,  h i s t o r y  o f  a l l e r g i e s ,  a n d  f a m i l y  h i s t o r y .  
F o r  y o u r  o w n  i n f o r m a t i o n ,  w e  c a n  p r o v i d e  y o u  w i t h  a p r i n t o u t  o f  
t h e  d i e t a r y  a n a l y s i s ,  w h i c h  w i l l  l et y o u  k n o w  h o w  w e l l  y o u r  d i e t  
is s u p p l y i n g  y o u  w i t h  t h e  m a j o r  n u t r i e n t s  t h a t  y o u  n e e d .
T h e  a b o v e  is o n l y  a v e r y  b r i e f  o v e r v i e w .  If y o u  h a v e  
q u e s t i o n s  o r  w o u l d  l i k e  t o  k n o w  m o r e  a b o u t  t h e  S t u d y ,  p l e a s e  
c o n t a c t  t h e  S t u d y  D i r e c t o r  M r s .  J o a n  B l a c k m o n  at L S U  ( 3 8 8 - 1 2 1 3 ) .
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D e a r  S i r :
W e  k n o w  t h a t  t h i s  is a m o s t  d i f f i c u l t  t i m e  f o r  y o u  a n d  w e  
w o u l d  n o t  b o t h e r  y o u  i f  t h e r e  w e r e  a n  a l t e r n a t i v e .  M y  c o l l e a g u e s  
a n d  I, w i t h  t h e  f i n a n c i a l  s u p p o r t  o f  T h e  C a n c e r  S o c i e t y  o f  
G r e a t e r  B a t o n  R o u g e ,  h o p e  t o  l e a r n  h o w  t o  i n t e r v e n e  t o  p r e v e n t  s o  
m a n y  p e o p l e  f r o m  d e v e l o p i n g  l u n g  c a n c e r .  O u r  r e s e a r c h  is 
d e s i g n e d  t o  l e a r n  m o r e  a b o u t  w h y  p e o p l e  g e t  c a n c e r  in t h e i r  l u n g s
a n d  in p a r t i c u l a r ,  w h y  s o m e  s m o k e r s  a r e  m o r e  l i k e l y  t o  g e t  it a n d
o t h e r s  n o t .  O n  t h e  n e x t  p a g e  i s  a v e r y  b r i e f  d e s c r i p t i o n  o f  t h e  
s o r t s  o f  f a c t o r s  w h i c h  w e  a r e  s t u d y i n g .
T h e  o n l y  w a y  t h a t  w e  c a n  s t u d y  t h i s  d i s e a s e  is t o  o b t a i n  t h e
h e l p  o f  p e o p l e  l i k e  y o u ,  w h o  h a v e  a l u n g  c a n c e r .  W e  a r e  a s k i n g  
t h a t  y o u  g i v e  u s  a s m a l l  s a m p l e  o f  b l o o d  ( a b o u t  1 T a b l e s p o o n f u l )  
o n  w h i c h  t o  d o  i m m u n o l o g i c a l  a n a l y s e s ,  a n d  t h a t  y o u  c o m p l e t e  a 
d e t a i l e d  q u e s t i o n n a i r e ,  w h i c h  w i l l  t a k e  a b o u t  a n  h o u r .  T h e  
i n f o r m a t i o n  r e q u e s t e d  i n  t h e  q u e s t i o n n a i r e  is r e s t r i c t e d  t o  
f a c t o r s  k n o w n  t o  b e  o r  t h o u g h t  t o  b e  a s s o c i a t e d  w i t h  l u n g  c a n c e r .  
O n l y  a n u m b e r ,  n o t  y o u r  n a m e ,  w i l l  b e  a s s i g n e d  t o  y o u r  b l o o d  
a n a l y s i s  a n d  q u e s t i o n n a i r e  d a t a  s o  t h a t  a l l  i n f o r m a t i o n  t h a t  y o u  
g i v e  u s  w i l l  b e  c o n f i d e n t i a l .
T h e  b l o o d  m u s t  b e  o b t a i n e d  b e f o r e  y o u  h a v e  y o u r  r a d i a t i o n  
t r e a t m e n t s .  I f  y o u  w o u l d  l i k e  t o  h e l p  w i t h  t h i s  r e s e a r c h ,  p l e a s e  
f i l l  in t h e  a t t a c h e d  g r e e n  f o r m  a n d  g i v e  i t  t o  t h e  a p p o i n t m e n t s  
s e c r e t a r y  w h e n  y o u  m a k e  t h e  a p p o i n t m e n t  f o r  y o u r  f i r s t  t r e a t m e n t .  
O u r  m e d i c a l  t e c h n o l o g i s t ,  M s .  M a r i l y n  D i e t r i c h ,  w i l l  b e  h e r e  at 
t h a t  t i m e  t o  o b t a i n  t h e  b l o o d  s p e c i m e n  a n d  t o  g i v e  y o u  t h e  
q u e s t i o n n a i r e .  It w o u l d  b e  b e s t  i f  y o u  c o m p l e t e d  t h e  q u e s t i o n ­
n a i r e  a t  t h e  C e n t e r  a n d  r e t u r n e d  it t o  t h e  r e c e p t i o n i s t  b e f o r e  
y o u  l e a v e ,  b u t  i f  t h a t  is a p r o b l e m ,  y o u  a r e  w e l c o m e  t o  t a k e  it 
h o m e  a n d  r e t u r n  it t o  t h e  r e c e p t i o n i s t  a t  y o u r  n e x t  v i s i t .  Y o u  
m a y  r e f u s e  t o  c o n t i n u e  i n t h e  s t u d y  a t  a n y  t i m e .  If f o r  w h a t e v e r  
r e a s o n  y o u  f e e l  t h a t  y o u  c a n n o t  p a r t i c i p a t e ,  i n d i c a t e  t h a t  o n  t h e  
g r e e n  f o r m ,  as w e l l ,  b u t  d o  p l e a s e  f i l l  o u t  t h e  g r e e n  f o r m  a n d  
t u r n  i t  in at t h e  r e c e p t i o n  d e s k  b e f o r e  y o u  l e a v e  t o d a y .  If y o u  
h a v e  a n y  q u e s t i o n s  a b o u t  t h e  s t u d y  o r  t h e  q u e s t i o n n a i r e ,  p l e a s e  
c a l l  M r s .  B l a c k m o n  a t  3 8 8 - 1 2 1 3  o r  3 4 6 - 3 3 5 3 .
W e  t h a n k  y o u  f o r  y o u r  h e l p  in t h i s  s t u d y .
S i n c e r e l y
J o a n  P. B l a c k m o n ,  M . S . P . H
S t u d y  D i r e c t o r
APPENDIX C
DATA PROCESSING PROGRAMS
267
268
THIS VERSION WAS DESIGNED FOR CD8 WHERE THERE ARE APPARENTLY AT LEAST 
TWO POSITIVE GROUPS. IT WILL SELECT TWO OF THREE OR FOUR CLUSTERS: THE ONE 
WITH THE HIGHEST FLUORESCENCE AND THE ONE WITH THE LOWEST. BIVARIATE (GF BY SS 
MEANS AND COVARIANCES ARE ESTIMATED FROM THE SELECTED CLUSTERS AND ALL EVENTS 
WITH FLUORESCENCE BETWEEN (THE LOWER MEAN + 2 STD. DEV.) AND (THE UPPER MEAN - 2 
STD. DEV.) ARE ASSIGNED TO A THIRD CLUSTER. THE BIVARIATE MEANS, COVARIANCES 
AND POPULATIONS OF THOSE THREE CLUSTERS THEN ARE USED AS STARTER VALUES TO FIT 
A MIXTURE OF 3 BIVARIATE NORMAL CURVES TO THE DATA.
//SAST8 JOB (1940,60434,,75),'J BLACKMON',NOTIFY-VTJOAN,MSGCLASS-S,
// TIME-5,REGION-1024K 
/♦JOBPARM SHIFT=D 
// EXEC SAS,TIME-5
//INC06309 DD DSN-VTJOAN.JBDAT8(JBC06309),DISP-SHR 
//INC06709 DD DSN-VTJOAN.JBDAT8(JBC06709),DISP-SHR 
//INC06809 DD DSN-VTJOAN.JBDAT8(JBC06809),DISP-SHR 
//INC06909 DD DSN-VTJOAN.JBDAT8(JBC06909),DISP-SHR 
//INC07009 DD DSN-VTJOAN.JBDAT8(JBC07009),DISP-SHR 
//INC07409 DD DSN-VTJOAN.JBDAT8(JBC07409),DISP-SHR 
//INP01308 DD DSN-VTJOAN.JBDAT8(JBP01308),DISP-SHR 
//INP01900 DD DSN-VTJOAN.JBDAT8(JBP01908),DISP-SHR 
//INP02008 DD DSN-VTJOAN.JBDAT8(JBP02008),DISP-SHR 
//OTC06309 DD DSN-VTJOAN.JBPROD8(JBC06309),DISP-SHR 
//OTC06709 DD DSN-VTJOAN.JBPROD8(JBC06709),DISP-SHR 
//OTC06809 DD DSN-VTJOAN.JBPROD8(JBC06809),DISP-SHR 
//OTC06909 DD DSN-VTJOAN.JBPROD8(JBC06909),DISP-SHR 
//OTC07009 DD DSN-VTJOAN.JBPROD8(JBC07009),DISP-SHR 
//OTC07409 DD DSN-VTJOAN.JBPROD8(JBC07409),DISP-SHR 
//OTP01308 DD DSN-VTJOAN.JBPROD8(JBP01308),DISP-SHR 
//OTP01908 DD DSN-VTJOAN.JBPROD8(JBP01908),DISP-SHR 
//OTP02008 DD DSN-VTJOAN.JBFROD8(JBP02008),DISP-SHR
//*****************************************************************
//♦This program takes crudely edited, decoded lymphocyte data 
//♦and edits it on forward and side scatter. The mean vector 
//♦covariance matrix for a bivariate normal distribution are 
//♦estimated using PROC CORR. These are used to calculate a 
//♦standardized, squared distance from the mean for each point 
//♦in the crude data and events which fall outside a 95% confi- 
//♦dence ellipse are excluded. To eliminate the distortion of 
//♦the parameter estimate caused by outliers in the crude data,
//♦the parameters are reestimated using the data from the first 
//♦edit. Then the crude data are edited again based on a 90% 
//♦confidence ellipse determined by the new estimate of the 
//♦parameters.
//♦ If the first edit of the data does not eliminate at least 4%
//♦of the points, so that most of the outlier platelets, etc. are 
//♦removed, the first edit is repeated using a 90% confidence 
//♦ellipse, then the second edit is done as above.
//♦ PROC FASTCLUS is used to estimate the number of events 
//♦fluorescence-positive and to estimate the mean fluorescence 
//♦and the standard deviation of the positive and negative popu- 
//♦lations. An ASCII file containing the number of events retained 
//♦after editing, the number of fluorescence parameters in the 
//♦file (1 or 2), the fluorescence channels for each retained 
//♦event, the mean vectors on fluorescence for the positive and 
//♦negative populations and their standard deviations, and the 
//♦estimated proportions for each population is constructed for 
//♦further analysis.
//♦For each antibody a slightly different clustering procedure might 
//♦be needed in that one may have to retain more than two clusters 
//♦for the final estimate so that a minor positive population will 
//♦be recognized. FOR T3 & T4, CLR—2 FOR LEU—14 & 3al, CLR—4 OR 3
//* FOR NKH-1, CLR-3 FOR T8, CLR-3
/ / * * * * * * * * * * * * * * * * * * ♦ ♦ * ♦ * ♦ ♦ ♦ * ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
//SYSIN DD *
%GLOBAL MESG TTL TITL SETT CELLS C H I ;
%MACRO DATAl;
OPTIONS REPLACE PS-60 LS-72;
DATA LYM (KEEP-P1 P2 P3 P4 ) ;
INFILE fiDSN END-ENDD;
INPUT gl TITLE $13.;
TITLI —SUBSTR(TITLE,2.8); 
SUBSTR(TITLI,1,2)— 'JB';
TITL2—SUBSTR(TITLE,4,6);
CALL SYMPUT('TTL',TITLI);
CALL SYMPUT('TITL'.TITL2); 
INDEX-SUBSTR(TITLE,5,3);
IF SUBSTR(INDEX,1,1)— 'A' THEN
DO Z-l BY 1 WHILE (ENDD-0);
IF INDEX<' 014 ' OR INDEX— '017 ' 
INPUT §1 PI 1-3 P2 4-6 P3 7 
IF Pl>50 THEN OUTPUT LYM; 
END;
ELSE DO;
INPUT 61 PI 1-3 P2 4-6 P3 7 
OUTPUT LYM;
END;
END;
DROP TITLE TITLl TITL2 INDEX; 
STOP;
RUN;
%MEND DATAl;
%MACRO COREDIT;
PROC CORR DATA-SSETT NOCORR NOPRINT 
TITLE;
VAR Pi P4;
RUN;
DATA &CELLS (KEEP-Pl P2 P3 P4);
DO 1-1 TO NPARM;
SET B POINT-I NOBS-NPARM;
SELECT (I);
WHEN (1) DO;
S1S1-P1;
S1S2-P4;
END;
WHEN (2) S2S2-P4;
WHEN (3) DO;
X1BAR-P1;
X2BAR-P4;
END;
WHEN (5) N-Pl;
OTHERWISE;
END;
END;
DET-1/(S1S1*S2S2-S1S2*S1S2); 
AIN-DET*S2S2 ;
BIN-DETM-S1S2) ;
CIN-DET*S1S1;
CHI95-5.99;
CHI90-4.61;
CHI85-4.15;
CHI75-2.77;
/♦MACRO TO READ IN D A T A V
/♦CRUDE DATAV
/♦READ FILENAME^/
/♦SHORTEN FILENAME^/
/♦MAKE 1ST 2 CHAR'S ' 3 B ' * /
/♦MAKE FILENAME GLOBAL VARIABLE^/ 
/♦MAKE FILENAME GLOBAL VARIABLE^/
SUBSTRlINDEX,1,1)-’0 ' ;
OR INDEX— '043' THEN DO; 
9 P4 10-12;
9 P4 10-12;
/♦READ IN FS, GF, RF.fi SS ♦/
/♦FOR EACH E V E N T V
COV OUTP-B(TYPE-COV);
/♦ESTIMATE BIVARIATE P A R A M ' R S V
/♦FETCH THE ESTIMATED P A R A M ' R S V
/♦CALCULATE THE ELEMENTS NEEDED♦/ 
/♦TO CALCULATE THE STANDARDIZED♦/ 
/♦DISTANCE FROM THE MEAN. ♦/
/♦THE CHISQ'S NEEDED DEPENDING ♦/
/♦ON WHICH EXECUTION OF THIS ♦/
/♦SUBROUTINE. ♦/
/♦SUBROUTINE. ♦/
CALL SYMPUT('MESG','NO'); /‘INITIALIZE MACROVARIABLE */
K-0;
DO 1-1 TO NLYM;
SET LYM POINT-I NOBS-NLYM; /*EDIT DATA */
X1-P1-X1BAR;
X2-P4-X2BAR;
TEST-(X1“ 2)*AIN + 2*X1*X2*BIN + (X2“ 2)*CIN;
IF TESTC-SCHI THEN DO;
K - K + l ;
OUTPUT {.CELLS;
END;
END;
IF (K/NLYM > 0.96) THEN CALL SYMPUTf'MESG','YES');
/‘IF > 96% KEPT THEN SET UP FOR */ 
/♦REEDIT. */
CALL SYMPUT('KA’ , K) ;
STOP;
RUN;
%MEND COREDIT;
%MACRO PLOT;
OPTIONS PS-62 LS-125;
PROC PLOT DATA-LYM;
TITLE "CRUDE LYMPHOCYTE CUT OF &TTL";
PLOT P4*P1 / VAXIS-0 TO 120 BY 20 HAXIS-20 TO 210 BY 30;
RUN;
PROC PLOT DATA-EDTD;
TITLE "FINAL EDIT OF &TTL";
PLOT P4*P1 / VAXIS-0 TO 120 BY 20 HAXIS-20 TO 210 BY 30;
RUN;
%MEND PLOT;
%MACRO CLUS;
PROC STANDARD DATA-EDTD MEAN-0 STD-1 OUT-STAN;
TITLE; /*STANDARDIZE DATA TO MEAN-0 AND STD*/
VAR P2 &P; /*DEV - 1 */
RUN;
PROC FASTCLUS DATA-STAN MAXITER—0 MAXC-6 NOPRINT MEAN-MN;
TITLE; /*FIND SEEDS FOR FINAL CLUSTER */
VAR P2 &P;
R U N ;
PROC SORT DATA-MN;
BY _FREQ_;
RUN;
DATA RMN;
SET MN;
NUM-6 - (SCLR - 1);
IF _N_<NUM THEN DELETE; /*SELECT N CLUSTERS FOR SEEDS, N DE-*/
/*PENDS ON WHICH ANTIBODY */
PROC FASTCLUS DATA-STAN MAXC-&CLR MAXITER—7 SEED-RMN NOPRINT 
OUT-T3 DRIFT MEAN—OUT1;
VAR P2 &P; /‘CLUSTER TO GET NUMBERS POSITIVE */
RUN; / ‘AND NEGATIVE. */
PROC SORT DATA-OUTl; 
BY DESCENDING P2; 
RUN;
/‘MAKE SURE THAT OUTl IS IN ORDER */ 
/‘OF DECREASING FLUORESCENCE */
DATA INTMED (KEEP-PR2 PR4 CLUSTER);
SET T3;
PR2-P2;
PR4-&P;
RUN;
DATA MIX (KEEP-P2 &P CLUSTER);
MERGE EDTD INTMED;
RUN;
PROC PLOT DATA-MIX;
TITLE "CLUSTERING &TTL ON GF AND SS, STD"; 
PLOT P2*&P-CLUSTER;
RUN;
DATA _NULL_;
DO K=1 TO OBS;
SET OUT1 POINT-K NOBS-OBS;
SELECT (K);
WHEN (1) DO;
CLSTR-CLUSTER;
CALL SYMPUT('INDl',CLSTR);
END;
WHEN (OBS) DO;
CLSTR=CLUSTER;
CALL SYMPUT('INDNG',CLSTR);
END;
OTHERWISE;
END;
END;
STOP;
RUN;
DATA CLUS1 CLUSNG;
KEEP P2 &P CLUSTER;
CLUSTRl-filNDl;
CLUSTRNG-&INDNG;
SET MIX;
IF CLUSTER-CLUSTRl THEN OUTPUT CLUS1;
ELSE IF CLUSTER-CLUSTRNG THEN OUTPUT CLUSNG;
ELSE;
RUN;
PROC CORR DATA-CLUS1 NOCORR NOPRINT COV OUTP-Bl(TYPE-COV);
TITLE;
VAR P2 &P; /‘ESTIMATE P2 MEAN & VARIANCE*/
RUN; /‘FOR CLUSTER 1 */
PROC CORR DATA-CLUSNG NOCORR NOPRINT COV OUTP-BNG(TYPE-COV);
TITLE;
VAR P2 £P; /‘ESTIMATE P2 MEAN & VARIANCE*/
/‘FOR NEGATIVE CLUSTER */
DATA CLUS1 CLUS2 CLUSNG PLOTIT;
KEEP P2 P4 CLSTR;
DO 1-1 TO NPARM;
SET B1 POINT-I NOBS-NPARM;
SELECT (I);
WHEN (1) SP2-P2;
WHEN ( 3 )  MNP2-P2;
OTHERWISE;
END;
END;
SDP2-SQRT( SP2) ;
LOWER—MNP2 - 2*SDP2;
DO 1-1 TO NPARM;
SET BNG POINT-I NOBS-NPARM;
SELECT (I);
WHEN (1) SPNG-P2;
WHEN (3) MNNG-P2;
OTHERWISE;
END;
END;
SDNG-SQRT(SPNG);
UPPER-MNNG + 2*SDNG;
/*CREATE A CLUSTER FROM OBS'NS */
DO 1-1 TO NLYM; /*WHICH BELONG NEITHER TO CLUSl*/
SET EDTD POINT-I NOBS-NLYM; /*OR CLUSNG ON GREEN FLUORESCENCE*/
IF P2 LE UPPER THEN DO;
CLSTR—3;
OUTPUT CLUSNG;
END;
ELSE IF P2 > UPPER AND P2 < LOWER THEN DO;
CLSTR-2;
OUTPUT CLUS2;
END;
ELSE DO;
CLSTR-1;
OUTPUT CLUSl;
END;
OUTPUT PLOTIT;
END;
STOP;
PROC PLOT DATA-PLOTIT;
TITLE 'PLOT OF THE THREE CLUSTERS';
PLOT P2*P4 - CLSTR;
PROC CORR DATA-CLUS1 NOCORR NOPRINT COV OUTP-Bl(TYPE-COV);
TITLE;
VAR P2 &P; / ‘ESTIMATE VAR-COVAR FOR */
RUN; /‘CLUSTER 2 */
PROC CORR DATA—CLUS2 NOCORR NOPRINT COV OUTP-B2(TYPE-COV);
TITLE;
VAR P2 SP; /‘ESTIMATE VAR-COVAR FOR */
RUN; /‘CLUSTER 2 */
PROC CORR DATA—CLUSNG NOCORR NOPRINT COV OUTP-BNG(TYPE-COV);
TITLE;
VAR P2 &P; /‘ESTIMATE VAR-COVAR FOR */
RUN; /‘CLUSTER 2 */
%MEND CLUS;
%MACRO CREATDS;
DATA _NULL_;
FILE OTSTITL;
NAME-SYMGET('TTL'); /‘CREATE A FILE TO BE USED BY */
PARAM-2; /‘NORFIT */
KAA-SYMGET('KA');
PUT NAME;
PUT KAA PARAM;
PAR-SYMGET('P ' );
DO 1-1 TO NLYM;
SET EDTD POINT-I NOBS-NLYM;
IF PAR-'P4' THEN PUT P2 P4 PI P3;
ELSE IF PAR-'P3' THEN PUT P2 P3 Pi P4;
ELSE;
END;
NG-3;
PUT NG;
NCOV-2;
PUT N COV;
NSWH-2;
PUT NSWH;
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DO J-l TO NGRP;
SET B1 POINT-J NOBS-NGRP;
SELECT (J);
WHEN (3)
PUT P2 S P ;
WHEN (5) EVTS-P2;
OTHERWISE;
END;
END;
DO J-l TO NGRP;
SET B2 POINT—J NOBS-NGRP;
SELECT (J);
WHEN (3)
PUT P2 &P;
OTHERWISE;
END;
END;
DO J-l TO NGRP;
SET BNG POINT—J NOBS-NGR1 
SELECT (J );
WHEN (3)
PUT P2 SP;
OTHERWISE;
END;
END;
DO J-l TO NGRP;
SET B1 POINT—J NOBS-NGRP 
SELECT (J);
WHEN (1) PUT P2 SP;
WHEN (2) PUT P2 SP;
OTHERWISE;
END;
END;
DO J-l TO NGRP;
SET B2 POINT—J NOBS-NGRP; /*WRITE COVAR MATRIX FOR 2ND CLUS */ 
SELECT (J);
WHEN (1) PUT P2 SP;
WHEN (2) PUT P2 SP;
OTHERWISE;
END;
END;
DO J-l TO NGRP;
SET BNG POINT—J NOBS-NGRP; /‘WRITE COVAR MATRIX FOR NEG CLUS */ 
SELECT (J);
WHEN (1) PUT P2 SP;
WHEN (2) PUT P2 SP;
OTHERWISE;
END;
END;
TOTPTS-O;
DO J-l TO OBS1;
SET B1 POINT—J NOBS—OBS1;
SELECT (J);
WHEN (5) N1-P2;
OTHERWISE;
END;
END;
DO J-l TO OBS2;
SET B2 POINT—J NOBS-OBS2;
SELECT (J);
WHEN (5) N2-P2;
OTHERWISE;
END;
END;
DO J-l TO OBSNG;
SET BNG POINT—J NOBS-OBSNG;
SELECT (J);
WHEN (5) NG-P2;
OTHERWISE;
/‘WRITE MEAN VECTOR FOR 1ST CLUS */ 
/‘Bl IS FROM PROC CORR ON 1ST CLUS*/
/‘WRITE MEAN VECTOR FOR 2ND CLUS */ 
/*B2 IS FROM PROC CORR ON 2ND CLUS*/
; /‘WRITE MEAN VECTOR FOR NEG CLUS */ 
/*B3 IS FROM PROC CORR ON NEG CLUS*/
/‘WRITE COVAR MATRIX FOR 1ST CLUS */
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END;
END;
TOTPTS - N1 + N2 + NG;
PRP1 - Nl/TOTPTS;
PRP2 - N2/TOTPTS;
PRPNG - NG/TOTPTS;
PUT PRPl PRP2 PRPNG;
STOP;
RUN;
%MEND CREATDS;
%MACRO OVERALL;
% DATAl; (*READ IN THE DATA;
%LET SETT—LYM; (*USE CRUDE DATA;
%LET CELLS-EDITD; (*CREATE INTERMEDIATE DATA SET;
%IF &KIND-A %THEN %LET CHI-CHI95;
(*USE 95 PERCENT ELLIPSE;
%ELSE %IF &KIND-B %THEN %LET CHI-CHI90;
%*USE 90 PERCENT ELLIPSE;
%ELSE %IF SKIND-C %THEN %LET CHI-CHI85;
%*USE 80 PERCENT ELLIPSE;
%ELSE %IF SKIND-D (THEN %LET CHI-CHI75;
%*USE 75 PERCENT ELLIPSE; 
%COREDIT; %*ESTIMATE BIVARIATE PARAMETERS;
%*THEN DO CHIPERCENT EDIT;
%IF &MESG-YES %THEN %DO;
%LET CHI-CHI90;
%COREDIT;
%END;
%LET SETT-EDITD;
%LET CELLS=EDTD;
%LET CHI-CHI90;
%COREDIT;
%PLOT;
%CLUS;
%CREATDS;
%MEND OVERALL;
OPTIONS NODSNFERR ERRORABEND;
DATA OUT;
INPUT NAME $ Xll X12 X21 X22 S1S1A S1S2A S2S2A S1S1B S1S2B S2S2B 
PRPl PRP2 TOTPTS;
CARDS;
RUN;
%LET CLR-3;
%LET P-P4;
%LET KIND-D;
»LET DSN-INP01308;
(OVERALL;
(LET KIND-A;
(LET DSN-INC06309;
(OVERALL;
(LET DSN-INC06709;
(OVERALL;
(LET DSN-INC06809;
(OVERALL;
(LET DSN-INC06909;
(OVERALL;
(LET DSN-INC07009;
(OVERALL;
(LET DSN-INC07409;
(OVERALL;
(*USE INTERMEDIATE DATA;
%*CREATE FINAL DATA SET;
(*USE 90 PERCENT ELLIPSE;
(*RE—ESTIMATE BIVAR. PARAM.;
(*DO 90-PCT EDIT ON CRUDE DATA;
(*PLOT CRUDE, INTERMED. & FINAL DATA;
%LET DSN-INP01908;
%OVERALL;
%LET DSN-INP02008;
%OVERALL;
/*%LET DSN-INP02608;
%OVERALL; */
%LET DSN-INP04709;
%OVERALL;
//
//RUNIT PROC MEM-DUMMY 
//GO EXEC PGM-NORFIT4 
//STEPLIB DD DSN-VTJOAN.FRT.LOAD,
// DISP-SHR
//FT05F001 DD DUMMY 
//FT06F001 DD SYSOUT-*
//FT21F001 DD DSN-VTJOAN.JBPROD8(&MEM),DISP-SHR 
//FT22F001 DD DSN-VTJOAN.JBFIT8(SMEM).DISP-OLD 
//FT23F001 DD DSN-VTJOAN.JBSUM8(6MEM),DISP-OLD 
//RUNIT PEND //*****★************************************
// EXEC RUNIT,MEM-JBC06309 
// EXEC RUNIT,MEM-JBC06709 
// EXEC RUNIT,MEM-JBC06809 
// EXEC RUNIT,MEM-JBC06909 
// EXEC RUNIT,MEM-JBC07009 
// EXEC RUNIT,MEM-JBC07409 
// EXEC RUNIT,MEM-JBP01308 
// EXEC RUNIT,MEM-JBP01908 
// EXEC RUNIT,MEM-JBP02008
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This program creates a permanent SAS file containing the relevant results from 
the SUM files (for NKH-1 in this case.)
//SUMRY JOB (1940,60434, ,15),'J BLACKMON',NOTIFY=VTJOAN,MSGCLASS=S,
// TIME=15,REGION=*1024K 
/*JOBPARM SHIFTED 
//*ROUTE PRINT LSUVAX.VTJOAN 
// EXEC SAS,TIME=15
//INP00121 DD DSN=VTJOAN.JBSUM20(JBP00121),DISP=SHR 
//ALL DD DSN=VTJOAN. JBSASOUT, DISP-OLD
//SYSIN DD *
OPTIONS PS=60 LS=132 NODSNFERR ERRORABEND;
%MACRO SET;
DATA PCT2;
INFILE SDSN;
INPUT #1 NAME $8. #5 GMNGF1 GMNSS1 / GMNNG GMNSSNG
#10 GVPOS1 / COVAR GVSSPOS1 #15 GVNEG / COVAR GVSSNEG 
#20 GPPOS1 #26 EPPOS1 #30 NPOS1 NNEG 
#34 ALOC1 ALOC2 #37 @50 OVRAL 
#41 EMNGF1 EMNSS1 / EMNNG EMNSSNG
#46 EVPOS.1 / COVAR EVSSPOS1 #51 EVNEG / COVAR EVSSNG;
TOTPTS = NPOS1 + NNEG;
FRPOS1 = NPOS1/TOTPTS;
SSTR=SUBSTR(NAME,4,3);
IF SUBSTR(SSTR,1,1)-'X' OR SUBSTR(SSTR,1,1)='P'
OR SUBSTR(SSTR,1,1)='A' OR SUBSTR(SSTR,1,1)='Y'
THEN SUBSTR (SSTR, 1,1)*='0' ;
DROP COVAR;
OUTPUT;
STOP;
RUN;
DATA ALL.NK2;
SET ALL.NK2 PCT2;
RUN;
%MEND SET;
%MACRO THREE;
DATA PCT3;
INFILE &DSN;
INPUT #1 NAME $8. #5 GMNGF1 GMNSS1 / GMNGF2 GMNSS2 / GMNNG GMNSSNG 
#11 GVPOS1 / COVAR GVSSPOS1 #16 GVPOS2 / COVAR GVSSPOS2 
#21 GVNEG / COVAR GVSSNEG #26 GPPOS1 GPPOS2 #32 EPPOS1 EPPOS2 
#36 NPOS1 NPOS2 NNEG #40 ALOC1 ALOC2 ALOC3 #43 @50 OVRAL 
#47 EMNGF1 EMNSS1 / EMNGF2 EMNSS2 / EMNNG EMNSSNG 
#53 EVPOS1 / COVAR EVSSPOS1 #58 EVPOS2 / COVAR EVSSPOS2 
#63 EVNEG / COVAR EVSSNEG;
TOTPTS = NPOS1 + NPOS2 + NNEG;
FRPOS1 - NPOS1/TOTPTS;
FRPOS2 - NPOS2/TOTPTS;
SSTR=SUBSTR(NAME,4,3);
IF SUBSTR(SSTR,1,1)»'X' OR SUBSTR(SSTR,1,1)='P'
OR SUBSTR (SSTR, 1,1) “ 'A' OR SUBSTR(SSTR, 1,1)“ ' Y'
THEN SUBSTR(SSTR,1,1)“ '0';
DROP COVAR;
OUTPUT;
STOP;
RUN;
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DATA ALL.NK3;
SET ALL.NK3 PCT3;
RUN;
%MEND THREE;
%MACRO FOUR;
DATA PCT4;
INFILE SDSN;
INPUT #1 NAME $ e .  #5 GMNGF1 GMNSS1 / GMNGF2 GMNSS2 
/ GMNNG1 GMNSSNG1 / GMNNG2 GMNSSNG2
#12 GVPOS1 / COVAR GVSSP0S1 #17 GVPOS2 / COVAR GVSSPOS2
#22 GVNEG1 / COVAR GVSSNEG1 #27 GVNEG2 / GVSSNEG2
#32 GPPOS1 GPPOS2 GPNEG1 #36 EPPOS1 EPPOS2 EPNEG1 
#42 NPOS1 NPOS2 NNEG1 NNEG2 #46 ALOC1 ALOC2 ALOC3 ALOC4 
*49 050 OVRAL #53 EMNGF1 EMNSS1 / EMNGF2 EMNSS2 
/ EMNNG1 EMNSSNG1 / EMNNG2 EMNSSNG2
#60 EVPOS1 / COVAR EVSSPOS1 #65 EVPOS2 / COVAR EVSSPOS2
#70 EVNEG1 / COVAR EVSSNEG1 #75 EVNEG2 / COVAR EVSSNEG2;
TOTPTS «• NPOS1 + NPOS2 + NNEG1 + NNEG2;
FRPOS1 <= NPOS1/TOTPTS;
FRPOS2 - NPOS2/TOTPTS;
FRNEG1 = NNEG1/TOTPTS;- 
SSTR=SUBSTR(NAME,4,3);
IF SUBSTR(SSTR,1,1)-'X' OR SUBSTR(SSTR,1 , 1 ) P'
OR SUBSTR(SSTR,1,1)='A' OR SUBSTR(SSTR,1,1)='Y ’
THEN SUBSTR(SSTR,1,1>«'0';
DROP COVAR;
OUTPUT;
STOP;
RUN;
DATA ALL.NK4;
SET ALL.NK4 P CT4;
RUN;
%MEND FOUR;
DATA ALL.NK2;
INPUT NAME $8. GMNGF1 GMNSS1 GMNNG GMNSSNG 
GVPOS1 GVSSPOS1 GVNEG GVSSNEG 
GPPOS1 EPPOS1 NPOS1 NNEG 
ALOC1 ALOC2 OVRAL 
EMNGF1 EMNSS1 EMNNG EMNSSNG 
EVPOS1 EVSSPOS1 EVNEG EVSSNG 
SSTR $3. TOTPTS FRPOS1;
CARDS;
RUN;
DATA ALL.NK3;
INPUT NAME $8. GMNGF1 GMNSS1 GMNGF2 GMNSS2 GMNNG GMNSSNG 
GVPOS1 GVSSPOS1 GVPOS2 GVSSPOS2 
GVNEG GVSSNEG GPPOS1 GPPOS2 EPPOS1 EPPOS2 
NPOS1 NPOS2 NNEG ALOC1 ALOC2 ALOC3 OVRAL 
EMNGF1 EMNSS1 EMNGF2 EMNSS2 EMNNG EMNSSNG 
EVPOS1 EVSSPOS1 EVPOS2 EVSSPOS2 
EVNEG EVSSNEG SSTR $3.
TOTPTS FRPOS1 FRPOS2;
CARDS;
RUN;
DATA ALL.NK4;
INPUT NAME $8. GMNGF1 GMNSS1 GMNGF2 GMNSS2 
GMNNG1 GMNSSNG1 GMNNG2 GMNSSNG2 
GVP0S1 GVSSP0S1 GVPOS2 GVSSPOS2 
GVNEG1 GVSSNEG1 GVNEG2 GVSSNEG2 
GPPOS1 GPPOS2 GPNEG1 EPPOS1 EPPOS2 EPNEG1 
NPOS1 NPOS2 NNEG1 NNEG2 ALOC1 ALOC2 ALOC3 ALOC4 
OVRAL EMNGF1 EMNSS1 EMNGF2 EMNSS2 
EMNNG1 EMNSSNG1 EMNNG2 EMNSSNG2 
EVPOS1 EVSSPOS1 EVPOS2 EVSSPOS2 
EVNEG1 EVSSNEG1 EVNEG2 EVSSNEG2 
TOTPTS FRPOS1 FRPOS2 SSTR $3.;
CARDS;
RUN;
%LET DSN-INP00121; 
%SET;
PROC SORT DATA—A L L .N K 2 ;
BY SSTR;
PROC PRINT DATA=ALL.NK2;
VAR NAME GMNGF1 GMNNG GPPOS1 EPPOS1 
EMNGF1 EMNNG OVRAL;
PROC SORT DATA-ALL.NK3;
BY SSTR;
PROC PRINT DATA=ALL.NK3;
V A R  NAME GMNGF1 GMNGF2 GMNNG GPPOS1 GPPOS2 EPPOS1 EPPOS2 
EMNGF1 EMNGF2 EMNNG OVRAL;
PROC SORT DATA-ALL.NK4;
BY SSTR;
PROC PRINT DATA*=ALL. NK4 ;
VAR NAME GMNGF1 GMNGF2 GMNNG1 GMNNG2 GPPOS1 GPPOS2 GPNEG1 
EPPOS1 EPPOS2 EPNEG1 EMNGF1 EMNGF2 EMNNG1 EMNNG2 OVRAL;
//
APPENDIX D
CODEBOOK
for the Analysis Database
The analysis database consists of two ASCII-coded 
data files called QUESDI.DAT and FACSFILE.DAT.
The former contains questionnaire data, medical data 
for the patients which is descriptive of their cancers, 
and the results of the analysis of the dietary portion of 
the questionnaire. The codebook for QUESDI.DAT occupies 
pages 2-32 of this section.
FACSFILE.DAT contains the estimates of proportions of 
lymphocytes carrying the eight subset-specific molecules 
which were analyzed in this study as well as the estimated 
mean fluorescence of the positive and negative cell 
groups. Its codebook begins on page 33.
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FILE QUESDI.DAT
(For the following codes, # indicates any integer from 
1 to 9)
Record Column Variable Code
Subject ID LCP### - Patient 
number 
LCC### - Control 
number
Birth state (See codes below) 
9 or 99 - Missing
State Code State Code State Code
Alabama AL Maryland MD S. Carolina SC
Alaska AK Massachusetts MA S. Dakota SD
Arizona AZ Michigan MI Tennessee TN
Arkansas AR Minnesota MN Texas TX
California CA Mississippi MS Utah UT
Colorado CO Missouri MO Vermont VT
Connecticut CT Montana MT Virginia VA
Delaware DE Nebraska NE Washington WA
Dist.of Col. DC Nevada NV W. Virginia WV
Florida FL New Hampshire NH Wisconsin WI
Georgia GA New Jersey NJ Wyoming WY
Hawaii HI New Mexico NM Puerto Rico PR
Idaho ID New York NY Virgin Isds. VI
Illinois IL N. Carolina NC Guam GU
Indiana IN N. Dakota ND Canada CN
Iowa IA Ohio OH Cuba CU
Kansas KS Oklahoma OK Mexico MX
Kentucky KY Oregon OR Rest of WorldRW
Louisiana LA Pennsylvania PA Unknown UN
Maine ME Rhode Island RI
STATE CODES
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Record Column Variable Code
11
12
Parish of residence
Neighborhood
2 - Suburban
3 - Rural
9 - Other/missing
Zip code
(See codes below) 
9 or 99 - Missing
1 - Urban
#####
9 or 99999 - Missing
17 Diet data quality GOOD - Good: no 
errors or minor, 
correctable errors. 
FIXD - "Skipped" 
assumed to mean 
"Never eat"
TUFU - Eat less 
than 6 
foods daily 
MDSM - Same
portion size for all 
or almost all items 
1 ' - Missing
Parish Code
Ascension AC
Assumption AS
E. Baton Rouge EB 
E. Feliciana EF
Parish Code
Iberville IB
Livingston LI
Pointe Coupee PC 
St. Helena SH
Parish Code
Tangipahoa TA
W . Baton Rouge WB 
W. Feliciana WF
Other OT
PARISH CODES
21 Birth month 01,02,...12
99 - Missing
1 23 Birth day 01,02, — 31 
99 - Missing
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Record Column Variable Code
1 25 Birth year
1 28 Age in years
1 30 Sex
1 31 Race, ethnicity
1 32
1 34
Highest grade of 
schooling
Marital Status
1 35
1 37
How many times have 
you changed resi­
dence in last 
10 years
Total household 
income
(1)890,(1)891,
...(1)960 
999 - Missing
31,32,... 90 
9 or 99 - Missing
1 - Male 
9 - Missing
1 - White
2 - Black
3 - Hispanic
4 - Native
American
5 - Asian
6 - Pacific Isl'dr 
9 - Missing
01-16+
99 - Missing
1 - Single
2 - Married
3 - Widowed
4 - Divorced/
separated 
9 - Missing
01-98
99 - Missing
1 - Under
$10,000/yr
2 - $10,000-$9,999
3 - $20,000-
$29,999
4 - $30,000-
$39,999
5 - $40,000-
$49,999
6 - Over $50,000
7 - Don't wish to
answer 
9 - Missing
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Record Column Variable Code
38 Number of persons in 1,2,...,98
household 99 - Missing
Of the past 3 0 years, for how many years did you live in a
1
1
1
40
42
44
46
47
48
49
Rural area
Suburban area
Urban area
Histologic type of 
lung cancer
Area of lung 
affected
Previous therapy
Stage
1 - 3 0
9 or 99 - Missing 
(As for 40)
(As for 40)
1 - Oat cell
2 - Squamous cell
3 - Adenocarcinoma
4 - Large cell
5 - Other (Mixed,
sarcoma, etc.)
. - Control
1 - Main bronchus
2 - Right lung
(RL) upper lobe
3 - RL, middle
lobe
4 - RL, lower lobe
5 - Left lung
(LL), upper lobe
6 - LL, lower lobe 
. - Control
1 - Surgery
2 - Chemotherapy
3 - None
. - Control
1 - Local
2 - Regional
3 - Disseminated 
. - Control
2 1 Subject ID (See record 1)
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Record Column Variable Code
2
2
8
20
Lived within mile of 
industry emitting 
dust, odors, or 
irritants
1st plant: Kind
For how many years
0 - No
1 - Yes
9 - Missing
(Up to 12 letters) 
01,02,... 98
2 22 Type of emission 1 - 
2 -
3 -
4 -
5 -
6 - 
7 - 
9 -
DUSt
Odors
Irritants
1 + 3
2 + 3
1 + 2 + 3 
1 + 2
Other/Missing
2 23 2nd plant: Kind (As for 8)
2 35 For how many years (As for 20)
2 37 Type of emission (As for 22)
2 38 3rd plant: Kind (As for 8)
2 50 For how many years (As for 20)
2 52 Type of emission (As for 22)
2 53 4th plant: Kind (As for 8)
2 65 For how many years (As for 20)
2 67 Type of emission (As for 22)
2 68 Smoked 100 cigar­
ettes over 
lifetime
1 - 
2 - 
9 -
No
Yes
Missing
69 How old when began 
(in years)
71 How many cigarettes 
per day on 
average
01.02.... 90
9 or 99 - Missing/ 
Nonsmoker (M/N-s)
01.02.... 98 
99 - M/N-s
Record Column Variable Code
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73 Smoke now 1 - No
2 - Yes 
9 - M/N-s
74 How old when quit 01,02,...90
(in years) 99 - M/N-s or
current smoker
76 How many cigarettes 01,02,...98
per day now 99 or 9 - M/N-s
78 Ever smoked pipe or 1 - No
cigars regularly 2 - Yes
79 For how many years 01,02,...90
9 or 99 - M/N-s
81 How many per time 01,02,...98
9 or 99 - M/N-S
83 Time unit 1 - Day
2 - Week 
9 - M/N-s
84 Since beginning, how 01,02,...90
many years 9 or 99 - M/N-s
without smoking or Current
smoker
86 Years smoking non- 01,02,...90
filter cigarettes 9 or 99 - M/N-s
88 Years smoking filter 01,02,...90
cigarettes 9 or 99 - M/N-s
90 How did you smoke 1 - Didn't inhale
2 - Into mouth &
throat only
3 - Deeply into
chest
4 - Different
levels
5 - Can't describe 
9 - M/N-s
Record Column Variable Code
2 91 How long was butt 1 - More than half
2 - 1/3 to 1/2
3 — 1/4 to 1/3
4 - Less than 1/4
9 — M/N-s
2 92 Between puffs, where 1 - On an ashtray
was the cigarette 2 - In mouth
3 - In fingers
4 - Other
9 — M/N-s
2 93 Parent smoked 0 — No
1 - Mother
2 - Father
3 - Both
9 — Missing
2 94 Spouse or roommate 0 — No
smoked
1 - Spouse
2 - Roommate
3 - Both
9 Other/Missing
2 95 Total years lived 01• / 102,...90
with a smoker 9 or 99 - Missing
2 97 Vitamins or minerals 1 — No
during last year 2 - Yes, fairly
regularly 
3 - Yes, not 
regularly 
9 - Missing
2 98 One-a-day ## - Number per
time period 
99 - Missing
2 100 Time period 1 - Day
2 - Week 
9 - Missing
2 101 Stresstabs (As for 98)
2 103 Time period (As for 100)
2 104 Therapeutic/Theragran (As for 98)
22
2
2
2
2
2
2
2
2
2
2
2
Column Variable Code
106 Time period (As for 100)
107
109
110
Vitamin A: how many 
Time period 
Mg or IU per pill
0 1 , 0 2 , 9 8  
99 - Missing
1 - Day
2 - Week
9 - Missing
1 - 50-100
2 - 200-250
3 - 400-500
4 - 1000
5 - 5000
6 - 10000
7 - 20000-25000
8 - 50000
9 - Unknown/
missing
111 Vitamin C (As for 107)
113 Time period (As for 109)
114 Mg or IU per pill (As for 110)
115 Vitamin E (As for 107)
117 Time period (As for 109)
118 Mg or IU per pill (As for 110)
119 Calcium/Dolomite (As for 107)
121 Time period (As for 109)
122 Mg or IU per pill (As for 110)
123 Other vitamin or
mineral supplement
1 -
2 -
3 -
4 -
5 -
6 - 
7 - 
9 -
Yeast
Selenium
Zinc
Iron
6-Carotene 
Cod liver oil 
Other 
Missing
1 Subject ID (See record 1)
Record Column Variable Code
Do you eat differ­
ently than you 
did 20 yrs ago
0 - No
1 - Yes
9 - Can't say/ 
Missing
3 8 Total Calories 0 - 
1 -
2 -
The
Less
More
same
i
i
3 9 Char-broiled meat (As for 8)
3 10 Butter & Oil (As for 8)
3 11 Fruit (As for 8)
3 12 Vegetables (As for 8)
3 13 Vitamin supplements (As for 8)
3 14 Take prescription 
drugs daily or 
almost daily
0 - 
1 - 
9 -
No
Yes
Missing
3 15 Most important or 
strongest kind
(Up 
9 -
to 12 letters) 
Missing/None
3 27 Second most important (As for 15)
3 39 Had cold, flu or 
other viral ill­
ness in last 
three weeks
0 - 
1 - 
2 - 
9 -
No
Yes
Possibly
Missing
3 40 Taken antibiotics in (As for 39)
last three weeks
41 How many times hos­
pitalized in 
past 5 years
0 , 1 , . . .  8 
9 - Missing
Have you ever had 
3 42 X-ray treatments for 1 - No 
acne, ringworm, 2 - Yes 
thymus, adenoids 9 - Missing
43 Number of times 0 , 1 , . .  .8
9 - Missing
Record Column Variable Code
3 44 Age at first treat­
ment (in years)
3 46 Treatment with radi 
oactive isotopes
3 47 Number of times
3 48 Age at first treat­
ment
3 50 Upper GI series
3 51 Number of times
3 52 Age at first treat­
ment
3 54 Lower GI series
3 55 Number of times
3 56 Age at first treat­
ment
5 a doctor ever told you that y
3 58 Heart disease/ 
angina
3 59 Kidney disease
3 60 Heart attack
3 61 Bladder disease
3 62 High blood pressure
3 63 Liver cirrhosis
3 64 Stroke
3 65 Hepatitis
3 66 Tuberculosis
3 67 Stomach ulcers
01,02,... 90 
99 - Missing
(As for 42)
(As for 43)
(As for 44)
(As for 42)
(As for 43)
(As for 44)
(As for 42)
(As for 43)
(As for 44)
have
1 - No
2 - YES
9 - Missing/Don't 
know
(As for 58)
Record Column Variable Code
3 68 Chronic bronchitis
/emphysema
3 69 Rheumatoid arthritis
3 70 Asthma
3 71 Other arthritis
3 72 Hay fever
3 73 Osteoporosis
3 74 Diverticulosis
3 75 Fractured hip
3 76 Rectal/colon polyps
3 77 Prostate trouble
3 78 Chronic colitis
3 79 Abnormal Pap smear
3 80 Diabetes
3 81 Skin cancer
3 82 Thyroid condition
3 83 Leukemia
3 84 Other cancer
First cancer:
3 85 Kind
3 87 Year first diagnosed
Second cancer:
3 89 Kind
3 91 Year first diagnosed
(See codes below)
(19)01,(19)02,
...(19)90 
9 or 99 - Missing/ 
cancer
(As for 85)
(As for 87)
Record Column Variable Code
the past year, have you had
3 93 Bleeding or sore 
gums
1 - No
2 - Yes
9 - Missing/Don' 
know
3 94 Difficulty seeing 
in the dark
(As for 93)
3 95 Bruise easily ii
3 96 Frequent or chronic 
fever
••
3 97 Nosebleeds
3 98 Frequent constipation 
or hemorrhoids
••
4 1 Subject ID (See record 1)
s a doctor ever told you that youi had
4 7 An autoimmune 
disease
0 - No
1 - Yes
9 - Missing
4 8 Kind Up to 12 letters
4 20 Aplastic anemia 0 - No
1 - Yes
9 - Missing
4 21 Food allergy (As for 20)
4 22 Dust allergy II
4 23 Pollen allergy II
4 24 Allergy to animal hair "
4 25 Allergy to insects II
4 26 Drug allergy II
4 27 Other allergy II
Record Column Variable Code
28 Current employment 
status
1 - Employed
2 - Homemaker
3 - Retired
4 - Disabled,
unable to work
5 - Unemployed
6 - Student
7 - Other
9 - Missing
4 29 Job/occupat ion Up to 12 letters
4 41 Years in this job 01,02,... 90 
9 - Missing
4 43 More time indoors or 1 - Indoors
outdoors
2 - Outdoors 
9 - Missing
your work, 
any of the
have you been exposed 
following:
Ifor a year or more
4 44 Asbestos 1 - No
2 - Yes
9 - Missing
4 45 Iron foundry (As for 44)
4 46 Radiation II
4 47 Nickel Smelting II
4 48 Welding II
4 49 Underground mining II
4 50 Coal tar, soot, pitch 
creosote, asphalt
II
f
4 51 Lumber industry, or 
heavy wood dust
II
4 52 Mineral, cutting or 
lubricating oil
II
4 53 Rubber or cablemaking 
industrv
II
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Record Column Variable Code
4 54 Benzidine, beta- 
napthylamine
4 55 Chemical or plastics 
industry
4 56 Benzene
4 57 Pesticides, herbicides
4 58 Isopropyl oil
4 59 Mustard gas
4 60 Dyestuffs
4 61 Chromium
4 62 Arsenic
4 63 Cadmium, beryllium, 
vinyl chloride
Cancer Code Cancer Code
Bladder 01 Mouth,Oral 13
Bone 02 Ovary 14
Brain 03 Pancreas 15
Breast 04 Prostate 16
Cervix 05 Rectum 17
Colon 06 Skin - Melanom 18
Esophagus 07 Skin - Not melanoma
Kidney 08 (Basal,squamous) 19
Liver 09 Skin - Not specif'd 20
Leukemia 10 Stomach 21
Lung 11 Thyroid 22
Lymphoma 12 Uterus 23
(Inc. Hodgkins) Other 24
CANCER CODES
Record Column Variable Code
64 Second longest
occupation
76 For how many years
78 More time indoors or 
outdoors
Subject ID
Up to 12 letters 
9 - Missing
## - Number 
99 or 9 - Missing
(As for 43)
(See record 1)
Have you worked for a year or more in the following 
industries:
5 7 Shipbuilding
5 8 Construction
5 9 Fishing
5 10 Lumber, wood, furni­
ture manufacturing 
or paper
5 11 Petrochemical
5 12 Other chemical
5 13 Metal refining, polish­
ing, manufacturing 
or plating
5 14 Sugar cane farming
5 15 Mining
5 16 Insulation manufacturing
or installation
5 17 Asbestos manufacturing
or asbestos-con­
taining products
5 18 Cement manufacturing
5 19 Demolition
0 - No
1 - Yes
9 - Missing
(As for 7)
II
55
5
5
5
5
5
5
5
5
5
5
5
5
Column Variable Code
20 Cook "
21 Gas station attendant "
or auto mechanic
22 Have any close rela- 1 - No
tives had cancer 2 - Yes
9 - Missing
23 Number of relatives # - Number
9 - Missing
24 Relation 1 - Mother
2 - Father
3 - Brother
4 - Sister
5 - Son
6 - Daughter
7 - Grandfather
8 - Grandmother
25 Alive or dead 1 - Alive
2 - Dead 
9 - Missing/No 
relatives with 
cancer (m/N-r)
26 Age if living or age 01,02,...98
at death 99 - M/n-r
28 Kind of cancer (See codes above)
30 Age at diagnosis (As for 26)
32 Relationship of 2nd (As for 24)
case
33 Alive or dead (As for 25)
34 Age if living or age (As for 26)
at death
36 Kind of cancer (See codes above)
38 Age at diagnosis (As for 26)
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Record Column Variable Code
In your work or hobbies, have you ever been exposed for a 
year or more to any of the following:
5
5
40 Petroleum refining
41 Smoke: wood, oil,
sugar cane
42 Gasoline/motor oil
43 X-rays, fluoroscopic
equipment, radio­
isotopes
44 Coke oven gases
0 - No
1 - Yes
9 - Missing
(As for 40)
(As for 40)
ii
How tall are you
45
46
48
51
54
5 55
Feet
Inches
How much do you 
weigh?
Most you ever 
weighed
How many times you 
have dieted to 
lose weight
How many hours of 
sleep do you get 
at night
4.5.... 7
9 - Missing
01.02.... 12 
99 — Missing
100,101,...500 
999 - Missing
(As for 48)
1 - Never
2 -  1-2
3 - 3-5
4 - 6-8
5 - 9-11
6 - 12 or more
1 - 6 or less
2 - 7
3 - 8
4 - 9 or more
Record Column Variable Code
56 How often do you
feel significant 
stress
1 - Everyday
2 - Several times/
week
3 - Several times/
month
4 - Several times/
year
5 - Rarely/never
(R/n)
How often do you do these active things: 
Active sports57 1 - >1/week
2 - About 1/week
3 -- Few times/
month
4 - Few times/year
5 - R/n
9 - Missing
5 58 Physical exercises (As for 57)
5 59 Jogging or running (AS for 57)
5 60 Swimming/long walks (As for 57)
5 61 Gardening, fishing, 
hunting
(As for 57)
5 62 Something else (As for 57)
5 63 How many close 
friends do you 
have
1 - 
2 - 
3 -
None 
1 or 2 
3 to 5
64 How many relatives
do you feel close 
to
65 How many friends or
relatives you see 
/talk to at least 
once a month
4 - 6 to 9
5 - 10 or more
(As for 63)
(As for 63)
Record Column Variable Code
How often do you participate in these groups or 
activities:
66 Church or temple
67 Clubs, PTA, profes­
sional, labor or 
service groups
Today's date:
5 68 Month
5 70 Day
5 72 Year
73 Version of diet
questionnaire.
1 - > 1/week
2 - 1/week
3 - Few times/
month
4 - A few times/
year
5 - R/n
(As for 66)
01,02,...,12 
99 - Missing
01,02,...,31
(198)8,(198)9, 
(199)0
6 1
6 7
6 8
Subject ID 
Line identifier 
On special diet
On second special 
diet
(See record 1)
A
1 - No
2 - Weight loss
3 - For medical 1
condition
4 - Vegetarian
5 - Low salt
6 - Low choles­
terol
7 - Weight gain
9 or 99 - Missing
(As for 7)
10 No meaning
Record Column Variable Code
6 11 Amount of weight 
change in last 
year
1 - No
2 - Lost 5-15 lbs
3 - Lost 16-25 lbs
4 - Lost > 25 lbs
5 - Gained 5-15
6 - Gained 16-25
7 - Gained > 25
8 - Two or more e
answers given
6 12 Desirable weight (DW) 100,101,...275
Female:
Male:
100 lbs. + 5 lbs. for 
106 lbs. + 6 lbs. for
each inch over 5 ft 
each inch over 5 ft
6 15 Lower bound for 
weight
DW X 0.95
6 18 Upper bound for 
weight
DW X 1.05
6 21 Grams solid food 
consumed daily
####
6 25 Daily carotene 
intake
####### micrograms 
( M g )
6 32 Retinol equivalents ####
6 36 Daily retinol intake # # # #  M g
6 40 Na/K ratio #.##
6 44 Linoleic/saturated 
fatty acids
#.##
6 48 Percent of daily
calories from fat
##.#
6 52 Percent of daily
cal. from protein
##.#
6 56 Pet. of daily cal. 
from carbohydrate
##.#
6 60 Daily calories from
C?T.7£i^ +" e
#####.#
Record Column Variable Code
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6
6
6
6
6
6
67 Pet. of daily cal.
from sweets
71 Daily calories from
alcoholic drinks
78 Pet. of daily cal.
from alcoholic 
drinks
82 "Other" vitamin
supplement
83 Supplemental Vit. A
90 Supplemental Vit. B
97 Supplemental Vit. C
104 Supplemental Vit. D
111 Supplemental Vit. E
118 Supplemental Iron
##.#
#####.#
##.#
(See record 2, 
col. 123)
#####.# IU
#####.# mgs
#####.# mgs
#####.# mgs
#####.# IU
#####.# mgs
7 1 Subject ID
7 7 Line identifier
(See record 1) 
'B'
Daily nutrient estimates averaged over whole year:
7 8 Total calories #####.#
7 15 Protein intake #####.# grams
7 22 Fat intake #####.# grams
7 29 Carbohydrate intake #####.# grams
7 36 Calcium intake #####.# mgs
7 43 Phosphorus intake #####.# mgs
7 50 Iron intake #####.# mgs
7 57 Sodium intake #####.# mgs
7 64 Potassium intake #####.# mgs
Record Column Variable Code
7 71 Vitamin A #####.# IU
7 78 Thiamin #####.# mgs
7 85 Riboflavin #####.# mgs
7 92 Niacin #####.# mgs
7 99 Vitamin C #####.# mgs
7 106 Saturated fat #####.# grams
7 113 Oleic acid #####.# grams
7 120 Linoleic acid #####.# grams
7 127 Cholesterol #####.# mgs
7 134 Dietary Fiber #####.# grams
(See record 12 for breakdown of fiber from beans
grains and fruits and vegetables.)
8 1 Subject ID (See record 1)
8 7 Line identifier C
Error flags:
8 8 Number of times fre- #
quency not given 
for vitamin pill 
questions
8 9 Number of times #
nutrient amounts 
not given for 
vitamins
8 10 Number of food items ##
skipped
8 12 Number of foods where ##
no portion size 
given
8 14 Number of foods where ##
no frequency given
88
8
8
8
8
8
8
8
8
8
8
8
8
Column
16
18
20
22
24
26
28
30
31
33
34
35 
42
Variable Code
Number of times large ## 
portion indicated
Number of times small ## 
portion indicated
Number of foods eaten ## 
(without beverages)
Average number of food ## 
servings eaten each 
day
Number of food time ##
units out of range
Number of foods with ##
frequency, time unit 
or serving size 
missing
Number of food serving ## 
sizes out of range
Number of foods with ##
frequency too high
Number where indicated ##
once/time. If 
onces/(# of foods 
eaten) > 0.7, probably 
unreliable data
Were recalculations 
done because sub­
ject was outlier
Was subject below 10th 
percentile or above 
90th percentile on 
total calories
Calcium from supple­
ments
Total vitamin A
1 - Yes 
Blank - No
1 - Below 10th
2 - Above 90th 
Blank - OK
#####.# mgs 
##### IU
47 Total vitamin C #### IU
303
Record Column Variable Code
8 51 Weekly freq. of fruit ##.#
8 55 Weekly freq. of ##.#
citrus fruit
8 59 Weekly freq. of all ##.#
vegetables
8 63 Vegetable freq. ##.#
excluding potatoes 
and rice
8 67 Weekly freq. of dark ##.#
green & deep yellow 
vegetables
8 71 Weekly freq. of ##.#
tomatoes
8 75 Weekly freq. of ##.#
carrots
8 79 Weekly freq. of ##.#
salad
8 83 Weekly freq. of beef ##.#
8 87 Weekly freq. of fish ##.#
and chicken
8 91 Weekly freq. of high- ##.#
fiber cereals & 
breads
8 95 Weekly freq. of alcohol ##.#
8 99 Number of eggs ##.#
eaten per week
8 103 Weekly freq. of pork ##.#
8 107 Weekly freq. of hot ##.#
dogs & lunch meat
8 111 Weekly freq. of butter ##.#
& margarine
8 115 Weekly freq. of cheese ##.#
except cottage cheese
304
Record Column Variable Code
8 119 Weekly freq. of whole ##.#
milk
8 123 Weekly freq. of ice ##.#
cream
8 127 Weekly freq. of ##.#
sweets, soft drinks 
and desserts
8 131 Weekly freq. of fried ##.#
fish & fried chicken
8 135 No. of different 01-12
fruits eaten at least 
once per week (1/wk)
8 137 No. of different fruits 01,02,.
eaten at least once 
per month 1/mo
8 139 No. of different vege- 01,02,.
tables eaten at 
least 1/wk
8 141 No. of different vege- 01,02,.
tables eaten at 
least 1/mo
8 143 No. of different meats, 01,02,.
main dishes & lunches 
eaten at least 1/wk
8 145 No. of different meats, 01,02,.
main dishes & lunches 
eaten at least 1/mo
8 147 No. of different 01,02,.
breads, snacks and 
breakfasts eaten 
at least 1/wk
8 149 No. of different 01,02,.
breads, snacks and 
breakfasts eaten 
at least 1/mo
. . 12
. .20
. .20
. .18
. . 18
. .17
. .17
Record Column Variable Code
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8 151 No. of different dairy 01,02,...17
products eaten at 
least 1/wk
8 153 No. of different dairy 01,02,...17
products eaten at 
least 1/mo
8 155 No. of different 01,02,...11
sweets (e.g. desserts 
or soft drinks) eaten 
at least 1/wk
8 157 No. of different 01,02,...11
sweets (e.g. desserts 
or soft drinks) eaten 
at least 1/mo
9 1 Subject ID (See record l)
9 7 Line identifier D
The following are calculated excluding alcoholic 
beverages:
9 8 Total calories per day 
before alcoholic 
beverages (bab)
#####.#
9 15 Daily protein intake 
(bab)
#####.# grams
9 22 Daily fat intake (bab) #####.# grams
9 29 Daily carbohydrate 
(bab)
#####.# grams
9 36 Daily calcium (bab) #####.# mgs
9 43 Daily phosphorus (bab) #####.# mgs
9 50 Daily iron (bab) #####.# mgs
9 57 Daily sodium (bab) #####.# mgs
9 64 Daily potassium (bab) #####.# mgs
Record Column Variable Code
9 71 Daily vitamin A (bab)
9 78 Daily thiamin (bab)
9 85 Daily riboflavin (bab)
9 92 Daily niacin (bab)
9 99 Daily vitamin C (bab)
9 106 Daily saturated
fat (bab)
9 113 Daily oleic acid (bab)
9 120 Daily linoleic
acid (bab)
9 127 Daily cholesterol (bab)
9 134 Daily dietary
fiber (bab)
#####.# IU 
#####.# mgs 
#####.# mgs 
#####.# mgs 
#####.# mgs 
#####.# grams
#####.# grams 
#####.# grams
#####.# mgs 
#####.# grams
10 1 Subject ID
10 7 Line identifier
(See record 1) 
E
The following represent "seasonal" consumption:
10 8 Total calories per
day in summer (is)
10 15 Daily protein intake
(is)
10 22 Daily fat intake (is)
10 29 Daily carbohydrate (is)
10 36 Daily calcium (is)
10 43 Daily phosphorus (is)
10 50 Daily iron (is)
#####.#
#####•# grams
#####.# grams 
#####.# grams 
#####.# mgs 
#####.# mgs 
#####.# mgs
Record Column Variable Code
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10 57 Daily sodium (is) #####.# mgs
10 64 Daily potassium (is) #####.# mgs
10 71 Daily vitamin A (is) #####.# IU
10 78 Daily thiamin (is) #####.# mgs
10 85 Daily riboflavin (is) #####.# mgs
10 92 Daily niacin (is) #####.# mgs
10 99 Daily vitamin C (is) #####.# mgs
10 106 Daily saturated fat 
(is)
#####.# grams
10 113 Daily oleic acid (is) #####.# grams
10 120 Daily linoleic acid 
(is)
#####.# grams
10 127 Daily cholesterol (is) #####.# mgs
10 134 Daily dietary fiber 
(is)
#####.# grams
11 1 Subject ID (See record l]
11 7 Line identifier F
The following represent "out-of-season" consumpt
11 8 Total calories per day 
excluding summer or 
"out-of-season" (os)
#####.#
11 15 Daily protein intake 
(os)
#####.# grams
11 22 Daily fat intake (os) #####.# grams
11 29 Daily carbohydrate (os) #####.# grams
11 36 Daily calcium (os) #####.# mgs
11 43 Daily phosphorus (os) #####.# mgs
Record Column Variable Code
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11 50 Daily iron (os) #####.# mgs
11 57 Daily sodium (os) #####.# mgs
11 64 Daily potassium (os) #####.# mgs
11 71 Daily vitamin A (os) #####.# iu
11 78 Daily thiamin (os) #####.# mgs
11 85 Daily riboflavin (os) #####.# mgs
11 92 Daily niacin (os) #####.# mgs
11 99 Daily vitamin C (os) #####.# mgs
11 106 Daily saturated fat 
(os)
#####.# grams
11 113 Daily oleic acid (os) #####.# grams
11 120 Daily linoleic acid 
(os)
#####.# grams
11 127 Daily cholesterol (os) #####.# mgs
11 134 Daily dietary fiber 
(os)
#####.# grams
12 1 Subject ID (See record i;
12 7 Line identifier G
12 8 Dietary fiber - beans ##.## grams
12 13 Fiber - fruits & 
vegetables
##.## grams
12 18 Fiber - grains ##.## grams
12 23 "Nonlycopene caroten- 
oids" (i.e. exclu­
ding tomatoes)
##### ng
12 28 Alpha-carotene ##### ng
12 33 Alpha-carotene (is) ##### mg
12 38 Alpha-carotene (os) ##### Mg
Record Column Variable Code
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12 43 Beta-carotene ##### Mg
12 48 Beta-carotene (is) ##### Mg
12 53 Beta-carotene (os) ##### Mg
12 58 Lutein ##### Mg
12 63 Lutein (is) ##### Mg
12 68 Lutein (os) ##### Mg
12 73 Cryptoxanthin ##### Mg
12 78 Cryptoxanthin (is) ##### Mg
12 83 Cryptoxanthin (os) ##### Mg
12 88 Xanthins ##### Mg
12 93 Xanthins (is) ##### Mg
12 98 Xanthins (os) ##### Mg
12 103 Lycopene ##### Mg
12 108 Lycopene (is) ##### Mg
12 113 Lycopene (os) ##### Mg
12 118 Carotene from milk, 
cream, & butter 
(0.27 of RE's)
##### Mg
12 123 "Carotene" from eggs 
(Zero, no 6-caro- 
tene in eggs, 
Beecher)
00000 Mg
a- and 6-carotenes and cryptoxanthin are the only 
carotenoids converted to Vitamin A, therefore their sum 
may be of interest.
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FILE FACSFILE.DAT
Record Column Variable Code
1 1 Subject ID LCP### - For
patient 
number 
LCC### - For 
control 
number
1 7 B-cells: Mean of nega- ###.####
tive population 
(NP) on green 
fluorescence (GF)
1 15 B-cells: Mean of posi- ###.####
tive population 
(PP) on GF
1 23 B-cells: Proportion 0.###
positive
1 28 HLA-DR: Mean of NP on ###.####
GF (Two groups 
fitted)
1 36 HLA88-DR: Mean of PP ###.####
on GF (Two groups 
fitted)
1 44 HLA-DR: Proportion in 0.###
PP (Two groups 
fitted)
1 49 HLA-DR: Mean of NP on ###.####
GF (Three groups 
fitted)
1 57 HLA-DR: Mean of higher ###.####
PP (PP1) on GF 
(Three groups fitted)
1 65 HLA-DR: Mean of lower ###.####
PP (PP2) on GF (Three 
groups fitted)
1 73 HLA-DR: Proportion in 0.###
PP1 (Three groups 
fitted)
12
2
2
2
2
2
2
2
2
2
2
2
Column Variable
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Code
78 HLA-DR: Proportion in
PP2 (Three groups 
fitted)
1 Subject ID
7 CD4-2H4 (green-red):
Proportion with 
neither CD4 nor 2H4
12 CD4-2H4: Proportion
with 2H4 but not CD4
17 CD4-2H4: Proportion
with CD4 but not 2H4
22 CD4-2H4: Proportion
with CD4 and 2H4
27 CD4-2H4: Mean on GF
of population with 
neither CD4 nor 2H4
35 CD4-2H4: Mean on RF
of population with 
neither CD4 nor 2H4
43 CD4-2H4: Mean on GF
of population with 
2H4 but not CD4
51 CD4-2H4: Mean on RF
of population with 
2H4 but not CD4
59 CD4-2H4: Mean on GF
of population with 
CD4 but not 2H4
67 CD4-2H4: Mean on RF
of population with 
CD4 but not 2H4
75 CD4-2H4: Mean on GF
of population with 
both CD4 and 2H4
0.###
(See record 1) 
0.###
0 . ###  
0 . ###  
0.###
###.####
###.####
###.####
###.####
###.####
###.####
###.####
Variable Code
CD4-2H4: Mean on RF 
of population with 
both CD4 and 2H4
Subject ID
CD4-4B4 (green-red): 
Proportion with 
neither CD4 nor 4B4
CD4-4B4: Proportion
with 4B4 but not CD4
CD4-4B4: Proportion
with CD4 but not 4B4
CD4-4B4: Proportion 
with CD4 and 4B4
CD4-4B4: Mean on GF 
of population with 
neither CD4 nor 4B4
CD4-4B4: Mean on RF 
of population with 
neither CD4 nor 4B4
CD4-4B4: Mean on GF 
of population with 
4B4 but not CD4
CD4-4B4: Mean on RF 
of population with 
4B4 but not CD4
CD4-4B4: Mean on GF 
of population with 
CD4 but not 4B4
CD4-4B4: Mean on RF 
of population with 
CD4 but not 4B4
CD4-4B4: Mean on GF 
of population with 
both CD4 and 4B4
###.####
(See record 1) 
0 .###
0.### 
0.### 
0 . ###
###.####
###.####
###.####
###.####
###.####
###.####
###.####
Record Column Variable
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Code
83 CD4-4B4: Mean on RF
of population with 
both CD4 and 4B4
4 1 Subject ID
4 7 NKH-1: Mean of higher
NP (NP1) on GF
4 15 NKH-1: Mean of lower
NP (NP2) on GF
4 23 NKH-1: Mean of PP1
on GF
4 31 NKH-1: Mean of PP2
on GF
4 39 NKH-1: Proportion in
NP1
4 44 NKH-1: Proportion in
PP1
4 49 NKH-1: Proportion in
PP2
4 54 NKH-1: Total
proportion positive 
(PP1+PP2)
4 59 CD3: Mean of NP on GF
4 67 CD3: Mean of PP on GF
4 75 CD3: Proportion in PP
5 1 Subject ID
5 7 CD4: Mean of NP on GF
5 15 CD4: Mean of PP on GF
5 23 CD4: Proportion in PP
5 28 CD8: Mean of NP on GF
###.####
(See record 1) 
###.####
###.####
###.####
###.####
0.###
0.###
0.###
0 .###
###.####
###.####
0.###
(See record 1)
###.####
###.####
0.###
###.####
55
5
5
5
6
6
6
6
6
6
6
6
6
314
Column
36
44
52
57
62
1
7
15
17
19
21
23
25
Variable Code
CD8: Mean of higher ###.####
PP on GF
CD8: Mean of lower PP ###.####
on GF
CD8: Proportion in 0.###
higher PP
CD8 : Proportion in 0.###
lower PP
The subject's number ###
Subject ID (See record 1)
Source of control (See codes
subject below)
Hours between collec- 1,2,...,17
tion of blood and 
labelling
Month sample collected 01,02,...,12
. - Missing
Day sample collected 01,02,...,31
' ' - Missing
Year sample collected (19)88,(19)89,
(19)90 
' ' - Missing
Month FACS done 01,02,...,12
. - Missing
Day FACS done 01,02,...,31
1 ' - Missing
27 Year FACS done (19)88,(19)89, 
(19)90 
' ' - Missing
Record
6
6
6
6
6
6
6
6
6
6
6
Column Variable
29 Month questionnaire
returned
31 Day questionnaire
returned
33 Year questionnaire
returned
35 Hour of day blood
drawn
37 Minutes after hour
of blood draw
39 Hematocrit, percent
41 Neutrophils, percent
43 Lymphocytes, percent
45 Monocytes, percent
47 Eosinophils, percent
49 Basophils, percent
315
Code
01,02,...,12 
. - Missing
01,02,...,31 
' ' - Missing
(19)88,(19)89, 
(19)90 
' ' - Missing
07, 08,...,24 
99 - Missing
00, 01,...,59 
99 - Missing
20, 21,... 65 
99 - Missing
30, 31,...,98 
99 - Missing
5, 6,...,65 
99 - Missing
5, 6,...,50 
99 - Missing
0, 1,...,10 
99 - Missing
0, 1,...,10 
99 - Missing
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Code
AARP
COAGING
KIWANIS
LIONS
AMLEG
AMLEGJAK
DUMAS
VFW
SALVARMY
PERSFRND
CHURCH
KOFC
GUARD
Group
American Assn. of Retired Persons 
Council on Aging 
Kiwanis International 
Lions Clubs 
American Legion
Amer. Leg. Veterans Home, Jackson, LA
Referred by former Baton Rouge Mayor 
Woody Dumas
Veterans of Foreign Wars
Salvation Army
Personal friend
University Baptist Church
Knights of Columbus
School of Veterinary Medicine security 
guard
CONTROL ORIGIN CODES
VITA
Joan Peters Blackmon was born in Pittsburgh, Pa. on 
August 23, 1942, the daughter of David Peters and Elinor 
Livelsberger Peters. She was educated in the public 
schools, then entered the University of Pittsburgh 
following her junior year in high school. As an 
undergraduate she received two National Science Foundation 
summer research fellowships and was elected to Phi Beta 
Kappa. She graduated magna cum laude with a B.S. degree in 
chemistry in April, 19 63. Upon graduation she was awarded 
a research assistantship in organic chemistry at Duke 
University, where she earned the A.M. degree in 1965. She 
was employed by the Research Triangle Institute in Durham, 
N.C. for five years as a synthetic organic chemist. As a 
chemist, she was coauthor of 13 journal articles in 
professional journals.
In 1971, she earned the M.S.P.H. degree in epidemiology 
at the School of Public Health, University of North 
Carolina at Chapel Hill . She married William J. Blackmon 
and temporarily retired from career pursuits to bear and 
nurture three children: Heather, and twins Amanda and 
Timothy. A recipient of an Alumnae Federation Fellowship 
at Louisiana State University in 1984, she is currently a 
candidate for the Ph.D. degree in the Department of 
Veterinary Microbiology and Parasitology, School of 
Veterinary Medicine.
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